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Abstract 
Development of Targeted Therapeutics for the Treatment of Glioblastoma 
Mohit Jain 
Glioblastoma is the most aggressive cancer of the brain. Despite recent advances 
in cancer biology and multimodality therapies, such as surgery, radiotherapy and 
chemotherapy, the outcome of patients with high grade glioma remains fatal. The 
major drawback of current glioma chemotherapeutics is their inability to cross the 
blood brain barrier, lack of tumour specificity agents and their consequent side 
effects. Matrix metalloprotease (MMP) activity is central to cancer development, 
angiogenesis and invasion. They are highly active in the tumour environment and 
absent or inactive in normal tissues, therefore they represent viable targets for 
cancer drug discovery. A better understanding of the role of MMPs in human 
gliomas could potentially have diagnostic, prognostic and therapeutic implications. 
This study aims to assess the expression of specific MMPs in preclinical human 
glioma models and clinical glioma samples; evaluate in silico docking to rationalise 
substrate binding preferences of homologous MMPs; rationally design MMP-
subtype-selective tumour activated prodrugs; and determine the feasibility of 
targeting MMP-selective anticancer prodrugs conjugated to graphene oxide as a 
local drug delivery approach for glioblastoma. 
This study found significant overexpression of MMP-10 in glioma relative to 
histologically normal brain tissues. Strong correlation was observed between 
MMP-10 protein and gene expression of glioma cell lines relative to low 
expression in a normal brain cell line. MMP-10 activity, as measured by 
fluorogenic substrate cleavage assay, also demonstrated a strong correlation 
between MMP-10 activity and gene expression levels. 
Following demonstration of selective overexpression of MMP-10 in glioma, a 
reiterative in silico proteolytic docking coupled in vitro biochemical assessment 
was utilised to rationalise functional similarity and differentiate substrate binding 
selectivity of homologous MMPs. The binding modes of MMP-substrates within the 
active site of closely related MMPs were able to accurately predict the cleavage 
subsites by specific MMPs, as confirmed by in vitro cleavage assay. The success 
of computational and experimental methodology provided a robust tool for 
identifying MMP-subtype differences and subsequent development of MMP-10 
selective peptide prodrugs.  
MMP-subtype selective and MMP-10 selective prodrugs were designed by rational 
exploitation of MMP-docked complexes of substrates. Peptide residues were 
modified to achieve selectivity for MMP-2 and MMP-10 (over MMP-3 and MMP-9) 
demonstrating predicted cleavage at distinct subsites. This selectivity was further 
exploited to attain MMP-10 selectivity, over MMP-2, MMP-3 and MMP-9. The 
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rationally designed peptide prodrugs were synthesised and were shown to be 
preferentially cleaved by MMPs at predicted subsites and demonstrated no 
activation by engineered-out MMPs, as predicted. Compared to MJ02 (MMP-2 and 
MMP-10 selective doxorubicin prodrug), MJ04 (MMP-10 selective doxorubicin 
prodrug) demonstrated selective metabolism by glioma cell lines to release 
chemotherapeutic agents. This therapeutic approach against glioma cell lines 
depended upon the involvement of MMPs, confirmed using pharmacological 
inhibition. MJ04 demonstrated negligible activity in the presence of an MMP-10 
selective inhibitor, suggesting MMP-10 selective activation of the prodrug in glioma 
cells relative to normal glial cells.  
Following successful development of MMP-10 selective prodrugs, the feasibility of 
targeting glioma tumour with local delivery of chemotherapeutics from 
functionalised graphene-oxide tethered prodrug implants, was assessed as a 
therapeutic strategy to circumvent the blood brain barrier. Graphene oxide 
conjugated prodrug was synthesised which is shown to be preferentially cleaved in 
MMP expressing glioma cell lines relative to normal glial cells. This study 
demonstrates that MMP-10 is overexpressed in glioblastoma and can be used to 
metabolise anticancer prodrugs that can be activated selectively by local tumour 
environment. 
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Chapter 1: Introduction 
1.1 Cancer  
Cancer is a complex and heterogenic disease that can exhibit a broad range of 
physiological, genetic and histological perturbations in all of the body systems. 
Cancer develops from normal cells that acquire the ability to proliferate 
uncontrollably and ultimately become malignant.1 Malignancy, by definition, allows 
the cancer cells to invade surrounding normal tissue and metastasise to vital 
organs resulting in disseminated disease state.  Unlike many other diseases, in its 
early stages cancer is often asymptomatic and remains hidden, with the problem 
only being identified later in the process once the cancer has become symptomatic 
and noticeable by the patient. Unfortunately, by this stage the cancer is commonly 
aggressive and in many cases, has disseminated to other sites within the body. As 
a consequence cancer is often life-threatening with patients having a poor 
prognosis and significantly reduced life expectancy.2 
In terms of development and progression towards life-threatening disease, cancer 
has been characterised as having six well-defined hallmarks. More recently a 
further four enabling characteristics have been identified; these account for the 
specific requirements of the cancers existence and thus can be exploited as 
targets for therapeutic cancer treatment.3, 4 The first four of the hallmarks 
comprising of sustained proliferative signalling, enabling replicative immortality, 
evading growth suppressors and resisting cell death; relate to the cancer cells 
ability to proliferate and survive. Whereas, the latter two hallmarks comprising of 
inducing angiogenesis, and activating invasion and metastasis; relate to gain of 
malignant potential and revolve around the central roles of extracellular 
proteases.3, 4 
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1.1.1 Angiogenesis 
In order for the tumour to expand beyond 2-3 mm3 it requires access to its own 
blood supply, before this point nutrient and oxygen are obtained from the 
surrounding normal vasculature which is close enough to facilitate diffusion. This 
physiological process by which new blood vessels are generated from existing 
ones is termed as angiogenesis. 3, 5, 6 
1.1.2 Invasion and metastasis 
The defining factor of cancer is malignancy, the ability to disseminate from its 
original location to another area of the body. The invasion-metastasis cascade is a 
sequence of cellular biological changes of cancer cells, initiated with local 
invasion, intravasation into surrounding blood and lymphatic vessels, transfer 
through hematogenous and lymphatic systems, followed by extravasation into 
parenchyma of distant tissues, formation of small cancer nodules 
(micrometastases) and finally the progression of micrometastatic lesions into 
macroscopic tumours (termed as ‘colonisation’).5-9 Several classes of proteins are 
found to be altered in cells possessing invasive and metastatic capabilities 
including cell-cell adhesion molecules, integrins and extracellular proteases. The 
activity of a set of proteases in cancer progression is known as cancer 
degradome. A great number of reports have suggested a strong correlation 
between the activity of extracellular proteases and, tumour progression, invasion 
and metastasis.10, 11 
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1.2 Cancer of the brain: Glioma 
Malignant gliomas are the most common neoplasms of the central nervous system 
(CNS). They form a special group of neoplasias, with restricted tumour migration 
and increased tumour infiltration into normal brain tissues, for which no cure is 
currently available and only modest research progress has been made in 
understanding their biology. Their specific origin derives from the normal neural 
stem cells- the microglial cells, with which they share morphological characteristics 
and molecular markers, i.e., oligodendrocytes (oligodendrogliomas), astrocytes 
(astrocytomas) and ependymal cells (ependymomas).12 
They account for 77% of all malignant primary CNS tumours. In adults, gliomas 
account for 29% of all brain tumours, 80% of all primary brain tumours occurring in 
patients 65-84 years of age. Gliomas also affect children and the most common 
types are astrocytomas (52%), medulloblastomas (21%), high grade gliomas 
(19%) and primitive neuroectodermal tumours (PNETs).13 The World Health 
Organisation (WHO) developed a universally accepted system for the 
classification of brain tumours. This classification includes a grading system that 
distinguishes gliomas into different stages depending on the tumour size, the level 
of penetration and spread to the lymph nodes or to distant organs.12 According to 
the malignancy, there are four different grades of glioma tumours: grades I 
(juvenile pilocytic), II (diffuse), III (anaplastic) and IV (glioblastoma multiforme) for 
astrocytoma; and grades II or III for oligodendrogliomas and oligoastrocytomas. 
Lower-grade glioma tumours (grades I and II) tend to be well-differentiated and 
possess few cellular atypias but in general they are closely similar to their non-
neoplastic cellular counterparts. These tumour types contain specific genetic 
mutations with progressive initiation of additional genetic alterations.14 This is 
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followed by the advancement of the tumour to higher malignancy and progression 
rates.15 Higher grade tumours (grades III and IV) are anaplastic, demonstrating 
increased vessel density, high mitotic activity, cellular anomalies and elevated cell 
density. Grade IV astrocytoma, better known under the name of glioblastoma 
multiforme (GBM), is the most common and aggressive form of brain tumour.  
Glioblastomas contribute for about 60-70% of all gliomas, anaplastic astrocytomas 
for 10-15%; and anaplastic grade II and III type accounts for 10%. Glioblastoma 
samples are characterised by areas of necrosis, very high cell density, robust 
neoangiogensis and numerous atypical cells.12 They are incurable, show a highly 
aggressive course and poor treatment response and, patients have short-term 
survival expectancies.16   
 
1.3 Glioblastoma molecular pathophysiology 
1.3.1 Epidermal growth factor receptor (EGFR) 
The EGFR gene is a common driver of glioblastoma progression and is involved in 
the control of cell proliferation. The amplification of EGFR is found in nearly 40% of 
all glioblastoma cases and can occur by reverse transcription from RNA or 
insertion.17 Essentially, all cases of EGFR amplification in glioblastoma are 
associated with EGFR overexpression, which is in contrast to the 97% of non-
amplified EGFR glioblastomas that demonstrate no EGFR overexpression.18  
EGFR amplification is accompanied with the presence of EGFR protein variants. 
68% of EGFR mutants have deletions in the N-terminal ligand binding regions 
between 6 and 273 amino acids, termed EGFRvIII. Deletion in the ligand-binding 
regions can lead to ligand-independent activation of EGFR.19 Common tyrosine 
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kinase inhibitors such as gefitinib have limited therapeutic use due to the specific 
nature of these exon 2-7 deletions in EGFRvIII.20 Therefore, approaches to 
address the lack of extracellular receptor are currently being pursued. However, 
EGFRvIII is not indicative of overall median survival except in cases of ≥ 1year 
survival which may limit the therapeutic value of this target.21 
1.3.2 p53 and PTEN 
Tumour suppressor protein, p53, plays important role in the formation of high-
grade tumours. P53 initiates DNA repair or apoptosis if the damage is 
irreparable.22 There is significant correlation between the presence of mutant p53 
and the advancement of low-grade astrocytoma to the high-grade glioblastoma. 
p53 mutant cells have the ability to expand to high-grade glioma as these cells 
proliferate expeditiously and overtake the non-p53 mutant cells population.23 There 
is strong evidence that shows nuclear localisation is correlated with long-term 
survival rates since nuclear p53 is required for apoptotic induction limiting tumour 
expansion. Long-term survivors (>3 years) have tumours with high levels of 
nuclear p53 compared to short-terms survivors, and this is not caused by 
differences in the mutation rate.24 Gene therapy experiments targeting 
glioblastoma and cancer stem cells with nanoparticle delivery of the p53 gene 
have showed induction of apoptosis after standard chemotherapy and improved 
survival in mouse models. This has not yet been tested in clinical trials.25 
Multiple simultaneous tumour suppressor mutations are common in glioblastoma 
progression. Studies have found that primary tumours expressing mutant p53 had 
associated PTEN mutations or deletions in the majority of glioblastoma samples. 
PTEN is a phosphatase tumour suppressor that is mutated in glioblastomas and is 
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considered as prognostic indicator in patients >45 years old.26 Under normal 
conditions, PTEN regulates cellular homeostasis by preventing cell cycle entry and 
maintaining the neural stem cell population. PTEN null mutants are sensitive to 
growth factors and more prone to proliferation than wild-type neural stem cells.27 
Bryostatin, an inhibitor of protein kinase C (PKC) downstream to PTEN, supressed 
the growth of tumours in non-sense PTEN background, suggesting that PTEN 
non-sense mutations can be indirectly targeted for glioblastoma therapy.28 
 
1.4 Role of angiogenesis and invasion in glioma 
Glioblastoma growth is closely linked with the formation of new blood vessels and 
one of the most serious clinical obstacles are the development of vasogenic brain 
oedema and intracranial pressure (ICP) due to blood brain barrier (BBB) 
leakage.29 Glioblastomas are the most vascularised tumours in humans and the 
grade of malignancy is directly related to endothelial proliferation. The vessel 
formation is highly defective with abnormal morphology and function. Histological 
samples show vessels with heterogeneous distribution, irregular basal lamina, 
variable diameters and permeability.30-32 One of the widely accepted arguments to 
explain disorganised vessel formation in GBM is the proportionately high amount 
of vascular epidermal growth factor (VEGF) present in the tumours.33 VEGF is one 
of most studied molecules in angiogenesis and acts as a hypoxia-inducible factor; 
the areas expressing highest levels of VEGF are also the regions of necrotic core. 
VEGF overexpression in GBM is responsible for the crosstalk between the tumour 
and the endothelial cells in order to promote angiogenesis.34  
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Besides strong angiogenic potential of glioblastomas, they are also highly 
infiltrative and diffuse, with different degrees of invasiveness.35  The tumours can 
penetrate the brain by colonising the entire organ and sending their invasive 
tumour cells far beyond the main tumour mass.  The invasion of gliomas into the 
brain parenchyma is characterised by preferential migration along white matter 
tracts around neurons, blood vessels and spread in subpial region. Despite the 
considerable invasive potential of gliomas, they seldom leave the nervous tissue to 
metastasise into other organs, remaining restricted in the skull, with only little 
evidence of systemic spread.12 The invasive properties of malignant brain tumours 
are of great clinical significance, as they are actively responsible for poor 
prognosis in patients. This invasive and infiltrative property of glioma tumours is 
primarily caused by the perturbation of factors and enzymes present in the 
extracellular matrix (ECM) of the brain. The ECM of the brain is dysregulated 
primarily due to the disruption of the blood-brain barrier which is the ‘first line of 
defence’ against impairment of central nervous system function.36 
 
1.5 Pathophysiological barriers of glioblastoma  
Solid tumours are commonly treated with surgical resection in conjunction with 
radiotherapy and systemic chemotherapeutic agents. A vast majority of 
chemotherapeutic agents used within the clinic are alkylating agents, 
anthracyclines and antimetabolites broadly termed as cytotoxic chemotherapy. 
These agents can be used at different stages of cancer progression and are 
generally directed at targeting nucleic acid replication or synthesis, many of which 
have been approved for clinical use since the 1960s.37, 38 Mechanistically these 
agents do not exclusively target cancer cells, and will also attack any rapidly 
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proliferating cell type such as those in the digestive tract and bone marrow; 
resulting in systemic toxicity. A prerequisite for the effective delivery of any cancer 
drug is that it reaches the tumour-site in therapeutic concentrations. This is difficult 
to achieve in most solid tumours because of pathological factors such as abnormal 
tumour vasculature, intra-tumoural pressure gradients and variable hypoxia.37, 38 In 
glioma, the situation is further complicated by the presence of the blood-brain 
barrier (BBB), which acts as a physiological and physical obstacle for delivery of 
drugs to the central nervous system.36 
1.5.1 The healthy blood-brain barrier 
The human brain is comprised of over 100 billion capillaries with a total length of 
400 miles, a median inter-capillary distance of about 50 µm and a total surface 
area of 20 m2, making it the most perfused organ in the body.39 The normal 
function of the vasculature in the central nervous system (CNS) is essential not 
only for the adequate supply of oxygen and nutrients, but also to protect the brain 
from neurotoxic compounds. This protective physiologic blood barrier that strictly 
regulates the entry of molecules to the brain is known as the blood brain barrier 
(BBB). The BBB refers to both passive and active mechanisms used by the brain 
endothelium to regulate access to the brain. The BBB is a cellular barrier that 
controls the ionic composition for efficient synaptic signalling function, prohibits 
macromolecules and unwanted cells from entering the brain as well as insulates 
the CNS from neurotoxic molecules and ensures brain nutrition.39-41 This barrier is 
modified in the context of glioma as evidenced by the penetration of gadolinium 
(Gd) through the BBB on magnetic resonance imaging (MRI) of patients with 
glioblastoma.42, 43 Gd enhancement increases concomitantly with the WHO grade 
of astrocytomas.44 Although BBB dysregulation is observed in many gliomas, the 
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disruption is often heterogeneous and the vasculature remains intact in regions 
where infiltrating cells are found, emphasising the need for tumour-selective 
methods to bypass the BBB. This section summarises the normal functioning of 
the BBB and the impact of brain tumours on BBB integrity. 
1.5.1.1 Astrocytes and pericytes 
The BBB is essentially formed by the endothelial cells that exert their barrier 
properties by the neurovascular unit comprising of astrocytes, pericytes and 
perivascular macrophages (Figure I.1).45 Astrocytic endfeet provide cellular 
connection to neurons and cover the basal lamina of the brain capillaries. 
Astrocytes play an important role in maintaining the barrier properties of the 
endothelium.46 Cerebral pericytes are additional components of the BBB, 
occupying the perivascular space. Pericytes cover the endothelium, provide 
structural integrity of the BBB and contribute to the induction of barrier properties 
during embryogenesis.47, 48 There is growing evidence that astrocytes and 
pericytes secrete soluble developmental signals like retinoic acid, sonic hedgehog 
and Wnt that control the initiation of barrier properties.49-52 Endothelial cells that 
form capillary-like structures in the presence of pericytes demonstrate apoptotic 
resistance, indicating a stabilising function of pericytes in angiogenesis.53 Studies 
have also demonstrated the pericyte role in vascular stability and repair, and in 
modulation of astrocyte function.54  
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Figure I.1: A healthy blood-brain barrier (BBB): In the healthy brain, astrocytic endfeet 
surround blood vessels. Vascular endothelial cells form the BBB through tight junctions, 
trapping cells and blood serum components in the vascular lumen (Adapted from55, 56). 
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1.5.1.2 Endothelial cells and tight junctions 
Brain endothelial cells are closely connected by intercellular tight junctions. Except 
for gaseous or very small molecules such as carbon dioxide and water, the tight 
junctions of the BBB are highly effective at prohibiting the exchange or influx of 
various toxins and regulating the fluctuations in ionic concentrations.45 One 
importance feature of the brain endothelial cells is the presence of specific 
transport systems that regulate the ingress of compounds necessary for brain 
metabolism, and principal among these are ATP-binding cassette (ABC) 
transporters.57, 58  A range of intracellular and extracellular enzymes also provide 
further resistance by metabolising molecules or substances ranging from peptides 
to neurotoxic compounds. Tight junctions are the links between capillary 
endothelial cells and are more complex in the brain than those found in peripheral 
tissues, and they serve to prevent paracellular diffusion. Tight junction affiliated 
proteins include claudin-1, claudin-5, occludin and junctional adhesion molecules 
(JAMs).59, 60 Occludins and claudin-1 are linked via zona occludens (ZO) protein 
complexes to tight junction proteins (eg. Jacop, 7H6, Cingulin) that are capable of 
binding to the actin/myosin cytoskeletal systems, resulting in overall modification 
of tight junction properties and functions. The BBB’s restriction of small ions is 
mainly contributed by claudin-3 and claudin-5 proteins of tight junctions. As a 
result of the integral structure of the endothelial cell layer and the lack of fenestrae, 
the BBB actively controls the transendothelial passage of soluble particles from 
the blood to the brain and vice versa.39 
1.5.1.3 Extracellular matrix 
The quality of BBB is directly related to the normal functioning of the microvascular 
endothelial tight junctions of the brain. Although it is well known that the 
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organisation and composition of the tight junctions depend on the brain 
microenvironment, it is still unknown which microenvironment components are 
directly associated with the maintenance of the tight junctions.60 The brain 
microenvironment components include the basal lamina and the “second line of 
defence” consisting of astrocytes, pericytes and microglia. The astrocytic endfeet 
membrane is the main residence of the K+ channel Kir4.1, which is adjacent to the 
water channel protein aquaporin-4 (AQP4).61 Aquaporins are a family of integral 
membrane transport proteins that regulate water efflux across cell membranes in 
response to osmotic pressure gradients.62 AQP4 is the molecular equivalent of the 
orthogonal array of particles (OAPs) which accumulates at the astroglial endfeet 
membranes. The accumulation of OAPs at this membrane domain is probably due 
to the presence of extracellular matrix (ECM) compounds such as fibronectin, 
laminins, collagens, and the heparansulphate proteoglycan (HSPG) agrin. 
Aquaporins participate in the buffering process of the brain extracellular space: 
synaptic activity induces the increase in the concentration of extracellular K+ ions 
which are taken up by astrocytes. The uptake of K+ causes the osmotic entry of 
water through the water channels of AQP4. To avoid swelling of astrocytes the 
water is released into the extracellular spaces comprising of regions around the 
vessels and the surface of the brain. Therefore, the directed water flow is essential 
for brain physiology and is thought to be closely regulated by this BBB-ECM 
complex. There are at least two components of the BBB-ECM that have been 
identified to be expressed during BBB maturation, suggesting a specific role in the 
BBB induction: agrin and laminin.63, 64 The HSPG agrin is present in the 
subendothelial basal lamina and is known to maintain the integrity of the BBB.64 
Laminin is situated in the basal lamina of the CNS vessels and demonstrates 
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elevated activity at the onset of BBB maturation.65 The normal functioning of agrin 
and laminin on protein level is closely connected to its degradation by the matrix 
metalloproteases (MMPs).29 
1.5.1.4 P-Glycoprotein 
The integrity and polarity of the BBB is also maintained through an efflux pump 
known as permeability-glycoprotein (P-gp), also known as multidrug resistance 
protein 1 (MDR1). This transmembrane protein belongs to the ABC transporter 
family and is encoded by the ABC1 or MDR1 gene.66 The P-gp is localised on the 
apical membrane that regulates transport in a single direction.  The normal 
physiological role of P-gp is to protect the body from synthetic compounds by 
effluxing cytotoxic molecules into luminal spaces for elimination.67, 68  
1.5.2 Tumour-associated changes in the BBB 
The lost barrier function can be detected through MRI using a contrast medium 
(CM) application. The standard CM used in MRI for GBM diagnosis is gadolinium 
(Gd), which in normal conditions is not able to cross the intact BBB. In case of 
GBM, Gd can diffuse into the tissues of the compromised or disrupted barrier and 
characteristic ring enhancing lesions are seen.43 
In low grade astrocytomas (grade I and II) there is no detectable disruption of the 
BBB; tumour vasculature looks mostly like normal brain vessels and the tumour 
mass is sustained by normal glial cells. As glioma progresses and becomes 
increasingly aggressive, the endothelial cells are separated from the normal vessel 
structure and form new tumour associated angiogenic spots. As these cells 
migrate, they disrupt normal brain vasculature to arrive at the tumour site (Figure 
I.2). In GBM, the BBB alterations involve the formation of blood vessel 
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fenestrations and tight junction disruption. In addition, the perivascular space is 
increased and the basal lamina is altered.69, 70 
1.5.2.1 Tight junctions in glioblastoma 
In human glioblastoma, it was found that a key component of BBB tight junctions, 
claudin-3, is absent. Claudin-3 is a promotor of glioblastoma vessel leakage.71 In 
addition, the loss of claudin-1 in tumour microvessels, downregulation of occludin 
and claudin-5 in hyperplastic vasculature has also been implicated. These 
alterations result in a phenotypical change in BBB function due to hyperpermeable 
endothelial cells and leaky tight junctions.72 
1.5.2.2 Aquaporins in glioblastoma 
The altered aquaporin (AQP) expression in the astrocytic endfeet of the BBB has 
been strongly correlated to glioma progression. AQP4 redistribution is responsible 
for the loss of agrin in cerebral capillary basal laminae in glioblastoma. It has been 
reported that the distribution of AQP4 is shifted from the glial membrane to the 
entire surface of glioma cells and there is eventual loss of OAP arrangement in 
glioblastoma.73  
1.5.2.3 Disruption of P-Glycoprotein activity 
The overexpression of P-gp is also a common feature to many multidrug resistant 
tumours. P-gp expression levels in glioma were correlated with multi-drug 
resistance and glioma grade.74, 75 In relation to the BBB, P-gp is disrupted at the 
necrotic region of glioblastoma but preserved at the tumour periphery. These 
residual border cells with an intact barrier can limit drug uptake and the tumour 
often relapse into larger and more aggressive tumours.76, 77 
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1.5.2.4 Dysregulation of brain ECM 
Besides vasculature disruption, the ECM is also modulated by glioma tumours 
(Figure I.2). It was demonstrated that agrin, an essential component of the basal 
lamina of BBB, is absent if the tight junction proteins are downregulated.53 The 
loss of agrin is a parallel event with the redistribution of the AQP4 over the surface 
of glioma cells. The loss of agrin and other ECM components on protein level is 
strongly linked to its degradation by matrix metalloproteases (MMPs).29 These 
proteases are thought to be involved in BBB-impairment in the following ways: (1) 
Shedding of growth factors such as VEGF and fibroblast growth factors which 
have been stored in the ECM vessel contributing to the angiogenic process; (2) 
ECM remodelling via stimulation of integrin receptors by binding to the Arg-Gly-
Asp (RDG) binding domains. In response, integrins are further upregulated in 
glioma endothelial cells causing induction of cell migration, invasion and 
angiogenesis;78 (3) The cleavage of the basal lamina which disrupts the ECM 
component functionalities (including agrin) which are important for the BBB 
integrity.79 
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Figure I.2: Disrupted BBB in glioma: Glioma cells migrate along blood vessels, leading 
to degradation of the ECM and breakdown of basement membrane; displacement of 
astrocytic feet and complete loss of tight junctions leading to the extravasation of serum 
components into the neural parenchyma (Adapted from 55, 56). 
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1.5.3 Disrupted BBB – A major obstacle to efficient drug delivery 
The high metabolic requirement of high-grade glioma creates hypoxic areas that 
trigger increased expression of VEGF and angiogenesis, leading to the formation 
of a dysfunctional BBB and abnormal vessels.80, 81 Moreover, the invasive potential 
of glioblastoma causes widespread proliferation of tumour cells outside regions of 
the disrupted BBB and inside areas of normal brain tissues where the function of 
the barrier is still intact. Essentially, this includes the areas that do not show Gd 
enhancement on MRI. As a result, the BBB dysfunction in both low-grade and 
high-grade glioma forms a major obstacle in brain tumour therapy by preventing 
the delivery of therapeutic agents selectively to the tumour site in sufficient 
amounts.82, 83  
The disrupted BBB is formed by brain tumour capillaries and consists of a barrier 
that is variably distinct from the normal BBB. Brain tumour capillaries demonstrate 
overexpression of receptors, growth factors and proteases that mediate ligand 
dependent drug delivery, which can be exploited as a strategy to selectively 
enhance drug delivery to tumour tissues.84, 85 Drug efflux transporters expressed at 
the normal BBB are also present in endothelial cells at the tumour BBB which can 
significantly impede drug delivery to the brain. In addition, ABC transporters 
present in tumour cells may confer chemoresistance to glioblastomas, thus 
forming another hurdle towards effective treatment.86 
 
1.6 Current standard of care for glioblastoma 
The treatment of glioblastoma currently consists of maximal surgical resection with 
combined radiotherapy and chemotherapy with temozolomide. The combination of 
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surgery and radiotherapy has been shown to increase patient survival upto 12 
months. Depending on malignancy, the responsiveness of the tumour to 
radiotherapy varies. Typically, as previously stated, the glioma tumour recurs at 
the original tumour site in 90% of the patients within 1 year.87-89  
1.6.1 Temozolomide 
The addition of temozolomide (TMZ) to radiotherapy improves both the overall 
survival and progression-free survival by 2-3 months. TMZ is an orally active DNA 
alkylating agent and was approved by the US Food and Drug Administration (FDA) 
in 2005 for the treatment of glioblastoma (Figure I.3). TMZ is an imidazotetrazine 
derivative of dacarbazine that possesses strong antitumour activity against high 
grade glioma. It also has the ability to bypass the BBB by increasing the transport 
of P-glycoprotein across the microvascular endothelial cells.87, 89  
 
Figure I.3: Chemical structure of temozolomide, an alkylating antineoplastic agent 
TMZ acts as a prodrug and is irreversibly converted into the linear triazine 5-(3-
methyltriazel-1-yl) imidazole-4-carboxamide (MTIC), the antitumour effector. 
However, the tumour cells are able to reverse damage to DNA and subsequently 
become resistance to TMZ, by expressing O6-alkylguanine DNA-alkyltransferase 
(AGT) enzyme encoded by an excision repair enzyme O6-methylguanine DNA-
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methyltransferase (MGMT).90-92 Furthermore, the median survival of patients with 
radiotherapy and TMZ is only limited to 3 months with high rate of glioblastoma 
recurrence. Another disadvantage to TMZ use is the risk of DNA damage in 
healthy cells and lack of selectivity for glioblastoma cells, leading to systemic 
toxicities such as bone marrow suppression, nausea and vomiting. No doubt the 
improvement and success of TMZ regime is significant compared to radiotherapy 
alone, but remains unsatisfactory and inefficacious in comparison with the 
treatment of other tumour types.93, 94 
1.6.2 Gliadel wafers 
In order to circumvent the therapeutic difficulties of BBB, the insertion of Gliadel 
wafers into the tumour resection cavity for the treatment of recurrent malignant 
glioma has been extensively reported and is currently a controversial topic among 
the neurosurgeons. Gliadel wafer is a biodegradable polymer infused with 3.85% 
alkylating agent carmustine (1,3-bis[2-chloroethyl]-1-nitrosourea) (BCNU) and has 
been approved by the US Food and Drug Administration (FDA) for the treatment of 
brain tumours.95-100 The mechanism of action of BCNU is mediated by its 
chloroethyl moieties, which can alkylate the reactive sites on nucleoproteins and 
interfere with DNA repair and synthesis. BCNU has a very short life, with the 
parent molecule not detectable after 5 minutes and its metabolites can rapidly 
enter the cerebrospinal fluid (CSF). However, the penetration of BCNU inside the 
brain tissue was observed for a very short distance.  The implant of BCNU 
eliminates the need for the encapsulated drug to cross the BBB and allows for the 
sustained release of carmustine in the extracellular fluid of the brain.95, 101-103 
These wafers could supply a controlled dose of 7.7 mg BCNU for 5 days and has 
been reported to extend median survival of patients by 2-4 months with newly 
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diagnosed malignant glioma, resulting in median survival of 13 months after 
tumour resection.  BCNU wafer in combination with TMZ can extend the overall 
survival to 14.6 months.89, 96-98, 100, 101, 104 Since postoperative treatment with 
radiotherapy plus concomitant TMZ does not deliver chemotherapeutic agent to 
the debulked tumour during the 3-week period between surgery and radiotherapy, 
the BCNU wafer provides a theoretical ‘therapeutic bridge’ allowing continuous 
adjuvant therapy immediately after tumour resection. However, it remains to be 
known whether this therapeutic bridge is associated with clinical benefit.87, 89 
It has been believed and emphasised that local chemotherapy with BCNU wafers 
offer a survival benefit compared to radiotherapy alone and is well tolerated in 
patients with glioblastoma. Contradictory results showed that BCNU wafers 
provided no significant clinical outcome relative to standard treatment. It was also 
suggested that neurotoxicity after Gliadel use was significantly higher in patients. 
Several complications have been associated with the implantation of BCNU wafers 
including cerebral oedema, convulsions, hydrocephalus, complications in wound 
healing and infection of the brain tissue.96, 100, 101 For instance, intracranial 
hypertension was present in Gliadel implanted patients compared to placebo 
patients (9.2% vs 1.7%). This was observed at a late stage; typically at the time of 
tumour recurrence. CSF leakage was also found to be more common in Gliadel 
implanted patients. The efficacy of BCNU wafers is limited due to lack of tumour 
selective targeting and adverse side effects. Therefore, additional research 
strategies are critical for successful glioma therapy.95, 101 
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1.7 Novel therapies in clinical trials 
Although current therapy regimes have improved over the past two decades, 
overall patient survival has not increased to the level obtained for other solid 
tumours. New therapies with novel empirical properties are currently in clinical 
trials (Table I.1). These therapies are designed for use in combination with current 
standard chemotherapeutics as a means to improve therapeutic efficacy and 
range from personalised medicine approaches targeting the tumour tissues to the 
disruption of tumour microenvironment.105 
1.7.1 Monoclonal antibodies 
One of the new classes of therapeutic agents is based on the use of monoclonal 
antibodies that identify cell surface receptors and ligands, to impede receptor 
signalling through disruption of receptor-ligand binding and downstream receptor 
activation. FDA approved Avastin (bevacizumab) is the mainstream antibody 
against VEGF. Avastin aims to block the response to VEGF in GBM and prevent 
the promotion of neoangiogenesis of the tumour.106 Avastin is not specific to a 
tumour type as it does not target tumour-specific antigens or receptors and there 
are associated side effects such as deep vein thrombosis, caused by broad 
blockage of VEGF signalling.107  
In contrast to the agnostic use of Avastin, AMG595 is currently being tested in 
phase I clinical trials. AMG595 is a non-cleavable immunoconjugate linker that 
specifically targets EGFRvIII. Once EGFRvIII is engaged by AMG595, receptor 
mediated internalisation occurs, thus targeting cytotoxic agent mertansine (DM1) 
to tumour cells. One potential limitation of AMG595 is that EGFR is mutated in 
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roughly 40% of GBM cases and of these mutated cases, 65% have EGFRvIII 
mutations, thus leaving only a limited percentage of total GBM cases that can 
potentially benefit from this approach.108  
1.7.2 Innate immunotherapy 
Some research groups are also attempting to reengineer the patient innate 
immune system in order to combat their own GBM tumours. DCVax-L is currently 
in phase III clinical trial for newly diagnosed GBM cases. This treatment uses the 
tumour cells and normal dendritic cells to improve the patient innate immune 
response to recognise GBM tumour for elimination. The clinical trials with DCVax-
L in patients have showed an increase in median life expectancy by 3 years with 
lesser side effects than standard treatment.109, 110 
1.7.3 Oncolytic viruses 
Oncolytic viruses have also been tested for their potential use against GBM. 
Oncolytic virus is a virus that selectively infects and kills cancer cells. These 
viruses lack the capability of replication except in specific cell population such as 
tumour. Once the selected viruses reach the tumour, they undergo lytic expansion, 
thus destroying the tumour population and become replicative incompetent once 
the tumour is eradicated. GBM adenovirus trials using DNX-2401 are currently 
underway. This adenovirus is selective against the deregulated retinoblastoma 
protein in GBM.111 The presence of RGD-4C peptide linker gives the virus an 
additional affinity for integrins. The mechanism of DNX-2401 remains unclear but it 
was found to promote cell death through autophagic activity and reduce the size of 
the tumour in mouse xenograft models.112 
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Table I.1: Treatment currently in clinical trials for their potential application in GBM 
(Adapted from105). As of January 2016 TRC105+Bevacizumab is in Phase-II clinical trials. 
In June 2016, DNX2401+pembrolizumab (a checkpoint inhibitor) entered Phase-II clinical 
trials for recurrent glioblastoma. 
 
 
 
 
 
 
 
 
 
Treatment Intervention Molecular target Clinical Phase
TRC105 + Bevacizumab (Avastin) Antibody + Drug Engoglin/VEGF I
Amgen386 Antibody Angiopoietin-1 and -2 I
AMG595 Antibody drug conjugate EGFRvIII I
DNX2401 and temozolomide Virus + TMZ - I
Axitinib (Inlyta) + Radiotherapy Drug + radiation
Tyrosine kinase receptors 
(multiple)
II
Bevacizumab (Avastin) + TPI 287 Drug VEGF/Tubulin II
AR-67 Drug Topoisomerase 1 II
PD 0332991 (Palbociclib) Drug CDK 4/6 II
Aldoxorubicin Drug DNA II
DC-Vax L Immunotherapy - III
Rindopepimut Immunotherapy EGFRvIII III
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While therapeutic antibodies, viruses and innate immunotherapies carry a great 
potential due to inherent binding specificity, there are specific issues in the case of 
GBM (and other brain tumours). Any drug administered systemically would require 
selective transport through the BBB, which normally impedes access to the vast 
majority of drugs.113 
1.8 Modification of existing drugs 
Chemical modification of standard chemotherapeutics as an approach to deliver 
drugs across the BBB has also been studied with varying levels of success (Table 
I.2). These modifications are mostly nanoparticle-based and they refer to the 
process of making existing drugs smaller in size, more perfectly charged (low 
hydrogen bonding capabilities) and more lipid soluble, in order to cross the BBB. 
Nanosystems are colloidal carriers that consist of liposomes and polymeric 
nanoparticles. To minimise the interaction of nanosystems with the 
reticuloendothelial systems (RES), polyethylene glycol (PEG) surface 
modifications on the surface of nanosystems have been widely used as an 
approach. If the modifications are specific and suitable for BBB transport, then 
these colloidal systems encapsulated with drug molecules could improve targeting 
to brain tumours as drug carriers. Further studies are ongoing towards selective 
passage of nanosystems across the BBB.114-117  
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Table I.2: Reported modifications of few important chemotherapeutics (Adapted from 117). 
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Table I.2: Continued 
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1.9 Invasive potential of glioblastoma and the role of proteases 
The modern era of brain tumour therapy is characterised by target specific drugs 
with efficient delivery strategies. However, the standard of care for GBM has not 
improved the overall patient survival and the prognosis remains poor. The annual 
incidence of glioblastoma is 5 in 100,000 individuals and from the time of 
diagnosis, the average survival of patients is 17 weeks without treatment and 30 
weeks with a combination of surgery and radiotherapy. Although there are severe 
side effects to the use of chemotherapy, the mean survival can be increased to 15 
months after diagnosis.87-89 However, the current treatment regime is ultimately 
inadequate and ineffective for the treatment of glioblastoma. The reasons for poor 
prognosis in patients with GBM are due to the following therapeutic limitations:  the 
presence of blood-brain barrier restricting the amount of systemic drug reaching 
the tumour-site; the lack of tumour-selective treatment options; intrinsic resistance 
of tumour cell to chemotherapeutic drugs;  severe neurotoxicity; restricted 
localisation and diffused infiltration of individual tumour cells into the surrounding 
normal brain tissue that prevents complete surgical tumour resection; and 
subsequent to this inevitable recurrence of glioblastoma. From a therapeutic 
standpoint, there is a critical need to understand the clinical hallmarks of GBM and 
their evolution from early stages of glioma.71, 105, 118-121  
Recent efforts to understand GBM biology has led to the discovery of molecular 
gene signatures.122, 123 Mutations in the p53 genes, genes regulating 
retinoblastoma (RB) protein function, EGFR signalling and MGMT promotor has 
also been identified to correlate with poor overall survival.124 Beyond these 
abundant genetic and epigenetic alterations, there is another crucial characteristic 
preventing complete eradication GBM, which is infiltrative (or invasive) growth 
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pattern. This tumour event complicates complete surgical removal causing tumour 
regrowth and further invasion of surviving tumour in close proximity to the 
resection area.125, 126   
The invasive capability of brain tumour cells has a clinical role in the 
ineffectiveness of current treatments, because the remaining tumour cells infiltrate 
into the surrounding brain tissue and lead to inevitable tumour recurrence. The 
invasion process includes the increased secretion and expression of several 
extracellular proteases such as serine, cysteine and metalloproteases, to further 
degrade the extracellular matrix (ECM) components selectively.125, 127 These 
proteases have established roles in maintaining the microenvironment that 
supports tumour cell survival. The ECM components of the tissue is involved in 
dynamic regulation of cellular functions during normal and diseased remodelling 
process such as tissue repair, embryogenic development, inflammation, and 
tumour invasion and metastasis.128-130 The invasion of brain tumour cells into the 
brain parenchyma is a biologically distinct process from invasion of tumour cells 
into other organ systems, because the ECM in the brain differs from that of most 
organs. Due to confinement of the brain into the skull and compact cellular 
assembly; the ECM is condensed to 20% of the tissue volume and the spread of 
tumour is restricted. Brain ECM is situated in intercellular spaces between glial 
and neuronal cells where it can be viewed as netlike feature on the neuronal 
surface and is therefore also known as perineuronal net (PNN).36, 128 This ECM 
network is composed of proteoglycans of the lectican family and 
glycosaminoglycans. Advanced stages of glioblastoma has been known to 
express the protein components of lectican family which are usually absent from 
normal brain. The overexpression of lectican proteins is one of the main reasons 
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for the dissemination of gliomas along myelinated white fibre tracts resulting in 
distant invasion of tumour cells through the corpus callosum. The lectican protein 
members are endogenously cleaved for activation by various extracellular 
proteases such as serine proteases, cathepsins and matrix metalloproteases 
(MMPs).127, 128 The extracellular proteases play an important role in degrading the 
ECM components, enhancing tumour invasion, affecting tumour cell behaviour, 
promoting tumour growth and proteolytically activating growth factors for cancer 
progression. Among these proteases, MMPs have been identified in the 
degradation of all the ECM macromolecules in the brain. They are overexpressed 
in many types of cancer including malignant brain tumours and significant 
research has focused on understanding this family of proteases in recent years.125, 
127, 129, 130   
1.10 Matrix metalloproteases (MMPs) 
Matrix metalloproteases (MMPs) are zinc dependent endoproteases, comprising of 
24 human genes divided into 5 main groups: collagenases, gelatinases, 
stromelysins, matrilysins and membrane-type MMPs (MT-MMPs) (Table I.3). They 
are a family of highly homologous endoproteases, capable of degrading most 
components of the basement membrane and ECM.131 All the MMPs except MT-
MMPs (cell membrane-bound) are secreted by the cell. MT-MMPs are activated 
intracellularly in the Golgi network by pro-protein convertases called furin and are 
therefore, already active at the extracellular surface. Secreted MMPs are mainly 
activated by MT1-MMP and plasmins, respectively.132 Cell surface associated 
plasmin, produced by the activity of receptor-bound urokinase-like plasminogen 
activator (uPA), is a key initiator of MMP activation, particularly stromelysin-1 
(MMP-3) and gelatinase B (MMP-9). Active MT1-MMP acts as a secondary 
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activator, cleaving gelatinase A (MMP-2) to potentiate downstream self-cleavage 
reactions (Figure I.4).131, 132  
 
 
Figure I.4: MMP activation cascades. Cleavage by activator proteases is required for 
the conversion of inactive MMP zymogens into active MMP enzyme. Cascades involving 
upstream and downstream MMPs form a complex network in which TIMP-mediated 
checkpoints are present. Adapted from 131, 132 
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MMPs typically have N-terminal signal peptide (pre-domain) to bind the enzyme to 
the endoplasmic reticulum and transport it out of the cell. Next to the pre-domain, 
there is a conserved pro-domain which contains a zinc-binding sequence. At the 
C-terminus end, most MMPs possess a hemopexin-like domain that regulates 
substrate recognition and is linked to the catalytic domain by a flexible hinge 
region.133 Although MMPs are classified based on their substrate selectivity (that 
is, the substrates for which they show greater hydrolysis as a unit of time), it has 
been suggested that MMP catalytic domains share considerable sequence 
homology (55-65%) with a common residue motif, HExGHxxGxxH, consisting of 
three histidine residues that coordinate the catalytic Zn2+ ion. This sequence 
similarity may mean that certain MMPs can support the function of others during 
pathological processes such as tumour-related proteolysis.133, 134 
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Table I.3: Classification of human MMPs, adapted from 135, 136 
 
 
 
Structural class MMP designation Common names (s)
Notable 
structural 
feature(s)
Simple Hemopexin
Domain
1 Interstitial collagenase, Collagenase-1
Standard signal 
peptide, 
propeptide
domain, catalytic 
domain, hinge 
region and C-
terminal 
hemopexin
domain
3 Stromelysin-1
8 Neutrophil collagenase, Collagenase-2
10 Stromelysin-2
12 Macrophage elastase
13 Collagenase-3
18 Collagenase-4
19 Rheumatoid arthritis-associated MMP
20 Enamelysin
22 MMP-23B
27
Gelatin-Binding
2
72 kDa Type IV gelatinase, Gelatinase 
A Fibronectin type ΙΙ 
repeats
9
92 kDa Type IV gelatinase, Gelatinase
B
Minimal Domain
7 Matrilysin No C-terminal 
hemopexin 
domain; no hinge 
region
26 Endometase, matrilyson-2
Furin-Activated and 
Secreted
11 Stromelysin-3 Furin recognition 
sites28 Epilysin
Vitronectin-like Insert 21 MMP-23A
Type I 
Transmembrane
14 MT1-MMP Transmembrane 
domain; 
cytoplasmic tail; 
MT loop
15 MT2-MMP
16 MT3-MMP
24 MT4-MMP
Type II 
Transmembrane
23 Cystein array MMP
No C-terminal 
hemopexin 
domain; no hinge 
region
GPI-linked
17 MT5-MMP Transmembrane 
domain; 
cytoplasmic tail
25 MT6-MMP
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1.11 Regulation of MMPs 
MMP activity is regulated both at the transcriptional and post-transcriptional levels 
and is controlled at the protein level by pro-enzyme activators and inhibitors. The 
expression of MMPs is stimulated by growth factors, cytokines, tumour promoters, 
cell-cell interactions, oncogenic transformation and physical stress.137, 138 The 
transcriptional binding sites involved in the regulation of MMP genes are: the 
polyomavirus enhancer-A binding protein-3 (PEA3) site, the activator protein (AP) 
-1 and -2 sites, the signal transducers and activators of transcription (STAT) site 
and the nuclear factor kappa B (NF-κB) site.139 Interestingly, co-regulated MMP 
genes share several transcriptional binding sites in their promotor sequences 
whilst functionally regulated MMPs such as gelatinases (MMP-2 and MMP-9) or 
collagenases (MMP-1 and MMP-8), differ in the composition of cis-elements 
present in their promotor sequences.140  
Secreted MMP zymogens are activated extracellularly, in a two-step process: an 
initial cleavage by an activator protease to destabilise the protein, followed by a 
final cleavage, generally by another MMP, releasing the N-terminal prodomain to 
produce a mature enzyme.141 In contrast, the membrane bound MT-MMP 
zymogens are activated intracellularly and produced on the cell surface in a 
proteolytically active state. Tissue inhibitors of metalloproteases (TIMPs) are 
endogenous tissue inhibitors of MMPs and are consequently important regulators 
of tissue remodelling, ECM turnover and cell behaviour.135 The balance between 
MMPs and the TIMPs is strictly regulated under physiological conditions and is 
critical in maintaining the net proteolytic activity. Malignant tumours have the ability 
to disrupt this balance and to produce uncontrolled proteolytic activity that 
accompanies tumour growth, invasion and metastasis. In malignancy, virtually all 
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MMPs are proteolytically active in the extracellular tumour microenvironment, 
incongruent from the lack of activity in normal tissues, but some are expressed at 
higher concentrations than others.142  
1.12 MMPs and glioma 
During development of carcinogenesis, tumour cells interact with the tumour 
microenvironment involving the ECM, growth factors and cytokines.143 Critical 
enzymes in this process are MMPs because they contribute to the formation of 
tumour microenvironment by degrading most components of the ECM and the 
basement membrane, thus promoting tumour growth, migration, invasion, 
metastasis and angiogenesis.144 Interactions of tumour cells with the basement 
membrane are thought to be the crucial event that initiates the metastatic 
signalling cascade. Several MMPs have been associated with tumour cell invasion 
as evidenced by the correlation between local tissue infiltration and increased 
MMP levels.135, 143, 144 For example, MMP-7 deficient mice showed reduction in 
intestinal tumourigenesis.127, 145 Tumour colonisation in the lungs was found to be 
decreased in the mice lacking MMP-2 or MMP-9.146, 147 During cancer progression, 
increased shedding of the epidermal growth factor receptor (EGFR) ligands was 
observed with the increased expression of MMP-3 and MMP-7.148, 149 MMPs are 
also associated with tumour angiogenesis and are required for ‘angiogenic switch’ 
that occurs during neovascularisation of tumours.150 MMP-9 participates in 
angiogenic switch because it increases the production of vascular endothelial 
growth factor (VEGF), which is an important mediator of tumour vasculature.150 
MMPs possess the ability to cleave a wide range of non-matrix substrates such as 
Fas ligand (involved in apoptosis); integrin, cadherins and β-catenin (involved in 
cell dissociation); VEGF and TNF-α (involved in cell-cell communication); and 
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TGF-β and FGF (involved in cell division).143, 151 In addition to MMP-2 and MMP-9, 
MT-MMPs have also been suggested as being overexpressed in many forms of 
cancer and the cause of malignant transformations.152, 153 Extensive studies show 
frequent overexpression of several MMPs in many forms of human tumour, indeed 
MMP levels serve as both prognostic indicators of clinical outcome and markers of 
tumour progression in several human types including colon (MMP-1), non-small 
cell lung cancer (MMP-10 and MMP-13), breast (MMP-11), gastric (MMP-2 and 
MMP-9) and small-cell lung cancer (MMP-3, MMP-11 and MMP-14).154-158  Due to 
these associations in cancer development, MMPs represent a significant 
therapeutic target.  
Several MMPs are suggested to be overexpressed in malignant brain tumours, but 
due to the association of vascular basement membrane with the typical invasion 
route of glioma cells, a large number of studies have focused on illustrating the 
function of gelatinases, MMP-2 and MMP-9, as promoters of glioma cell 
invasion.127 The ECM-bound cytokine TGF-β is an important cytokine regulator of 
the MMP-system because it induces MMP expression and suppresses TIMP 
expression thereby promoting invasion of glioma cells. TGF- β is secreted by 
various proteases such as furin, calpain and plasmin.159 It has been reported that 
MMP-2 expression increases in glioma tumours compared to normal brain in vivo. 
In association with this, MT1-MMP, which is the endogenous activator of MMP-2, 
is also overexpressed in glioma tissues and the correlation was demonstrated with 
MMP-2 activation.128 In addition, the neural stem cells demonstrating extensive 
tumour migration expressed MMP-2 but not MMP-9, suggesting that MMP-2 is 
closely linked to invasive character.160-165 On the contrary, the inhibition of MMP-2 
protein levels decreased tumour growth and invasion of glioma cells in vitro. MMP-
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9 expression was detected at the sites of endothelial proliferation and at tumour 
margins, suggesting their prominent role in promoting tumour angiogenesis. Like 
MMP-2, MMP-9 expression has been shown to correlate with increasing 
malignancy of brain tumour cells.162, 164-169  
Very few studies have focused on the role of MMPs, other than gelatinases and 
MT-MMPs, in glioblastoma tumours. Although most of them are expressed by 
glioma cells, MMP-1, MMP-3 and MMP-12 were reported to be localised in glioma 
cells;130, 170, 171 and MMP-8 is expressed by neutrophils.172 MMP-1, MMP-7, MMP-
10 and MMP-19 were shown to cleave brevican, a proteoglycan of the lectican 
family of the brain ECM.173, 174 Brevican cleavage products have been shown to 
increase glioma cell dispersion, invasion and EGF receptor activation.175, 176 It has 
been suggested that the upregulation of extracellular proteases in glioma tumours 
is either associated with a compensatory mechanism or corresponding reduction 
of their endogenous inhibitors, enabling rampant or controlled proteolysis. In 
addition, divergent reports on the dual role of TIMPs in MMP inhibition and 
proMMP activation has either been linked to increased glioma invasion or 
increased survival time. A host of proteases found in glioblastoma have congruent 
functions but there are some with opposing functions.177-182 Therefore, increased 
knowledge is necessary to clarify the role of MMPs and TIMPs in glioma 
development; and to detect the most important ones appropriate for tumour-
selective targeting strategy.  
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1.13 Pharmacological targeting of MMPs for cancer therapy 
On the basis of their clear role in several steps of cancer progression, MMPs were 
the first proteases to be considered as targets for cancer due to well-known 
functions in ECM degradation.131 Over the past two decades significant drug 
discovery effort has focused on the inhibition of MMPs as a strategy to prevent 
tumour invasion and subsequent metastasis. As a result the pharmaceutical 
industry produced a number of well tolerated orally active MMP inhibitors (MMPIs), 
in an attempt to control the secretion, enzymatic activity and activation of MMPs. 
These agents were largely peptidomimetic zinc-binding hydroxamates, based 
upon MMP peptide substrate.131, 133, 183, 184 By the early 2000s, many MMPIs had 
reached clinical trials with the majority of them representing a broad spectrum due 
to structural similarities between MMPs and lack of selective binding within the 
MMP active sites. The first MMPI that had entered the clinical development was 
batimastat (BB-94), a broad spectrum hydroxamate derivative with poor water 
solubility.185 To circumvent the solubility problem, it was soon replaced by an orally 
administered analogue, marimastat. However, both batimastat and marimastat 
were associated with musculoskeletal side effects in patients and lack of efficacy 
at tolerated doses.186, 187 In addition, preclinical studies with both these inhibitors 
showed that they can interact with TIMP-2 for direct activation of proMMP-2 by 
MT1-MMP, thus increasing the net proteolysis.148, 188 The lack of efficacy could be 
attributed to the poor clinical trial design, in which inhibitors were administered to 
late stage cancer patients with extensively disseminated disease. In a similar trial 
to marimastat, a comparatively selective inhibitor of MMP-2, MMP3 and MMP-9; 
tanomastat, proved to be inefficacious than the standard treatment. Many such 
phase III clinical trials failed to reach the stage of increased survival probably as a 
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result of broad spectrum subtype specificity of MMPIs and insufficient knowledge 
about the complexity of the disease biology.131, 189, 190  
As opposed to monotherapy with MMPIs, clinical studies combining temozolomide 
with marimastat in glioblastoma showed significant increase in patient survival by 
5 months, compared to temozolomide alone. Although the combination therapy 
with MMPIs delayed the progression of glioblastoma, the treatment itself resulted 
in severe normal tissue toxicity. A better outcome is expected with more selective 
and less toxic inhibitors targeting mostly the tumour-associated proteases.191  
Altogether the failure of MMPIs could be attributed to two factors; i) naivity 
regarding the MMP family and subsequent lack of enzyme specificity, and ii) poor 
clinical trial design, in which inhibitors were administered to late stage cancer 
patients with extensively disseminated disease. The generation of MMP selective 
inhibitors still proves mostly elusive however, because of broad MMP structural 
similarity of their catalytic site, substrate complexity and identification of specific 
MMPs as anti-targets. The overlap of different MMPs in substrate specificity, 
functions and expression pattern along with a multitude of factors that regulate 
their activation, stimulation and inhibition also pose tremendous challenge in the 
design of selective, effective and safe MMPIs. It is also important to identify which 
MMPs are therapeutic targets (pro-tumourigenic) and which ones are anti-targets 
(anti-tumourigenic). Inhibiting the activity of anti-targets counterbalances the 
efficiency of target inhibition thus causing the failure of MMPIs.133, 141, 192-194  
These rationale hypotheses have now prompted re-evaluation of research 
strategies in understanding of protease specificity and identification of specific 
protease targets to improve therapeutic efficacy and reduce side effects. Several 
54 
 
 
additional strategies have been evaluated over recent years, including 
development of inhibitors exploiting the enzymatic transition state, inhibitors 
binding enzyme cavity subsites or alternative zinc chelation groups. As the 
research in the pathological role of MMPs continue, careful consideration in 
rationalised pharmacological and biochemical design of MMPIs for selective 
treatment of cancers may prove to be clinically beneficial.133, 192, 195-197  
In contrast to inhibition of MMP function, exploitation of MMP-mediated proteolysis 
within diseased tissues has been heavily investigated as a diagnostic, therapeutic 
and prognostic approach.198, 199 These studies used activity-based probes 
comprising of a broad-spectrum or selective MMP-cleavable peptide labelled with 
a quenched fluorophore or imaging moiety. In this approach, elevated MMP 
activity in the diseased tissue results in activation of the probe via selective 
cleavage of the peptide and release of the contrast agent, facilitating imaging and 
quantification of MMP activity.198, 199 In line with the MMP-activated probe-based 
approaches, elevated activity of MMPs within diseased tissue has also been 
explored as strategy for conversion of a non-toxic peptide-conjugated prodrug into 
a potent therapeutic entity within the tumour microenvironment. These prodrugs 
are drug delivery molecules where a potent chemotherapeutic is coupled to a 
peptide sequence which inactivates the therapeutic and serves to provide 
selective cleavage by MMPs expressed within the tumour microenvironment.200-204 
1.14 Exploitation of tumour microenvironment for the treatment of cancer 
Based on the distinct role of MMPs in natural and pathologic states, MMPs are 
well known to cleave the components of the ECM by degrading proteins and 
contribute to the formation of tumour microenvironment. When specific MMPs are 
identified as pharmacologic targets for therapeutic intervention, they can either be 
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inhibited or their proteolytic activity can be used to cleave prodrugs and thus 
release the drug selectively in the tumour tissue overexpressing MMPs. The 
advantage of prodrug approach is dose intensification and reduced systemic 
exposure. A requirement for success in this approach is the incorporation of 
peptide sequence selectively cleaved by MMPs overexpressed within the tumour 
microenvironment, relative to normal tissue.203, 205 
A small number of studies have focused on developing MMP-activated prodrugs, 
most commonly directed towards gelatinases MMP-2 and MMP-9 with varying 
levels of success.206-211 One of the initial studies assessed MMP-2 mediated 
tumour-selective activation of the prodrug comprising of an alkylating agent 
melphalan incorporated within the MMP-2 cleavable hexapeptide.211 The in vitro 
cytotoxicity of this prodrug proved disappointing however, but the melphalan 
warhead was successfully released in MMP-positive tumour cells, thereby 
suggesting the therapeutic potential of MMP-activated prodrugs.211 Subsequent 
studies were based on conjugating the drug molecule to the terminus of peptide 
sequence rather than incorporating within it.  One such strategy involved the 
incorporation of albumin as a macromolecular carrier with the peptide-doxorubicin 
conjugate to increase the tumour accumulation of doxorubicin.209, 210 The albumin-
prodrug demonstrated efficient activation by MMP-2 tissue homogenates to 
release doxorubicin.209 The maximum tolerated dose was substantially higher than 
free doxorubicin in vivo and subsequent studies showed superior anticancer 
activity against A375 melanoma at equitoxic doses.209 Several other studies have 
also investigated the concept of macromolecular drug delivery of MMP-activated 
prodrugs with varying success rates.212-214  
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Contrary to the use to macromolecular drug carriers, the use of MMP-activated 
prodrugs conferring to a simple ‘endcap-peptide-warhead’ structure have shown 
significant potential as tumour targeted therapeutics. One study involved the 
development of an anthraquinone linked to the C-terminus of MMP-9 cleavable 
heptapeptide and the N-terminus was ‘endcapped’ with fluorescein isothiocyanate 
(FITC).206 The FITC allowed for prodrug cleavage to be observed fluorescently, as 
the FITC is chemically quenched by anthraquinone in the intact prodrug. Using 
tissue homogenates of a murine myeloma model, the prodrug metabolism was 
higher in MMP-9 expressing tumours (bone marrow, spleen) relative to other 
tissues (heart, lung, kidney), as determined by FITC fluorescence release. There 
was however, a significant level of prodrug cleavage in non-diseased tissues, 
suggesting the prodrug lacked specificity towards MMP-9.206 In an attempt to 
further increase MMP-selectivity, peptidomimetic analogues of peptide-prodrugs 
were also developed, incorporating doxorubicin, duocarmycins and auristatins.208 
However, these peptidomimetic MMP-prodrugs were either not selective against 
MMP-positive versus MMP-negative models or demonstrated no activation by 
MMPs. Therefore, careful consideration of the peptide sequence selectivity and 
the choice of effector molecule are crucial for enhancing the tumour targeting of 
these MMP-activated prodrugs. 
In one of the most detailed studies reported to date, MMP-activated prodrugs of 
doxorubicin were demonstrated to have a higher therapeutic index than 
doxorubicin alone, using the pan-MMP expressing HT1080 preclinical tumour 
model.207 In this study, the length of peptide chain was suggested to be important 
for both MMP-cleavage efficiency and compound stability, with a heptapeptide 
comprising three or four amino acid to the carboxy-end of the scissile bond being 
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optimal. The optimised peptide-prodrugs examined were preferentially activated by 
the secreted MMP-2 and MMP-9, as well as membrane-bound MT1-MMP, but not 
by the endoprotease neprilysin; supporting their selectivity towards MMP family.207 
These prodrugs demonstrated pharmacological stability in vivo and preferential 
metabolism in MMP-positive tumours relative to heart and plasma. In addition, the 
administration of optimised prodrug in mice resulted in 80% cure rate compared to 
only 10% with doxorubicin alone. One limitation of this approach was that a 
considerable fraction of Leu-doxorubicin produced in the tumour was not readily 
metabolised to release doxorubicin, allowing for free circulation of Leu-doxorubicin 
from the tumour into other tissues before its conversion to doxorubicin.207  
The prodrug of vascular disrupting agent (ICT2588) with rationalised modification 
of peptide sequence for selective activation by MT1-MMP has also been 
demonstrated.203, 215 ICT2588 was shown to be preferentially hydrolysed to its 
active metabolite (colchicine derivative) in tumour homogenates of MT1-MMP 
expressing HT1080 relative to MT1-MMP-negative model and normal tissues. In 
addition the administration of prodrug in HT1080 tumour-bearing mice resulted in 
the production of active metabolite, diminution of tumour vasculature and 
haemorrhage necrosis of the tumour; with reduced toxicity, higher therapeutic 
index and increased pharmacodynamic effect relative to the active metabolite.215 
Co-administration of ICT2588 with doxorubicin resulted in tumour growth delay by 
22.6 days and complete tumour regressions, which was superior to 
monotherapeutic administration of ICT2588 or doxorubicin.215 ICT2588 achieved 
clinical cure in 60% of treated animals and is currently in Phase I clinical trial. 
The development of anticancer agents activated by the increased proteolytic 
activity of endoproteases, such as MMPs, is an area of drug development showing 
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tremendous potential and great promise. Several studies on MMP-prodrug 
strategies to date have endeavoured to exploit the proteolytic activity of MMP-2 
and MMP-9 based on the significant levels of data on their tumour expression. In 
many cases, these attempts have not proved as fruitful as anticipated. The likely 
cause for this is the primary focus of strategies is directed towards peptide 
conjugation of the chemotherapeutic and inactivation of this agent to form a 
prodrug rather than improving the selectivity of the peptide sequence. It is also 
important to realise that many MMP-activated prodrug systems are bound to face 
similar difficulties as MMPIs in the clinic.194, 205 Therefore, the clinical expression 
profile of the MMP system must be clear for individual cancers so that specific 
MMPs overexpressed in malignancy can be targeted by choosing selectively 
cleavable substrates as linkers. In addition, certain MMPs may be targets in one 
disease and anti-targets in another, so identifying the appropriate MMPs will be 
one of key steps in the development of targeted drug delivery systems. For 
example, choice of multi-MMP targeting should be carefully validated. MMP-2 and 
MMP-9 have very identical substrate specificity and usually difficult to differentially 
target. These two MMPs have been determined as targets as well as anti-targets 
for cancer. Identifying substrates specific towards MMP-2 (validated target) over 
MMP-9 (suggested anti-targets) for prodrug systems would be beneficial. Similarly, 
peptide substrates that target MMP-10 (validated target) but not others would be 
beneficial since it has been identified as a target. Determination of the optimal 
peptide sequence to facilitate selective cleavage of the prodrug by a specific MMP 
family (or even a sub-family member) is now known to be the most important and 
difficult step in the design of MMP-activated prodrugs.194, 205 The correct 
identification of an MMP as a viable drug target and MMP substrate selectivity 
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requirement is extremely crucial in the future development of tumour targeted 
prodrugs.  
 
1.15 Project Aims and objectives 
The aim of this study is to investigate the potential for the development of novel 
MMP-activated prodrugs as a strategy for the targeted treatment of glioma. 
Specific objectives of this research project include: 
1. To identify and characterise specific MMPs as targets for protease activated 
anticancer prodrugs. 
2. To rationalise functional similarity of MMP subfamily substrate selectivity 
utilising in silico proteolytic docking coupled to in vitro biochemical 
assessment for enabling progress towards subsequent development of 
MMP-selective anticancer prodrugs. 
3. Rationalised design, synthesis and preclinical screening of peptide-
prodrugs conjugated to potent chemotherapeutics, for evaluating MMP-
mediated tumour selective drug release. 
4. Development of graphene-oxide tethered prodrug implants as a therapeutic 
strategy for localised drug delivery following tumour resection, with an aim 
to halt the recurrence of glioblastoma. 
These objectives will form the chapters within this work with the thesis as a whole 
addressing the overall aim of the project.  
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Chapter 2: Preclinical and Clinical Expression of MMPs 
 
II.1 Drug target validation 
Rational drug discovery is a multidisciplinary and stepwise process. The 
preliminary phase in drug development is the identification and validation of a 
suitable molecular target. Tumour drug targets can be identified by proteomic, 
genomic and genetic-linkage studies, but these approaches only relate to a certain 
gene, protein or mutation with disease. The expression levels of therapeutic 
targets might change in response to a disease, so these alterations must be 
elucidated to focus on those that are truly pathogenic. In the targeting of signalling 
pathways, it is crucial to establish that the downregulation of target is not 
compensated by changes in other pathways mediators. Therefore a validation 
process is required to determine whether a drug target has a role in tumour 
maintenance.194 
When protein family members have a high degree of structural and functional 
homology, it is likely that the drugs targeted at one family member will also affect 
other proteins in the family that are not involved in disease pathogenesis – these 
are called ‘family counter-targets’.194 It is also important to identify which family 
members are also anti-targets – molecules that could have severe side-effects on 
the patients if inhibited or disrupted.194 A molecule classified both as an anti-target 
in one disease and a target in the other supersedes its classification as a target 
from the viewpoint of drug development. For example, millions of patients who 
took cyclooxygenase 2 (COX2) inhibitors for the treatment of osteoarthritis and 
other inflammatory diseases, experienced rare anti-target side effects indicating 
COX2 was an anti-target in these patients.216  Therefore, human safety concerns 
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must be carefully considered before drug development without prior knowledge of 
the drug target. The ability to chemically inhibit a target specifically is an important 
criterion in assessing whether to proceed with the development of a drug against 
the validated target – An issue that also applies to the development of MMPIs for 
cancer therapy.194 
In selecting MMPs as targets, it is important to understand whether the function 
and activity of MMPs correlate with malignancy and tumour lesion location, and 
whether the expression is congruent with substrates that are involved in 
pathogenesis. Furthermore, the expression and proteolytic activity of MMPs in 
normal tissues should also be low to avoid drug side effects. When an MMP is 
upregulated in a tumour, it is also important to determine whether the MMP is 
actually contributing to the pathogenesis or is a secondary effect of the disease 
where MMP regulation might actually be a host-protective response.193, 194, 205 If 
the MMP function is involved in reversing the tumour progression or mediating the 
immune-response against the tumour then the MMP is an anti-target.194 
As discussed in chapter 1, MMPs represent a valid biological source of potential 
drug targets for the treatment of cancers. Due to their degradative capacity, MMPs 
can be chemically exploited for anti-tumour prodrugs, to allow selective activation 
of a non-potent prodrug to a toxic chemotherapeutic agent within the tumour 
microenvironment.204 The following section of work demonstrates the utilisation of 
techniques by which the genetic and protein expression of the MMPs can be 
identified in preclinical in vitro glioma models. The rationale for viewing these 
MMPs as potential molecular targets for anti-tumour therapy is demonstrated by 
their involvement in various cancer types and is supported by a wealth of 
literature. 
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II.2 Aims and objectives 
To identify and characterise specific MMPs as targets for protease-activated 
anticancer prodrugs 
Specific objectives of this section include: 
1. To determine the genetic expression of MMPs in preclinical human glioma 
cell models and rationally identify MMP expression profiles for further 
evaluation as drug targets. 
2. To evaluate protein expression and activity of key MMPs in preclinical 
glioma tumour models, as putative targets for drug development 
3. To assess the clinical expression of key MMPs human glioma relative to 
histologically normal brain tissues, to verify their potential as clinically 
relevant targets. 
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II.3 Materials and Methods 
All reagents were supplied by Sigma-Aldrich (UK) unless otherwise stated. Sterile 
plastic cell culture ware was obtained from Sarstedt (UK). 
II.3.1 Cell lines 
All cell lines were purchased from ATCC (Manassas, Virginia, USA) or ECACC 
(Salisbury, Wiltshire, UK) and grown in vitro. Human cell lines used in these 
studies include: U87-MG (grade IV glioma), 1321N1 (grade II glioma), SVG-P12 
(normal glial cells), H460 (NSCLC) and MCF7 (breast carcinoma) (See Appendix 
1).  
II.3.2 Tissue culture 
1.3.2.1 Passaging of cells 
Tissue culture procedures were performed in a sterile MSC-Advantage Class II 
biological safety cabinet (Thermo Fisher Scientific, Massachusetts, US). Cell lines 
were grown in monolayer culture in complete Roswell Park Memorial Institute 
(RPMI) 1640 media, Dulbecco’s Modified Eagle Medium (DMEM) or Eagle’s 
Minimum Essential Media (EMEM) (containing 1% NEAA); all containing 10% fetal 
bovine serum (FBS) and 2 mM L-glutamine (See Appendix 1). Cells were 
incubated in a humidified atmosphere of 5% CO2 at 37°C. The medium was 
replaced every 3 to 4 days. The cells were routinely passaged when they attained 
70 to 80% confluence. The medium was discarded and the contents of the flask 
rinsed twice with 10 ml Hanks Balanced Salt Solution (HBSS). Cells were 
detached from the surface of the flask by the action of 2 to 4 ml 0.25% 
trypsin/ethlyenediaminetetracetic acid (EDTA) followed by incubation at 37°C for 5 
minutes. The cells were then resuspended in 10 ml of fresh medium and 
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centrifuged at 1000 x g for 5 minutes at room temperature in Heraeus Megafuge16 
(Thermo Fisher Scientific, Massachusetts, US). The medium was discarded and 
the cell pellet resuspended in 10 ml fresh media. Between 0.5-1 ml of the 
resuspended cells were transferred to a new non-vented flask containing 10 ml 
fresh medium. After 10 passages, cells were discarded and replaced with fresh 
stocks.  
1.3.2.2 Cell counting 
Cells were lifted using 0.25% trypsin-EDTA solution and resuspended in 10 ml 
fresh medium. A 10 µl sample of the cell suspension was then placed into a 
haemocytometer chamber. Cell counts were taken from 5 grids of the 
haemocytometer chamber and calculated as the mean of 5 counts. Cell numbers 
were expressed as (mean cell count) x 104/ml medium. 
13.2.3  Harvesting of cells for gene and protein expression analysis 
Harvesting of cells occurred whilst still within their exponential growth phase. Cells 
were lifted using trypsin/EDTA as described above. Following centrifugation, the 
pellet was resuspended in 1 ml of fresh medium, placed in a 1.5 ml 
microcentrifuge tube and centrifuged again at 1000 x g for 5 minutes. The 
supernatant was discarded and the remaining pellet was snap frozen in liquid 
nitrogen and then stored at -80°C. 
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II.3.3 Reverse transcription-polymerase chain reaction (RT-PCR) for 
detection of MMP gene expression 
II.3.3.1 Total RNA extraction 
Total RNA extraction was performed using the QIAshredder and RNeasy Mini kits 
according to manufacturer’s instructions (Qiagen,Hilden, Germany). Briefly, cell 
lines were grown as described in section II 2.2, and cell pellets collected following 
centrifugation at 10,000 x g. Excess media was removed from cell pellets and 350 
µl buffer RLT (See Appendix 2) was added to each pellet (in RNase-free centrifuge 
tubes) and vortexed to mix. Resultant lysates were homogenised by transferring 
buffer RLT contents into Qiashredder spin columns and centrifuging for 2 min at 
10,000 x g. Equal volumes of ethanol (70%) were added to the homogenised 
lysate, and the resulting lysate transferred to RNeasy spin column and centrifuged 
for 15 s at 10,000 x g. The flow-through was discarded and, buffer RW1 (See 
Appendix 3) was added to the spin columns and the column centrifuged for 15 s at 
10,000 x g. Buffer RPE (See Appendix 4) was added to the RNeasy spin column 
and centrifuged at 10,000 g. To elute the RNA, RNase-free water (30-50 µl) was 
added directly into the spin column membrane and centrifuged for 1 min at 10,000 
x g to collect the RNA. All RNA samples were stored at -80°C until required for 
use. 
II.3.3.2 Analysis of RNA concentration 
RNA samples were diluted in RNase-free water. Purity of RNA was analysed by 
measuring the relative absorbance spectrophotometrically at 260 nm and 280 nm 
using semi-micro polystyrene cuvettes (RNA purity shown by ratio of absorbance 
between 1.7 and 2.0). The concentration of RNA samples was analysed by 
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measuring their absorbance at 260 nm (assuming absorbance of 1.0 is equivalent 
to 40 µg/ml RNA (Warburg & Christian, 1942)). 
II.3.3.3 cDNA Synthesis: Reverse transcription 
Synthesis of cDNA from RNA was performed using Protoscript First Strand cDNA 
Synthesis Kit (New England Biolabs, Massachusetts, USA) according to 
manufacturer’s instructions. Briefly, random Primer Mix (60 µM) was added to 1 µg 
of RNA and the volume adjusted to 8 µl using nuclease-free water in 0.2 ml 
microcentrifuge tube. RNA samples were denatured at 70°C for 5 minutes and 
then rapidly cooled on ice to ensure primer annealing. To each RNA sample a 
cDNA synthesis mix was added consisting of: M-MuLV (Moloney Murine 
Leukaemia Virus) reaction mix and M-MuLV enzyme mix. The sample was mixed 
and incubated at 25°C for 5 minutes followed by incubation at 42°C for 1 h to 
facilitate cDNA synthesis. Samples were diluted 1:1 with nuclease-free water (final 
volume 40 µl). cDNA samples were stored at -20°C. Appropriate negative controls 
(RT-) were prepared by treating RNA samples with the reagents described above 
but without the addition of M-MuLV enzyme mix in the cDNA synthesis mix, to 
highlight any genomic DNA contamination in subsequent PCR analyses. 
II.3.3.4 Primer design 
MMP and GAPDH primer design were based on the findings of Kohrmann et al.,217 
and provided by Invitrogen Life Technologies (Massachusetts, USA ). MMP primer 
sequences (Table II.1) were evaluated by BLAST search 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) to confirm agreement with human 
DNA sequence. On delivery, primers were reconstituted to 10 µM stock solutions 
in nuclease-free water, and stored at -20°C.  
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II.3.3.5 Polymerase chain reaction (PCR) of MMP expression 
PCR reactions were performed using the Protoscript Taq RT-PCR kit (New 
England Biolabs, Massachusetts, USA). All reaction reagents and samples were 
kept on ice throughout. To each cDNA sample (5 µl) a PCR reaction mix was 
added consisting of: Taq 2X Master mix (10 µl) (See Appendix 5), sense primer 
(10 µM), antisense primer (10 µM) and the volume adjusted to 20 µl using 
nuclease-free in 0.2 ml PCR centrifuge tubes. The contents of each tube were 
mixed well and centrifuged briefly. All samples underwent the following PCR 
programme, 94°C for 5 minutes followed by cycles of 94°C for 30 s, primer 
annealing for 30 s and elongation at 68°C for 1 minute (Table II.2). Each program 
finished with 10 minutes incubation at 68°C to ensure complete elongation of 
newly synthesised cDNA. 
After the reaction was complete, all PCR samples were stored at 4°C ready for 
analysis. The additional following controls were included in the PCR reaction 
described above: Positive controls consisted of sample cDNA with known 
expression profiles whilst negative (RT-) controls consisted of PCR products from 
cDNA samples created without the addition of M-MuLV enzyme mix (as detailed in 
section II.3.3.3). 
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Table II.1: Primers used for RT-PCR for MMPs and the house keeping control gene 
GAPDH, supplied by Invitrogen Life Technologies. 
 
 
Table II.2: RT-PCR conditions used for MMPs and the house keeping control gene 
Gene Primer Primer sequence
MMP-2
Forward F-5’-TTTCCATTCCGCTTCCAGGGCAC-3’
Reverse 5’-TCGCACACCACATCTTTCCGTCACT-3’
MMP-3
Forward 5’-GGCTTTCCCAAGCAAATAGC -3’
Reverse 5’-GTGCCCATATTGTGCCTTCT -3’
MMP-9
Forward 5’-CCTGCCAGTTTCCATTCATC-3’
Reverse 5’-GCCATTCACGTCGTCCTTAT-3’
MMP-10
Forward 5’-GTCACTTCAGCTCCTTTCCT-3’
Reverse 5’-ATCTTGCGAAAGGCGGAACT-3’
MMP-12
Forward 5’-ACAGATGATGGACCCTGGTT-3’
Reverse 5’-AGAGTCAAGCAAGAATGGACAA-3’
GAPDH
Forward 5’-CCACCCATGGCAAATTCCATGGCA-3’
Reverse 5’-TCTAGACGGCAGGTCAGGTCCACC-3’
Primer set
Annealing
temperature ( C)
Number of 
cycles
MMP-2 57 32
MMP-3 52 32
MMP-9 52 35
MMP-10 52 35
MMP-12 52 35
GAPDH 55 35
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II.3.3.6 Agarose gel electrophoresis to analyse PCR products 
PCR products were separated through a 1% v/w agarose/Tris-Acetate EDTA 
(TAE) gel containing 0.01% ethidium bromide. Prior to loading samples into the 
gel, 10% loading dye (30% glycerol, 0.25% bromophenol blue) was added to each 
reaction tube to allow sample visualisation. Quickload 1kb DNA Ladder (New 
England Biolabs) was loaded into the gel, allowing for later determination of PCR 
product sizes. Electrophoresis was carried out in 1 x TAE buffer at 100 V for 1 h to 
separate PCR products. cDNA in the gel was visualised under a UV light using a 
UV-transilluminator and digital gel images saved. 
II.3.4 Western Blotting of MMP-10 expression 
II.3.4.1 Sample preparation  
II.3.4.1.1 Extraction of protein from cells  
Cells were grown to subconfluency in 75 cm2 flasks. The culture medium was 
transferred into sterile 15 ml centrifuge tube, for later extraction of protein from the 
medium. Ice cold lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 
1 mM Na3VO4, 10 mM β-glycerol phosphate, 50 mM NaF, 5 mM Na3PO4, 0.27 M 
sucrose and 1% TritonX-100) was applied directly onto the cell monolayer and 
incubated at 4°C for 15 minutes to allow for lysis of the cells and release of 
cytoplasmic proteins. The resulting extract was collected, centrifuged at 10,000 
rpm, 4°C for 10 minutes and stored at -20°C until use. 
II.3.4.1.2 Extraction of protein from cell culture medium  
Media protein extraction was performed using Vivaspin-2 Protein Concentrator 
Spin Columns (GE Healthcare, Buckinghamshire, UK). The concentrator was filled 
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up to 2 ml and centrifuged at 4000 x g for 10 minutes. The concentrated protein 
collected in the concentrator cap was transferred into microcentrifuge tubes and 
stored at -20°C until use. 
II.3.4.2 Polyacrylamide gel electrophoresis 
Proteins were separated through 10% polyacrylamide SDS gels. Each lane was 
loaded with a relevant amount of sample (representing 30 µg of protein from cell 
lysates) diluted in lysis buffer and 2 x sample buffer (65.7 mM Tris-HCl (pH 6.8), 
2% SDS, 10% glycerol, 0.01% bromophenol blue, 2% β-mercaptoethanol) to make 
final 30 µl volume. Samples were denatured at 95°C for 5 minutes and incubated 
on ice prior to loading. Gels were immersed in electrophoresis running buffer (25 
mM Tris, 190 mM glycine, 0.1% SDS) and the samples loaded into the gel. In 
addition, one lane was loaded with Full Range Rainbow Marker (Amersham 
Biosciences) to allow for later protein mass determination. Electrophoresis was run 
at 50 V until samples reached the edge of stacking gel, followed by 150 V until the 
marker relevant to the size of protein of interest was located in the middle of the 
separating gel. 
II.3.4.3  Protein transfer to polyvinyl membrane 
Protein was transferred from the acrylamide gel to Hybond-P membrane 
(Amersham) using a VWR transfer kit immersed  in transfer buffer (20 mM Tris, 
150 mM glycine, 20% methanol). The transfer tank was placed in an ice bath and 
the transfer run for 2 h at 300 mA.  
II.3.4.4 Antibody incubations 
Blots were incubated in 5% non-fat milk in TBS-Tween buffer (10 mM Tris, 150 
mM NaCl (pH 8.5), 0.1% Tween 20) for 90 minutes at room temperature to block 
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non-specific antibody binding. Antibodies were diluted to their final concentration 
(Table II.3) in 1% non-fat milk in 0.1% TBS-Tween and incubated overnight at 4°C 
with agitation. Excess antibody was removed by washing the blot thrice for 15 
minutes in 0.1% TBS-Tween. The blot was incubated with the appropriate 
horseradish peroxidase conjugated secondary antibody at a 1:2000 dilution in 1% 
non-fat milk in TBS-Tween, for 60 minutes at room temperature. Blots were rinsed 
for a further 3 times for 5 minutes in TBS-Tween to remove excess secondary 
antibody. 
Antibody Supplier 
Final 
concentration 
Secondary antibody 
Ab-5 
(Rabbit polyclonal) 
Neomarkers, 
Fremont, CA 
0.3 µg/ml  
(1:3000 dilution) 
Goat anti-rabbit 
Clone 5E4 
(monoclonal) 
Novocastra, 
Newcastle, UK 
1 µg/ml 
(1:1000 dilution) 
Rabbit anti-mouse 
 
Table II.3: Optimised western blotting conditions for MMP primary antibodies. This 
represents a subset of antibodies tested in these studies. 
 
II.3.4.5 Visualisation of antibody binding 
Antibody binding was detected chemiluminescently using ECL substrate (125 mM 
Luminol, 45 mM p-Coumaric acid, 1 mM Tris-HCl (pH 8.5), 15% H2O2). Blots were 
exposed to ECL substrate for 3 minutes in the dark at room temperature, excess 
reagent was blotted from the surface and the blot wrapped in Saran Wrap. Each 
blot was exposed for an appropriate time (between 10 s and 3 minutes) and the 
staining intensity determined using a Biorad Chemidoc Imaging System. 
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II.3.5 Immunohistochemistry 
Immunohistochemical (IHC) images and raw data of MMP expression in tumour 
sections were kindly provided by the Human Protein Atlas.218-220 The complete IHC 
staining scores provided by the Human Protein Atlas were analysed further to 
assess the level of MMP expression in a panel of human glioblastoma tissues 
relative to normal brain tissues. All IHC staining in the Human Protein Atlas project 
was performed using a standard protocol as described.218-220   
II.3.5.5 Scoring of immunohistochemical staining of clinical samples 
Sections of clinical tissue samples were examined using a light microscope (Leica 
biosystems, CA, USA).218-220 Immunoreactivity was scored according to both its 
intensity and its distribution throughout the tissue observed within the field of view. 
The level of staining intensity was scored as follows: Score 0: no staining (no 
protein expression or below detectable levels); Score 1: low staining (low protein 
expression); Score 2: moderate intense staining (moderate protein expression); 
Score 3: high or strong intense staining (high protein expression); Score 4: very 
high intense staining (very high protein expression). Similarly, the extent of the 
staining thoughout the field of view was scored as follows: Score 1: represented 
≤10% positively stained cells (low distribution of protein expression); Score 2: 11-
40% positively stained cells (low to moderate distribution of protein expression); 
Score 3: 41-70% positively stained cells (moderate to very common distribution); 
Score 4: 71-100% positively stained cells (very common to ubiquitous distribution). 
The samples were assessed from dataset of five individual patients for each tissue 
type tested. 
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II.3.6  Assay of MMP activity 
i) Determination of MMP-selective proteolytic activity 
Recombinant human MMP proteins (MMP-2, MMP-3, MMP-9 and MMP-10) (R&D 
Systems, UK) were assayed for their ability to hydrolyse the stromelysin-selective 
fluorogenic substrate M-2110 (Mca-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-
Lys(Dnp)-NH2) and gelatinase-selective fluorogenic substrate M-2055 (Dnp-Pro-β-
cyclohexyl-Ala-Gly-Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH2) (Bachem, Switzerland). 
The stock solution of MMP proteins were prepared by dilution in MMP activity 
buffer (100 mM Tris-HCl pH 7.6, 10 mM CaCl2, 100 mM NaCl, 0.16% v/v Brij-35), 
to a concentration of 20 ng/µl. The assay was performed in a 96-well plate by 
reacting 200 ng recombinant protein and 1 µM substrate in 100 µl MMP activity 
buffer. Using a fluorescent spectrophotometer (Varioskan Flash, Thermo Fisher 
scientific), continuous fluorescence was measured (excitation wavelength, λex = 
325 nm and emission wavelength, λem = 393 nm with M-2110 substrate; and λex = 
365 nm and λem = 450 nm with M-2055 substrate) at 37°C following a 200 minute 
incubation.  
ii) Determination of MMP activity in human tumour cell lines 
Similarly, MMP activity was defined as the ability of the protein extract, from 
tumour cell media, to hydrolyse the fluorescent MMP subfamily selective 
substrates: M-2110 and M-2055. Briefly, the reactions (100 µl) contained protein 
extract from cell media representing 1 x 105 cells (10 µl) and 1 µM fluorogenic 
substrate in MMP activity buffer. Continuous fluorometric assay was performed in 
96-well plate at 37°C using fluorescent spectrophotometer.  
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A negative reaction blank was included by omission of recombinant MMP/media 
protein extract. For each sample, the relative activity was calculated as the 
fluorescence obtained from the sample minus that obtained from the reaction 
blank following the 200 minute incubation. Activity was expressed as change in 
fluorescence per minute per ng of protein (or 1 x 105 cells). The reliability and 
reproducibility of the assay were determined using three independent studies. 
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I.4 Results 
II.4.1 Expression of MMP mRNA in human tumour cell lines  
II.4.1.1 Optimisation of RT-PCR evaluation of MMPs 
To assess the gene expression of the MMP subfamily in cell lines, primer pairs 
were optimised in order to identify an appropriate annealing temperature, 
elongation time and number of PCR cycles to yield optimum reaction products. A 
panel of four human tumour cell lines were screened for gene expression of MMP 
using semi-quantitative RT-PCR. The amount of cDNA used in each PCR reaction 
was optimised using a range of cDNA concentrations, with 5 ng being identified as 
optimal (Figure II.1). Primer concentrations were optimised in the same way (2.5 
µM-12.5 µM). Addition of each primer at a concentration of 25 nM per reaction (for 
MMPs and GAPDH) resulted in adequate PCR products and this was chosen as 
optimal concentration for future studies (Figure II.2).  
II.4.1.2 Expression of MMPs in human tumour cell lines determined by 
RT-PCR 
A range of human tumour cell lines including glioma grade-IV (U87-MG), glioma 
grade-II (1321N1), lung (H460) and breast (MCF7); and a normal brain cell line 
(SVG-P12) were screened for MMP (MMP-2, MMP-3, MMP-9, MMP-10 and MMP-
12) gene expression based primarily on studies of Nuttall et al.173 The lack of gene 
product in control lanes (without reverse transcriptase, RT-) for each well indicated 
that there was no genomic DNA contamination of samples (Figure II.3). 
The H460 and MCF7 cell lines were used as positive/negative controls for MMP 
gene expression based on studies of Atkinson et al.203 All the human cell lines 
demonstrated a differential expression of the MMPs evaluated. The U87-MG and 
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1321N1 cell lines expressed all studied MMPs, supporting their use as relevant 
tumour models in prospective studies. Whereas SVG-P12 cell line showed 
low/negligible expression of MMP-10 (Figures II.3, II.4 and II.5).  
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Figure II.1: Identification of optimal cDNA concentration for RT-PCR analysis. 
Optimum cDNA concentration identified as 5 ng U87-MG cDNA per reaction for GAPDH 
and MMPs.                 
 
 
Figure II.2: Detection of MMPs by RT-PCR. Product sizes; GAPDH, 561 bp; MMP-2, 
253 bp; MMP-3, 205 bp; MMP-9, 455 bp; MMP-10, 471 bp; MMP-12, 392 bp. 
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Figure II.3: RT-PCR analysis of the MMPs in human tumour cell lines and a normal 
glial cell line, demonstrating varied expression of MMPs 
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Figure II.4: Quantitative densitometry of the relative gene MMPs detected by RT-
PCR. Human cell lines; U87-MG (glioma grade-IV), 1321N1 (glioma grade-II), SVG-P12 
(normal glial) and H460 (NSCLC) and MCF7 (breast cancer). The values of gene 
quantified are after normalisation to GAPDH and therefore gene specific, thus precluding 
comparison of expression between genes. 
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Figure II.5: Relative abundance of human MMP gene expression in human tumour 
and normal glial cell lines as analysed by RT-PCR and quantified by densitometry. 
The expression grade is representative of the genes quantified after normalisation to 
GAPDH.  
 
 
 
 
 
 
 
 
Relative gene expression
Cell line MMP-2 MMP-3 MMP-9 MMP-10 MMP-12
U87-MG +++ +++ ++ +++ +++
1321N1 +++ + +++ +++ +
SVG-P12 +++ + +++ +/- +
H460 + - - ++ -
MCF7 - - + + -
- Negative + Low ++ Moderate +++ High expressionKey:
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II.5.1 Optimisation of MMP-10 protein in human preclinical cell lines by 
western blotting 
Western blotting was employed  to assess the protein expression of MMPs in the 
preclinical tumour model panel. Human MMP-10 Ab-5 polyclonal (Neomarkers) 
and 5E4 monoclonal (Novocastra) antibodies were evaluated for the determination 
of MMP-10 protein by western blotting. These antibodies have previously been 
shown to be specific for MMP-10, detecting both active and pro forms of the 
enzyme by Western blot analysis.155 H460 cell line was used a positive control for 
MMP-10 detection based on literature.155  
Differential bands were detected indicating different specificities of the two 
antibodies (Figure II.6). Ab-5 and Clone 5E4 produced bands of approximately the 
correct size for pro- and active MMP-10; 57 kDa and 44 kDa respectively, with Ab-
5 being more specific for active MMP-10 and 5E4 demonstrating specificity for pro-
MMP-10 (Figure II.6). The two antibodies were successful in this study in 
demonstrating differential expression of MMP-10 between the positive sample 
(H460), glioma cell models (U87-MG and 1321N1) and normal glial cells (SVG-
P12) (Figure II.6).  
 
II.5.2 MMP-10 protein expression in human preclinical glioma cell lines 
Expression of MMP-10 protein was evaluated in human cell lines by western 
blotting. MMP-10 expression was probed using Ab-5 and Clone 5E4 anti-MMP-10 
antibodies, to differentially detect active and pro MMP-10, respectively. Cells 
grown in monolayers were assayed for western blot analysis of MMP-10 
expression at 48 h and 96 h post cell seeding. The tumour cell lines demonstrated 
82 
 
 
a time-dependent increase in expression of active form of MMP-10, whereas 
normal glial cells demonstrated an unchanged and low/negligible expression 
pattern (Figures II.6 and II.7). Active MMP-10 protein detected in all the cell lines 
demonstrated differential varying level of expression; in agreement with gene 
expression data obtained using RT-PCR (Figure II.8).  
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Figure II.6: Western blotting of human cell lines for MMP-10 at 48 h and 96 h post-
seeding. (A) Ab-5 anti-MMP-10 polyclonal antibody detected active MMP-10 protein. (B) 
5E4 NCL-MMP-10 monoclonal antibody detected pro-MMP-10 protein in the cell lysates. 
(C) Equal loading of protein sample in each well was confirmed by β-Actin protein 
expression. 
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Figure II.7: Quantitative densitometry of the protein expressions of active and pro 
MMP-10 in human tumour and normal glial cell lines at 48 h and 96 h post-seeding. 
The values of protein quantified are after normalisation to β-Actin for each cell line at 
specific time point. 
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Figure II.8: Relationship between MMP-10 gene expression and active protein 
expression in human tumour and normal glial cell lines. (A) MMP-10 relative gene 
expression, normalised to GAPDH, (B) Active MMP-10 relative protein expression, 
normalised to β-Actin, (C) Correlation between MMP-10 protein and gene expression, 
R2=0.9962. Results demonstrated a good correlation between gene expression and 
protein expression of MMP-10. 
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II.6 Expression of MMPs in clinical tumour specimens, by 
immunohistochemistry  
The glioma samples demonstrate a very high expression of MMP-2, high 
expression of MMP-3 and; moderate expression of MMP-9 (Figures II.9, II.10 and 
II.11). However, MMP-2, MMP-3 and MMP-9 are also expressed at moderate 
levels in normal brain samples (Figures II.9, II.10 and II.11). In contrast, strong 
positive staining of MMP-10 was detected in the glioma tissues with expression 
throughout the whole specimen relative to low/negligible staining in normal brain 
tissues (Figure II.12). More specifically, in the normal brain tissues; cerebral 
cortex, hippocampus and cerebellum from glial and neuronal origin demonstrate 
low expression of MMP-10. In contrast, expression of MMP-10 in glioma tissues is 
very high (Figure II.12). The staining pattern observed in the panel of glioma and 
normal brain tissues correlate well with the MMP-10 expression as determined by 
western blotting or RT-PCR (Figures II.4, II.8 and II.12).  
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Figure II.9: Immunohistochemical detection of MMP-2 in glioma and normal brain 
tissues; demonstrating overexpression in clinical glioma specimens and moderate 
expression in histologically normal brain tissues. Classification of expression levels was 
determined from the IHC staining score of each tumour as either very high (score of 4), 
high (score of 3), moderate (score of 2), low (score of 1) or negative (score of 0) MMP-2 
expression. (Image credit: Human Protein Atlas) 
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Figure II.10: Immunohistochemical detection of MMP-3 in glioma and normal brain 
tissues; demonstrating overexpression in clinical glioma specimens and moderate 
expression in histologically normal brain tissues. Classification of expression levels was 
determined from the IHC staining score of each tumour as either very high (score of 4), 
high (score of 3), moderate (score of 2), low (score of 1) or negative (score of 0) MMP-3 
expression. (Image credit: Human Protein Atlas) 
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Figure II.11: Immunohistochemical detection of MMP-9 in glioma and normal brain 
tissues; demonstrating moderate expression in both clinical glioma specimens and 
histologically normal brain tissues. Classification of expression levels was determined 
from the IHC staining score of each tumour as either very high (score of 4), high (score of 
3), moderate (score of 2), low (score of 1) or negative (score of 0) MMP-3 expression. 
(Image credit: Human Protein Atlas) 
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Figure II.12: Immunohistochemical detection of MMP-10 in glioma and normal brain 
tissues. Representative images of Clone 5E4 NCL antibody. MMP-10 is overexpressed in 
clinical tumour specimens relative to low expression in histologically normal tissues. 
Classification of expression levels was determined from the IHC staining score of each 
tumour as either very high (score of 4), high (score of 3), moderate (score of 2), low (score 
of 1) or negative (score of 0) MMP-3 expression. (Image credit: Human Protein Atlas) 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
H
ig
h
 g
ra
d
e
 g
lio
m
a
L
o
w
 g
ra
d
e
 g
lio
m
a
C
e
re
b
ra
l 
c
o
rt
e
x
H
ip
p
o
c
a
m
p
u
s
C
e
re
b
e
ll
u
m
L
iv
e
r
K
id
n
e
y
IH
C
 s
ta
in
in
g
 s
c
o
re
High grade glioma Low grade glioma
Cerebral cortex Hippocampus Cerebellum
MMP-10
Low Moderate High Very high expressionKey:
91 
 
 
II.7  Measurement of MMP activity: Fluorometric enzyme assay 
II.7.1 Determination of MMP-selective proteolytic activity 
In order to assess levels of functional MMPs, a continuous fluorometric assay was 
used and optimised using recombinant MMPs. For initial optimisation, the activity 
of recombinant MMPs was measured for their ability to hydrolyse MMP-subfamily 
selective fluorescently labelled substrates, M-2055 and M-2110 (Bachem, 
Switzerland). A time dependent increase in absorbance was observed at all 
concentrations of substrate (ranging from 50 µM to 500 nM) with 1 µM being 
chosen as the optimum concentration for testing MMP activity. M-2110, 
stromelysin-selective substrate, was preferentially cleaved by stromelysins (MMP-
3 and MMP-10) with very slow hydrolysis by MMP-9 and negligible activity with 
MMP-2 (Figure II.13).221 Conversely, M-2055, a gelatinase-selective substrate, 
was efficiently hydrolysed by gelatinases over stromelysins (Figure II.13).222 The 
activity of recombinant MMPs with selective substrates and the initial rates of 
reaction demonstrated a correlation with the available literature, thus verifying the 
utility of these substrates for further assessment of MMPs in tumour cell models.  
 
II.7.2 Differential levels of active MMP sub-families in culture media of 
human tumour cell lines 
Using the stromelysin-selective substrate, M-2110, the MMP-10 expressing cell 
lines, U87-MG, 1321N1 and H460, produced high MMP activity levels compared to 
SVG-P12 cell line, which possess low levels of MMP-10 protein (Figure II.14). The 
active MMP levels, demonstrated against M-2110, observed in the cell lines 
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correlated to gene and protein expression of these MMPs (Figures II.4, II.8 and 
II.15).  
With the gelatinase-selective substrate, M-2055, the MMP-2 and MMP-9 
expressing glioma (U87-GM and 1321N1) and normal glial (SVG-P12) cell lines 
demonstrated high MMP activity levels. The H460 and MCF7 reference cell lines 
possess low or negative levels of gelatinases (Figure II.14). The MMP activities in 
these cell lines showed a good correlation to that detected by RT-PCR. (Figure 
II.4, II.8 and II.15).  
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Figure II.13: Continuous fluorometric assay of MMPs with M-2110 (Mca-Arg-Pro-
Lys-Pro-Val-Glu-Nva-trp-Arg-Lys(Dnp)-NH2) and M-2055 (Dnp-Pro-β-cyclohexyl-Ala-
Gly-Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH2) substrates. Assay was performed at 37°C by 
reacting 1µM substrate and 200 ng of MMPs in 100 µl solution of assay buffer. 
Fluorescence was read with λex = 325 nm and λem = 393 nm for M-2110; and λex = 365 nm 
and λem = 450 nm for M-2055. 
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Figure II.14: Continuous fluorometric assay for determination of active MMPs in 
human preclinical cell models, measured with M-2110 and M-2055 substrates. Assay 
was performed at 37°C by reacting 1µM substrate and culture media protein extracts 
(representing 1 x 105 cells) in 100 µl solution of assay buffer.  
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Figure II.15: Relationship between MMP expression and active MMP levels in human 
glioma and normal glial cell lines. (A) RT-PCR analysis demonstrating varied 
expression of MMPs in preclinical cell lines. (B) Relationship between MMP activity levels 
and gene expression. Activity of MMPs demonstrated by the ability of human cell media 
protein to cleave stromelysin-selective (M-2110) and gelatinase-selective (M-2055) 
substrates. (C) Expression and activity profile of MMP-10 in human glioma and normal 
brain cell lines demonstrating strong correlation between gene, protein and active 
proteolytic levels. 
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1.8 Discussion 
The strong correlation between RT-PCR, western blotting and fluorogenic 
substrate cleavage assay to demonstrate overexpression of MMP-10 in tumour 
cell lines relative to normal glial cell line, suggests a predominant role of MMP-10 
in the growth and development of tumour in glioma. The immunohistochemical 
overexpression of MMP-10 in clinical samples of human glioma relative to normal 
brain also established the viability of MMP-10 as a target for therapeutic 
intervention in human glioblastoma. 
Overexpression of MMP-10 has been shown in several malignancies including oral 
carcinoma, head and neck squamous cell carcinoma (HNSCC), skin cancer, 
oesophageal carcinoma and non-small cell lung carcinoma (NSCLC).155, 223-226 
However, the expression of MMP-10 protein in human glioblastoma has not been 
previously reported. To our knowledge, the present study is the first to address the 
overexpression and elevated proteolytic activity of MMP-10 in preclinical models of 
human glioma relative to normal glial cells. MMP-10 expression was significantly 
higher in the analysed glioblastoma tumour tissues compared to histologically 
normal brain tissues.  
In this study we demonstrated that MMP-10 expression is concomitantly increased 
with glioma cell proliferation relative to the low MMP-10 expression maintained at 
basal level in normal glial cells in vitro. The human glioma cells demonstrating a 
higher expression of MMP-10 also showed a greater ability to cleave the 
stromelysin-selective fluorogenic substrate. In contrast, normal glial cells 
demonstrating low expression of MMP-10 showed no significant increase in 
fluorescence. This result confirmed the clear differential of MMP-10 proteolytic 
activity between normal glial and glioma cells. Indeed, the overexpression of 
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MMP-10 in a large population of tumour cells and tissues were positively 
correlated with tumour size, suggesting the importance of MMP-10 function in 
tumour growth and expansion.227, 228 In fact, MMP-10 expression is elevated in 
NSCLC tissues with NSCLC patients whose tumours showed high MMP-10 
proteolytic activity exhibited significantly worse survival than those whose tumours 
express low MMP-10.155, 229  
Glioblastoma is a fatal malignant primary brain tumour and contains self-renewing, 
tumorigenic cancer stem cells (CSCs) that contribute to tumour initiation and 
therapeutic resistance.230 CSCs are defined by their ability to clonally expand, 
differentiate into tumour cells and initiate tumours. The ECM is an essential non-
cellular component of the adult stem cell niche.230, 231 In malignancy, increased 
ECM stiffness can be a physical barrier for chemotherapeutics and thus protect 
CSCs from therapeutic agents.230 MMPs can degrade components of ECM in 
tumours, releasing cytokines, growth factors and other molecules from the cell 
surface.230 Unlike many MMPs that are implicated in tumour invasion and 
metastasis, it was recently demonstrated that MMP-10 overexpression can 
promote tumour initiation and growth through maintenance of CSCs.231-233 The 
involvement of MMP-10 is suggested to be involved in early stages of tumour 
formation and invasion. MMP-10 overexpression in CSC-enriched cultures of 
mouse lung adenocarcinoma has been linked to enhanced tumour growth and 
clonal expansion in vitro, and tumour initiation in vivo.231-233 Inhibition of MMP-10 
expression leads to a significant decrease in CSC related gene expression.232 
Interestingly, the U87-MG and 1321N1 cells are enriched in CD133+/Notch4+ cell 
population, the two markers implicated in both human CSCs from various tumour 
types, including glioblastoma.234 Notch inhibition blocks the proliferation and 
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tumour initiating activity of human lung CSCs.235 Likewise, Inhibition of Notch 
signalling blocks the ability of glioblastoma-derived CSCs to propagate tumours 
and depletes CD133+ stem-like cells in neurospheres.234, 236 The enhanced 
expression of MMP-10/Notch is required for tumour invasion of human NSCLC 
cells in vitro and primary oncosphere-derived lung tumours.232 More specific to this 
study, MMP-10 expression is also elevated in these CSC-like U87-MG and 
1321N1 glioma cells, suggesting that MMP-10 may also function in the 
maintenance of glioma stem cells. Inhibition of MMP-10 leads to significant 
reduction in tumour migration and blocks the growth and metastatic behaviour.232 
Therefore MMP-10+/Notch+ may be useful markers of glioma stem cell species. 
CSCs also enhances the expression of Wnt genes, that are significantly 
overexpressed in U87-MG cells and implicated in glioma progression and 
aggressiveness.237 Interestingly, MMP-10 knockdown inhibited the invasion 
promoted by Wnt overexpression in HNSCC.228 In support of these findings, MMP-
10 could be a potential marker for predicting the tumour migration and invasion in 
glioblastoma. 
 Analysis of expression profiling data on preclinical glioma cells revealed a 
significant correlation between MMP-10 expression and proteolytic activity. H460 
(NSCLC) reference cell line has been demonstrated to possess high expression 
and proteolytic activity MMP-10, which was confirmed in this study.155 The 
expression and proteolytic activity of MMP-10 is elevated in human NSCLC and 
unlike the majority of MMPs, MMP-10 was suggested to play a central role in 
tumour growth and development rather than invasion and metastasis.155 In this 
study similar associations were observed between MMP-10 expression and 
proteolytic activity of human glioma cells. Thus, MMP-10 may play a widespread 
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role in the glioma malignancy. MMP-10 is an upstream regulator of the MMP 
activation cascade demonstrated by its ability to cleave several proMMPs such as 
MMP-1, MMP-7, MMP-8, MMP-9 and MMP-13.238, 239 This broad activity could be 
suggestive of glioma tumour initiator role of MMP-10 in the MMP cascade.  
The excessive proteolytic processing by various MMPs via cleavage of substrates 
or interacting proteins have pivotal roles in the regulation of myriad of biological 
pathways and is described as an initial step in the degradation of ECM 
components in numerous pathological processes such as tumour growth, 
angiogenesis, invasion and metastasis. In this study, MMP-10 was proteolytically 
active in glioma cells relative to normal glial cells. However, glioma and normal 
glial cells demonstrating a higher expression of gelatinases (MMP-2 and MMP-9), 
also showed greater ability to cleave the gelatinase-selective fluorogenic 
substrate. This observation also correlated with the expression of gelatinases in 
brain tumour and normal brain samples. It is proposed that moderate to high 
proteolytic activity of MMPs in normal tissues are not necessarily tumour specific 
but may be indicative of physiological processess, such as maintanance of the 
ECM.240 Importantly for this study however, validation of specific MMP as a drug 
target is important for the efficient functioning of drug targeting systems such as 
prodrugs. Though MMP-2 and MMP-9 have been implicated in glioblastoma 
progression and invasion, the proteolytic function of MMPs in glioma vs normal 
brain has never been elucidated. The observation that gelatinases are 
proteolytically active in normal brain cells suggests their role as anti-targets in 
glioma. These MMPs have been implicated as targets in one disease and counter 
or anti-targets in another.194 The proteolytic activity of MMPs is essential for 
efficient cleavage of substrates, peptide linkers or prodrugs and targeting by 
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inhibitors.205 It is therefore vital to realise the the clinical implication of the MMP 
systems in glioblastoma so that specific MMPs that are overactive in the tumour 
microenvironment relative to surrounding normal tissues, can be selectively 
targeted by choosing specific linkers, selective substrates or peptide-prodrugs. 
Taken together with the observation that MMP-10 is overexpressed in glioma 
samples analysed and is active in glioma cell lines, this further supports MMP-10 
as a potential glioma tumour initiator and a clinically viable target for therapeutic 
intervention of glioblastoma. 
Since MMP-10 is involved in tumour initiation and growth, it is directly secreted by 
tumours and CSCs, and its inhibition leads to reduction in metastasis and 
invasion; it is therefore reasonable to postulate that inhibitors or selective peptide 
prodrugs with specificity against overactive MMPs, such as MMP-10, may be a 
better approach for the treatment of glioblastoma.  
In conclusion, this study shows the increased expression and activity of MMP-10 
in human glioma tumours, suggesting MMP-10 is a potential drug  target for 
therapeutic intervention of glioblastoma. This observation led to the development 
of in silico model to rationalise the functional similarity and substrate cleavage 
preferences between the members of MMP subfamily, to facilitate progress 
towards the development of MMP-10 selective anticancer prodrugs. 
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Chapter 3: Rationalised drug design approaches through 
identification of proteolytic selectivity of MMPs via molecular 
modelling 
 
III.1 Introduction 
A requirement for success in prodrug approaches is MMP selectivity through 
incorporation of MMP-subtype unique peptide sequence. Rational drug discovery 
approaches can fine-tune the selectivity of peptide substrates and inhibitors. 
Visualising and quantifying binding preferences and motifs can provide valuable 
insight into the structural determinants of substrate selectivity and enable MMP-
targeted drug development.134, 241  
III.1.1 Rational drug discovery 
Therapeutic drugs are essential for the prevention and treatment of diseases such 
as cancer, to restore the normal functioning of the human body when it goes 
wrong. The process of drug discovery is challenging, time consuming, expensive 
and relies on trial-and-error approach for testing of chemical compounds on 
cultured cells or animals to match the desired effects of treatment. To overcome 
these challenges, several multidisciplinary stages are required for successful drug 
discovery and these form the basis of rational drug design.  Rational drug 
discovery begins with the identification and characterisation of a biological 
macromolecule implicated in disease pathology i.e. finding a target.242  
Once a target is identified, the most fundamental goal in rational drug design is to 
predict whether a given drug molecule will bind to the target and if so how strongly, 
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with minimal cross selectivity with other biomolecules. This can be achieved in two 
broadly categorised ways:243-246 
A. Ligand-based approach relies on the knowledge of small molecules and their 
binding potencies to the target of interest. A spatial understanding within the 
binding pocket is built up by rational systematic changes to small molecule 
backbones. Thus though trial and error, using such approaches as matched pair 
analysis, a structure activity relationship can be built without molecular level 
knowledge of the target protein.247, 248 However, accurate knowledge of the 
receptor or protein structure is unknown and 3D-quantitative structure activity 
relationships (3D QSAR) using pharmacophore modelling is routinely used 
instead, to predict the activity of new analogues (Figure III.1).247, 248 A 
pharmacophore is defined as a molecular framework that carries the essential 
features responsible for a drug’s biological activity.246 QSAR is a mathematical 
model that relates to biological or chemical activity of a drug. In the absence of a 
target protein the 3D pharmacophore and QSAR models would predict the key 
amino acid positions within the active site of the target protein, based on the 
activity of known ligands. However, without the accurate knowledge of the target 
protein, the prediction results may be prone to error.249 
B. Structure-based approach relies on the knowledge of the three dimensional 
(3D) structure of the drug target bound to its natural ligand or a drug which is 
determined either by X-ray crystallography or by NMR. Once the ligand bound 3D 
structure is known, a virtual screening or computational technique is used to 
identify new drug ligands for a given receptor. The obtained 3D structure further 
enables the researchers to identify its binding site, the so called active site.250 The 
concept of this approach is to predict the binding affinity and selectivity of new 
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drug candidates for the drug target through knowledge of its 3D conformation. The 
identification of new ligands for a given receptor is achieved in a step-wise 
manner: determination of 3D structure of the drug target and identification of its 
binding site through in silico study, docking of minimum energy conformers of 
known drug ligands into the target to highlight key binding sites, rational design of 
novel drugs through the exploitation of the binding site and; experimentally 
validate the in silico prediction (Figure III.2).250 
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Figure III.1: Pharmacophore query for molecular binding recognition of MMP 
inhibitor (Ilomastat). The features represent recognition motifs such as hydrogen bond 
acceptors (cyan) or donors (pink), and hydrophobic groups (green). The radius of the 
sphere determines the strictness of the geometric constraint. For features where the 
correct orientation of the interaction is important such as hydrogen bonds and the 
aromatic plane, the vector indications are added to the structure. Pharmacophore 
modelling is useful for predicting of interaction of known ligand with a theoretical or similar 
receptor structure.  
 
 
 
Figure III.2: A structure-based drug design approach uses the 3D structure of the drug 
bound (e.g. MMP inhibitor, Ilomastat) to a target protein (e.g. MMP-10 protein) as a direct 
means for visualising protein-ligand interactions. The ligand bound receptor allows for 
determination of chemical modifications that can improve drug potency and selectivity.  
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III.1.2 X-Ray crystallography 
X-Ray crystallography is the most reliable and preferred technique for structural 
determination of biological macromolecules and proteins. The availability of protein 
structure can provide a more detailed understanding on structure-based drug 
design, elucidation of enzyme mechanisms and site-directed mutagenesis and 
improving specificity of protein-ligand interactions.251 
The aim of X-Ray crystallography is to obtain a three dimensional atomic and 
molecular structure from a crystal. A purified protein sample at high concentration 
is crystallised and exposed to an X-Ray beam. The resulting pattern of diffraction 
spots are then processed to yield information about the symmetry of crystal 
packing and size of the repeating unit that constitute the crystal. The intensity of 
the diffraction spots are used to calculate the map of electron density. The 
resulting molecular structure is then refined to adopt a thermodynamically 
favoured conformation and to fit the map more accurately.251 The following 
methodologies briefly describe the process from protein crystallisation to model 
building: 
III.1.2.1 Protein crystallisation 
Successful protein crystallography is achieved when a reliable protein source is 
available, along with high quality and homogenous yields are achieved from 
purification and concentration protocol. The growth of protein crystals is the rate 
limiting and a complex step in most protein crystallographic work. The principle of 
protein crystallisation is to take a high concentration solution of the protein sample 
and cause it to come out of solution.251, 252 For the purpose of analysing the 
catalytic binding sites of the protein and drug design, a synthetic/endogenous 
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inhibitor or a ligand bound protein is also prepared and purified prior to 
undertaking the crystallisation experiment.251, 253 Crystal growth is dependent upon 
factors such as the concentration of the protein concentration, buffer, the choice of 
precipitant and its concentration, its pH, temperature and the crystallisation 
technique. Crystal screen packages (commercially available) consisting of 
solutions varying widely in buffer, precipitant, pH and salt are often used at this 
stage.251, 253 The experiments can be set up using techniques like hanging drop 
vapour diffusion, sitting drop vapour diffusion and dialysis, commonly at both 4°C 
and room temperature.251, 254 Under correct conditions crystals will grow. At this 
stage it is more usual to see showers of microcrystals or a few tiny crystals, 
indicating that the crystal subunits possess sufficient intrinsic structural symmetry 
to make crystallisation achievable and also encourages the researcher to proceed 
for diffraction analysis of the crystals.254, 255 For the purpose of diffraction analysis, 
protein crystals should be a minimum of 0.1 mm in length, to provide sufficient 
exposure of crystal lattice to the X-Ray beam.251, 256 
III.1.2.2 Optical setup and diffraction analysis 
The X-Rays are generated from electrons striking a copper anode or from 
accelerating electrons in a synchrotron storage ring. The X-Rays must be focused 
into a beam and then collimated with sets of adjustable slits to 0.1-0.3 mm 
diameter.251, 256 The crystal is mounted in this beam and adjusted to a device 
called goniometer head. For cryogenic data collection, a cold liquid nitrogen gas 
stream is used to keep the crystal at 100K throughout the experiment.251, 257 
Before the exposure, the distance from the crystal to the detector is adjusted to 
allow for collection of diffraction spots up to maximum of 1.5-3.0 Å resolution. A 
collimator produces focused X-Rays on to the crystal to produce diffraction 
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pattern, detected on the X-Ray detector. The diffraction data is analysed by 
confirming the diffraction to sufficient resolution to make structure determination to 
inter-atomic detail possible. Usually, diffraction spots beyond 3 Å are required with 
carbon-carbon bond of approximately 1.5 Å and the resolution of 3 Å is sufficient 
to detect the amino acid side chains in the electron density map.251, 257 
III.1.2.3 Data processing  
There are many software packages available with well-established algorithms to 
overcome the mathematical complexity involved in processing of diffraction data. 
The first step involves the accurate determination of the crystal structure and of 
the unit cell dimensions in the space. The next step of the data processing is the 
measurement of the intensities of the diffraction spots. In theory, the larger the 
volume of the protein crystal the stronger the diffraction, so larger proteins are 
preferred to fully determine all atom positions.251  
III.1.2.4 Model building and refinement 
The quality of the electron density map can be refined by the geometrical 
operation that connects the non-crystallographic symmetry (NCS) subunits.251, 258 
This is further confirmed by comparing the observed structure factors with the 
calculated ones and the difference is expressed as the percentage of correlation 
factor known as the R-factor.251, 258, 259 Model building involves the use of a 
computer graphics program to display the electron density map and with the 
alignment of protein sequence, the insertion of each amino acid residue. The 
model of a molecule’s structure that has been built is then published and 
deposited in a crystallographic database; such as the Protein Data Bank (PDB) 
(for protein structures). PDB files can be downloaded from the RSCB PDB 
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(http://www.rcsb.org/pdb/home/home.do) and viewed using molecular modelling 
software such as Discovery Studio and PyMOL.251, 260 
 
III.1.3 Molecular dynamics and force field 
Further refinement of the molecular structure of the protein is carried out by 
computational modelling programs to minimise the energy conformation of the 
protein. In the field of computational chemistry, energy minimisation or geometry 
optimisation is the process of aligning the collection of atoms arranged in space 
where the net interatomic force on each atom is close to zero.261 This can be 
achieved by utilising a computer simulation method called molecular mechanics 
(MM) or molecular dynamics (MD). MD is used to estimate the strength of the 
intermolecular interaction between the small molecule and its receptor or drug 
target. These methods further enable the researcher to rationally predict and 
modify the conformation of the small molecule docked into the receptor. During the 
course of simulation, MD uses a combination of the mathematical parameters and 
functions commonly referred to as a force field. A force field is defined as a 
mathematical expression designating the dependence of the energy of the system 
on the coordinates of its particles.261-263 A Force field consists of a set of 
parameters used to calculate the interatomic potential energy of a system, U (r1, 
r2,….,rN) (Where ‘r’ represents the interatomic distance between molecules).  
These parameters are typically obtained either from the beginning or semi-
practical molecular mechanical calculations or by aligning to experimental data 
such as X-Ray and electron diffraction, Raman spectroscopy and NMR. Molecules 
are described as a series of atoms held together by simple elastic forces and the 
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force field simulation replaces the true of potential of the molecules with a 
simplified model effective in the region being simulated. Ideally it is sufficiently 
detailed to reproduce the molecular geometry and selected properties of the 
system studied, but must be simple enough to be evaluated quickly. 
Many force fields are available in the literature, designed for different simulation 
purposes and having different degrees of complexity. A force field is generally 
represented by the following equation (1):261-264 
𝑈 = ∑
1
2
𝐾𝑏 𝑏𝑜𝑛𝑑𝑠 (𝑟 − 𝑟0)
2
 +  ∑
1
2
𝐾𝑎 𝑎𝑛𝑔𝑙𝑒𝑠 (𝜃 − 𝜃0)
2  + ∑
𝑉𝑛
2
 [1 + cos (𝑛𝜙 − 𝛿)]𝑡𝑜𝑟𝑠𝑖𝑜𝑛𝑠   (1) 
      +  ∑ 𝑉𝑖𝑚𝑝𝑖𝑚𝑝𝑟𝑜𝑝𝑒𝑟  +  ∑ 4𝜖𝑖𝑗 𝐿𝐽 (
𝜎𝑖𝑗
12
𝑟𝑖𝑗
12 −
𝜎𝑖𝑗
6
𝑟𝑖𝑗
6 )+ ∑
𝑞𝑖𝑞𝑗
𝑟𝑖𝑗
𝑒𝑙𝑒𝑐  
Where the first four terms refer to intermolecular or local contributions to the total 
energy (angle bending, bond stretching, improper torsions and dihedral), and the 
last two terms describe the Van der Waals interactions (by application of 12-6 
Lennard-Jones potential) and the Coulombic interactions.261-263 
Widely used biomolecular protein force fields are CHARMM (Chemistry at Harvard 
Macromolecular Mechanics), AMBER (Assisted Model Building with Energy 
Refinement), GROMOS (Groningen Molecular Simulation), MMFF (Merck 
Molecular Force Field) and CFF (Consistent Force Field). These force fields were 
developed by different academic research groups, the associated parameters 
have been peer reviewed and made publicly available.264-267 By default, when a 
force field is applied in silico, attempts are made to ensure that the molecule 
simulates correctly by performing the following steps: 
1. Add hydrogens appropriate for the selected force field. 
2. Evaluate and assign partial charges to the system. 
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3. Determine atom types by applying forcefield-specific typing rules or by 
using residue templates. 
4. Identify missing forcefield types and assign the correct mathematical 
parameters for that force field.264-267 
 
III.2 Aims and objectives 
In this chapter, a reiterative approach using in silico proteolytic docking coupled to 
in vitro biochemical assessment have been applied to characterise the MMP 
catalytic site domains responsible for specific binding with known selective 
substrate residues. The rationale for this study is to examine the differences 
between the active site of MMPs docked with selective substrates and prodrugs; 
and create a robust approach which could be exploited for development of MMP-
activated diagnostic probes and therapeutics. The availability of 3-D crystal 
structures of MMPs allowed us to critically examine the differences existing 
between the catalytic domains of two closely related MMP subfamilies, the 
gelatinases: MMP-2 (PDB ID: 1QIB268) and MMP-9 (PDB ID: 1GKC269); and the 
stromelysins: MMP-3 (PDB ID: 1CIZ270) and MMP-10 (PDB ID: 1Q3A271). This 
allowed rational characterisation of the substrate cleavage site for a particular 
MMP and its selective substrate.  The commercially available (Bachem, 
Switzerland) MMP-cleavable fluorogenic substrates were used: M-2055222 and M-
2110221, reportedly to be selectively hydrolysed by gelatinases and stromelysins 
respectively. M-2055 is hydrolysed efficiently by MMP-9 at the Gly-Cys(Me) 
scissile bond and less efficiently by MMP-2 and stromelysins, whereas M-2110 is 
hydrolysed efficiently by stromelysins at the Glu-Nva scissile bond and less 
efficiently by MMP-9. The specific cleavage site of M-2055 by stromelysins and M-
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2110 by MMP-9 are yet to be determined. In order to rationally characterise these 
cleavage sites an in silico model was developed utilising 3-D flexible docking, 
identifying P1-P1’ substrate subsites chelating the Zn+2 ions in the active site of 
gelatinases and stromelysins; and subsequently analysing the intermolecular 
atomic distances and associated binding energies. To experimentally validate the 
computation study LC-MS was carried out to determine the product of MMP-
mediated cleavage of these substrates.  
Specific objectives include: 
1. To optimise in silico molecular dynamics model by complete energy 
minimisations using the appropriate forcefields supported by the Discovery 
Studio Client, Accelrys. 
2. To develop in silico models of MMPs based on the reported crystal 
structures and define the catalytic domains of the disease relevant 
proteases. 
3. To validate the models through flexible-ligand docking of MMP-selective 
substrates and highlight key catalytic binding determinants. 
4. To identify the cleavage site on substrates based on Zn+2 ion interaction 
and calculate total binding energy of the docked models. 
5. To experimentally validate the predictability of the in silico model for 
development of MMP-selective therapeutics. 
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III.3 Materials and methods 
III.3.1 3D-Molecular modelling 
All molecular modelling and calculations were performed using the BIOVIA 
Discovery Studio 4.0 molecular modelling package, developed by Accelrys. The X-
ray crystal structure of proteins MMP-2 (PDB ID: 1QIB), MMP-3 (PDB ID: 1CIZ), 
MMP-9 (PDB ID: 1GKC) and MMP-10 (PDB ID: 1Q3A) were acquired from the 
Protein Data Bank (PDB) and were prepared by omitting the ligands associated 
with the co-crystal structure. Substrate ligand structures were prepared in the 
Discovery studio in MOL format.  
Preparation of proteins: The protein structure (receptor) was acquired from the 
Protein Data Bank, the ligand was deleted and the protein structure was prepared 
for ‘flexible docking’. The ‘Prepare Protein’ protocol ensured the MMP protein was 
ready for input into future calculations, performing tasks such as cleaning the 
protein, optimising side-chain conformations, for those residues with inserted 
atoms and protonating the structure at the specified pH range (6.8 – 7.2 pH). After 
preparation, the receptor binding sites were identified from the receptor cavities 
(those cavities created on the removal of the original X-ray structure ligand). PDB 
files often have active sites defined using the SITE records. When a PDB file is 
imported, groups are created for each SITE. This tool highlights each site with a 
transparent red sphere which enables a check against the original co-crystal X-ray 
structure.  
Preparation of ligands: The new ligand structures were built and CHARMM 
(Chemistry at Harvard Macromolecular Mechanics) forcefield minimisation (using 
100,000 minimisation cycles) was applied until the final energy state of the 
molecule was near to zero kcal/mol. Following minimisation, the ligands were 
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prepared for ‘flexible docking’. The Prepare Ligand protocol helps to prepare 
ligands for input into other protocols, performing tasks such as removing 
duplicates, enumerating isomers and tautomers, and generating 3-D 
conformations. The minimum energy conformation was selected and used as the 
input for future calculations. Discovery Studio has a maximum allowable ligand 
size, so once minimised the peptide conformation was locked and the protecting 
groups along with the drug molecule (doxorubicin) were removed. This left the 
conformationally constrained peptide chain for docking.  
Once the protein and ligand structures were prepared and receptor binding sites 
identified, the docking was initialised using ‘flexible receptor-ligand docking’ tool. In 
this method the substrate ligands were docked into the active site clefts of MMPs 
via the DS flexible docking tool, wherein the protein structure was selected as the 
‘receptor molecule’ and the substrate structures as the ‘ligand molecule’. This 
protocol allows for some flexibility in receptor cavities during docking of low energy 
ligand conformations. The amino acid side-chains of specified binding site are 
allowed to move during docking. This allows receptors to adapt to different ligands 
in an induced-fit model. The protocol uses a combination of components from 
other protocols to perform docking, and utilises CHARMM based methods to 
sample side-chain and ligand conformations. The Flexible Docking protocol 
performs the following steps:  
1. Generation of protein conformations  
2. Rigid docking of low energy ligand conformers to protein  
3. Flexible docking. A final simulated annealing and energy minimisation of each 
ligand pose is performed using CDOCKER algorithm.  
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This procedure is automated within the Discovery Studio package and undertakes 
the process described by Koska and co-workers, which is outlined below.  
Adapted from J. Chem. Inf. Model., Vol. 48, No. 10, 2008 
 
Once completed for the respective substrates, docking results were analysed 
using Discovery Studio by viewing the ligand interactions hydrophobic receptor 
surfaces and the location of zinc ion in the receptor with respect to the ligand. This 
enabled the determination of any coordination of water molecules within the active 
site, interaction of active site residues with the ligand and the interatomic 
distances. The binding free energies between a receptor and a ligand were also 
calculated using the CHARMM implicit solvation models. The binding energy was 
calculated using the following equation:  
Energy binding = Energy complex – Energy ligand - Energy receptor (in kcal/mol) 
III.3.2 Liquid Chromatography-Mass spectrometry (LCMS) detection of 
substrates 
LC conditions: High-purity HPLC-grade solvents (Sigma-Aldrich), analytical grade 
chemicals (Sigma-Aldrich) and triple distilled water were used throughout. 
Reverse-phase chromatographic separation of substrates was performed using an 
Acquity UPLC comprising a BEH C18 1.7 µm column (2.1 mm x 100 mm) (Waters, 
UK). Mobile phases were as follows: Mobile Phase A consisted of 90% HPLC 
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grade water, 10% HPLC grade MeCN and 0.1% HCO2H. Mobile phase B 
consisted of 40% HPLC grade water, 60% MeCN and 0.1% HCO2H. 
MS conditions: A Micromass ZMD single quadrupole electrospray MS was used in 
positive mode (Micromass, Manchester, UK) and MassLynx software was used to 
identify substrates and anticipated metabolites. MS source parameters were 
optimised to: desolvation gas 375 L/hr, cone gas 33 L/hr, capillary 2.9 kV, sample 
cone 16 V, extraction cone 5 V, fR lens 0.1 V, source block temperature 150°C 
and desolvation temperature 200°C. Parent compounds and metabolites were 
detected as singularly charged ions using selected ion readings (SIR). 
III.3.3 Cleavage of substrates by recombinant MMPs 
Recombinant human MMP proteins (MMP-2, MMP-3, MMP-9 and MMP-10; R&D 
Systems, UK) were assayed for their ability to cleave fluorogenic substrates, M-2055 
(Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(N-Me-Abz)-amide) and M-2110 (Mca-Arg-Pro-
Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2). Reactions (100 µL) contained 20 ng 
recombinant protein and 10 mM substrates in MMP activity buffer (100 mM Tris-HCl pH 
7.6, 10 mM CaCl2, 100 mM NaCl, 0.16% v/v Brij-35), and incubated at 37˚C for 12 h. At 
T12, The sample was removed and diluted 1:3 with MeCN to precipitate proteins. The 
sample was then centrifuged at 10,000 x g for 3 minutes and supernatant assayed for 
substrate cleavage by LCMS. 
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III.4 Results 
III.4.1 Optimisation of force fields for in silico modelling  
A collection of well-known classes of force fields supported by the Discovery 
Studio Client allowed for rationalised optimisation and selection of the appropriate 
force field for in silico drug discovery studies. The peptide fragment of the MMP-
cleavable substrate, M-2055 (Dnp-Pro-β-cyclohexyl-Ala-Gly-Cys(Me)-His-Ala-
Lys(N-Me-Abz)-NH2), is presented as an example demonstrating the energy 
minimisation characteristics acquired in the presence of different force fields. 
(Figure III.3).  Firstly, the substrate was prepared for simulation by selection and 
application of a force field using the ‘forcefield tool’. When the process was 
finished and ready for simulation, the substrate was exposed to complete energy 
minimisation using the selected force fields until the final minimised energy state 
was close to zero. The substrate was able to minimise to the lowest energy state 
with CHARMM (Chemistry at HARvard and Macromolecular Mechanics) force field 
(0.55 kcal/mol). Whereas, the complete energy minimisation was not possible with 
MMFF (Merck Molecular Force Field) and CFF (Consistent Force Field) force 
fields (102.3 and 87.3 kcal/mol) (Figure III.3). The protein folding characteristics of 
the substrate further elucidated these energy states. The CHARMM, MMFF and 
CFF force field molecules attained α-helix conformation, near-straight chain and 
loop conformations, respectively; suggesting the differences in flexibility attained 
by the molecules and their minimised energies. With different energy minimisation 
capabilities of the force fields, the resulting structural conformations and the 
previously mentioned inherent energetic properties ascertained that CHARMM 
force field is a suitable force field for further in silico studies involved in this project.  
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Figure III.3: Energy minimisation simulation of M-2055 substrate with different force 
fields. Representative images of M-2055 peptide sequence minimised with CHARMM, 
MMFF and CFF force fields. The substrate residues are labelled and represented as white 
sticks. The respective structural conformations of CHARMM is shown as pink (sticks) and 
purple (folding); MMFF as green (sticks) and yellow (folding); and CFF as cyan (sticks) 
and blue (folding). 
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III.4.2 Description of MMP structures 
The catalytic domain of MMPs consists of five β-sheet strands and three α-helixes. 
The catalytic centre comprises of a catalytic zinc ion coordinated by three histidine 
residues and a glutamic acid. The N-terminal part of the molecule is rich in 
secondary structures with amphiphilic Helix αβ separating the β-strands of the 
twisted β-sheet. The Helix αβ provides two of the histidine residues, which bind the 
catalytic zinc ion, and the third being provided by the wide loop connecting the 
Helix αβ and the specificity loop. The specificity loop (S1’ subsite) within the 
catalytic site of MMPs shows the largest structural differences, this can be 
visualised in Figures III.4 and III.5.  
III.4.2.1 Comparison between the MMP binding sites 
The overall folding of the gelatinases and stromelysins resemble those of other 
MMPs, which is expected based on their structural similarity. The cavity of S1’ 
pockets in MMPs are well-suited to accommodate a wide-range of hydrophobic 
residues, with the main functional difference between MMP subtypes lying in this 
region (Figure III.4 and III.5).  
Although highly similar (75% structural similarity), the two gelatinase residues are 
different at the catalytic centre.  In MMP-9, residues 421 – 423 form the wall of the 
binding pocket and the specificity loop is formed by the residues 424 – 430. 
Arg424 is present at the bottom of S1’ pocket and closes off the end of the pocket. 
Arg424 is therefore responsible for making the pocket cavity smaller in MMP-9 
than MMP2 (Figure III.4). Due to this difference, the S1’ pocket of MMP-9 can host 
only smaller hydrophobic groups. Whereas in MMP-2, the external wall of the S1’ 
pocket is largely formed by Thr227 – Phe232 specificity residues. These specificity 
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determinants can potentially be exploited for rational design of MMP-selective 
substrates/conjugates (Figure III.4).  
 
Figure III.4: Overall 3D-structures of MMP-2 (PDB ID: 1QIB- represented as pink ribbons) 
and MMP-9 (PDB ID: 1GKC- represented as cyan ribbons). Helix αβ and specificity loops 
are shown in MMP-2 and MMP-9 respectively. Zinc and calcium ions in both MMPs are 
shown in purple and green respectively. Close-up view of the specificity loops in MMP-2 
and MMP-9 (lower images) represents the difference between their S1’ pocket size and 
depth. Specificity loops also show the different amino acid residues responsible for the 
difference between their S1’ pockets sizes. 
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With the highest structural similarity (89%) between the stromelysins (MMP-3 and 
MMP-10),271 the catalytic residues are also very similar with slight differences 
(Figure III.5). The specificity loop is larger in stromelysins compared to the 
gelatinases. The external wall of MMP-3 and MMP-10 specificity pockets are 
comprised of residues His224 – Phe232 and Asn240 – Phe248. This is the only 
region between the two MMPs where relatively large variability in amino acids can 
be observed in one stretch. In MMP-3, Leu226 is present at the bottom of the 
pocket and closes off the end of the pocket. The side chain of Phe232 is facing the 
wall of the pocket which is further responsible for the narrowing of the pocket. 
Therefore the S1’ pocket of MMP-3 is long and narrow. In MMP-10, Phe242 and 
Thr243 are present at the bottom of the pocket but the residue side chains are 
facing away from the pocket making the pocket slightly longer than MMP-3. 
Compared to Phe232 in MMP-3, Phe248 in MMP-10 is facing away from the wall 
of the pocket, which is further responsible for the widening of the pocket. 
Therefore, the S1’ pocket of MMP-10 if larger and wider compared to MMP-3 
(Figure III.5). These binding characteristics of MMPs can potentially be considered 
as determinants for rationalising the substrate binding and examining binding 
subsites to enable progress towards developing MMP-selective therapeutics. 
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Figure III.5 Overall 3D-structures of MMP-3 (PDB ID: 1CIZ- represented as orange 
ribbons) and MMP-10 (PDB ID: 1Q3A- represented as blue ribbons). Helix αβ and 
specificity loops are shown in MMP-3 and MMP-10 respectively. Zinc and calcium ions in 
both MMPs are shown in purple and green respectively. Close-up view of the specificity 
loops in MMP-3 and MMP-10 (lower images) represents the difference between their S1’ 
pocket size and depth. Specificity loops also show the different amino acid residues 
responsible for the difference between their S1’ pockets sizes. 
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To probe the selective binding of potential substrates, the peptide sequences of 
the non-specific gelatinase substrate (M-2055) and stromelysin substrate (M-2110) 
were input into BIOVIA Discovery Studio 4.0, minimised with respect to their 
geometry and then docked into the MMPs. Before undertaking this computational 
work, attempts at crystallisation of substrates were undertaken in order to 
determine the X-Ray crystal structure. Crystallisation experiments failed to yield 
suitable crystals for structure determination, therefore the optimised CHARMM 
minimised geometries of the substrates were employed throughout this study. 
III.4.3 Flexible-ligand docking of substrate M-2055 and MMPs 
M-2055 is a fluorogenic substrate (Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(N-Me-
Abz)-amide) known to be efficiently cleaved by interstitial collagenase (MMP-1) 
and gelatinase-2 (MMP-9).222 Both enzymes cleave this substrate at the Gly-
Cys(Me) bond, liberating a cleavage product with a fluorescent signal suitable for 
determining enzymatic activity. The gelatinase-1 and Stromelysin subfamilies also 
cleave this substrate at a relatively slower rate compared to MMP-9, however the 
cleavage sites are unknown. In order to determine the proteolytic cleavage and 
rationalise the binding selectivity, in silico flexible-ligand docking was applied using 
the substrate peptide residues and X-Ray crystal structures of gelatinases (MMP-2 
PDB ID: 1QIB268 and MMP-9 PDB ID: 1GKC269) and stromelysins (MMP-3 PDB ID: 
1CIZ270 and MMP-10 PDB ID: 1Q3A271).  
In both MMP-2 and MMP-9, the zinc ion interacts with the carboxylic acid between 
Gly and Cys(Me) bond, the known cleavage site according to Bickett et al.222 
MMP-9 is able to bind tightly with the substrate residues compared to MMP-2, as 
determined by differences in their interatomic zinc distances and overall binding 
energies. The substrate bound MMP-complexes provided crucial insights into the 
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differences in their subsites as S1 and S3 subsites in MMP-2 demonstrated affinity 
to accommodate longer side-chains than MMP-9. The charged nature of the S2 
subsite (presence of His205) in MMP-2 lends affinity for acidic residues, whereas 
this feature is not observed in MMP-9. 
In the MMP-9 structure, the carboxylic acid between Gly and Cys(Me) 
chelates the zinc ion (2.1 Å) and is involved in a strong H-bond to the carboxylate 
O of Glu402. The zinc ion is further coordinated by three Histidine residues namely 
His 401, His 405 and His 411 present in Helix αβ segment of the protein. Only the 
P1’ amino acid is involved in strong H-bonds with Arg424 (2.2 Å), which creates 
the wall-forming segment. Arg424 closes off the end of the S1’ pocket and forms a 
more enclosed pocket. The strong binding of Arg424 with the P1’ residue is an 
important determinant of the specificity pocket. Remaining substrate residues are 
involved in strong interactions with the bulge-edge segment molecules (Gly186 to 
His190) with interatomic distances ranging from 2.5 to 3.1 Å. The docked complex 
of M-2055 and MMP-9 has an overall binding energy of 706 kcal/mol (Figure III.6). 
 Consideration of the interaction of M-2055 with the active site of MMP-2 
shows a marked reduction in affinity in energetic terms, the predicted interaction 
seven times weaker than the M-2055 and MMP-9 complex (binding energy of 101 
kcal/mol). Gly forms the P1 subsite and Cys(Me) forms the P1’ subsite and the 
presence of a zinc ion, chelated by the carboxylic acid between P1-P1’ residues 
(3.8 Å), further confirms this. The P1’ residue, although favourable for the MMP-2 
specificity pocket, is not involved in any significant interaction with MMP-2 
residues. The remaining substrate residues have weak H-bond interactions with 
wall-forming and bulge-edge segments of MMP-2 with interatomic distances 
124 
 
 
ranging from 3.1 to 5.1 Å. This is expected as M-2055 residues are oriented away 
from further MMP-2 binding pockets (Figure III.6).  
 
When considering the interaction of M-2055 with the active sites of MMP-3 and 
MMP-10 the binding affinity was nine times weaker than the M-2055 and MMP-9-
complex (binding energy of 77 kcal/mol for MMP-10 and 79 kcal/mol for MMP-3). 
In the case of both stromelysins, proline forms the P1 subsite and β-cyclohexyl-
Alanine forms the P1’ subsite. The presence of the zinc ion, chelated by the 
carboxylic acid between P1-P1’ residues (3.8 Å), further confirms this. The P1’ 
residue, although favourable for the stromelysin, specificity pocket is not involved 
in any significant interaction with MMP-10 residues. The remaining substrate 
residues have weak H-bond interactions with wall-forming and bulge-edge 
segments of stromelysins with interatomic distances ranging from 2.8 to 5.0 Å. The 
M-2055 residues are oriented further away from stromelysin binding pockets 
where it occupies the S1, S1’ and S2’ subsites (Figure III.7). 
 
125 
 
 
 
Figure III.6: (Left) Stereo view of the docked complexes of M-2055 substrate (white 
sticks) and the catalytic domain of human MMP-2 (PDB ID: 1GKC) and MMP-9 (PDB ID: 
1GKC). Catalytic and structural zinc ions are shown as purple spheres. Active-site cleft 
residues (the αβ-helix loop and the specificity loop) are shown in green. (Right) Schematic 
representation of M-2055: active site binding interaction in human MMP-2 and MMP-9. 
MMP-2 and MMP-9 enzyme binding pockets are shown in red and green respectively. 
Substrate chemical structure and its scissile bond is shown in black. The zinc ion 
coordinated by histidine is indicated in blue.  
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Figure III.7 (Left) Stereo view of the docked complexes of M-2055 substrate (white sticks) 
and the catalytic domain of human MMP-3 (PDB ID: 1CIZ) and MMP-10 (PDB ID: 1Q3A). 
Catalytic and structural zinc ions are shown as purple spheres. Active-site cleft residues 
(the αβ-helix loop and the specificity loop) of MMP-3 and MMP-10 are shown in orange 
and blue respectively. (Right) Schematic representation of M-2055: active site binding 
interaction in human MMP-3 and MMP-10. MMP-3 and MMP-10 enzyme binding pockets 
are shown in orange and blue respectively. Substrate chemical structure and its scissile 
bond is shown in black. The zinc ion coordinated by histidine is indicated in blue.  
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III.4.4 Experimental validation of M-2055 and MMP binding 
To experimentally validate the predictability of this model, and confirm the in 
vitro cleavage position of M-2055, hydrolysis of the substrate by recombinant 
MMPs was assessed over a 12 h period.  The resultant products were assessed 
by LCMS using a reverse phase gradient system to separate the substrate (M-
2055) and proteolytic products. The identification of these species was confirmed 
by retention time and mass spectrometry (MS) data. M-2055 demonstrated a 
retention time (tR) of 2.8 minutes (Figure III.8) and rapid cleavage  by MMP-9 at 
Gly-Cys(Me) bond was confirmed by LCMS, two peaks corresponding to Dnp-Pro-
β-Cyclohexyl-Ala-Gly at tR of 2.3 minutes (
m/z 491.5Da, [M+H]
+) and Cys(Me)-His-
Ala-Lys(N-Me-Abz)-NH2 at tR of 2.47 minutes (
m/z 604.7Da, [M+H]
+) (Figures III.9 
and III.10). Slow hydrolysis of M-2055 by MMP-2 (compared to MMP 9) at Gly-
Cys(Me) bond was confirmed by two peaks at tR 2.3 minutes and tR of 2.47 
minutes. MMP-2 cleavage experiments displayed a parent peak of M-2055, 
detected at tR 2.8 minutes (
m/z 1077.5Da, [M+H]
+) (Figures III.9 and III.11, 
suggesting that MMP-2 metabolised M-2055 at a slower rate than MMP-9 (Section 
II.7.1, Figure II.13).  
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Figure III.8: Detection of M-2055 at retention time (tR) of 2.8 minutes (m/z 1077.5Da, 
[M+H]+), confirmed by LC-MS  
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Figure III.9. Schematic representation of the cleavage of M-2055 substrate by 
recombinant MMP-2 and MMP-9 enzymes at Gly-Cys(Me) bond.  
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Figure III.10: Cleavage of substrate M-2055 by recombinant MMP-9, detected by 
LCMS: (A) LC of MMP-9 mediated cleaved metabolites, (tR 2.3 and 2.47 minutes); (B) MS 
identification of Dnp half of cleaved substrate (Dnp-Pro-β-Cyclohexyl-Ala-Gly), tR 2.3 
minutes (m/z 491.5Da, [M+H]
+); (C) MS identification of Abz half of cleaved substrate 
(Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH2) tR 2.47 minutes (
m/z 604.7Da, [M+H]
+). 
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Figure III.11: Cleavage of substrate M-2055 by recombinant MMP-2, detected by 
LCMS: (A) LC of MMP-2 mediated cleaved metabolites, (tR 2.3 and 2.47 minutes); (B) 
MS identification of Dnp half of cleaved substrate (Dnp-Pro-β-Cyclohexyl-Ala-Gly), tR 2.3 
minutes (m/z 491.5Da, [M+H]
+); (C) MS identification of Abz half of cleaved substrate 
(Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH2) tR of 2.47 minutes (
m/z 604.7Da, [M+H]
+). 
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Whereas, the cleavage of M-2055 by MMP-3 and MMP-10 at the Pro – β-
Cyclohexyl-Ala bond was confirmed by the production of two peaks of cleaved 
metabolites corresponding to Dnp-Pro at tR 1.75 minutes (
m/z 282.2Da, [M+H]
+) 
and; β-Cyclohexyl-Ala-Gly-Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH2 at tR 2.68 minutes 
(m/z 815.4 Da, [M+H]
+) (Figures III.12, III.13 and III.14). As expected, with MMP-3 
and MMP-10 cleavage, a parent peak of M-2055 was also detected at Rt of 2.8 
minutes (m/z 1077.5Da, [M+H]
+) suggesting that MMP-3 and MMP-10 metabolised 
M-2055 at a slower rate than MMP-9. This in vitro assessment successfully 
supports the validity of the predicted in silico model of M-2055 substrate and MMP 
interactions (Figures III.6 and III.7). 
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Figure III.12: Schematic representation of the cleavage of M-2055 substrate by 
recombinant MMP-3 and MMP-10 enzymes at Pro- β-Cyclohexyl-Ala bond.  
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Figure III.13: Cleavage of substrate M-2055 by recombinant MMP-3, detected by 
LCMS: (A) LC of MMP-3 mediated cleaved metabolites, (tR 1.77 and 2.68 minutes); (B) 
MS identification of Dnp half of cleaved substrate (Dnp-Pro), tR 1.77 minutes (
m/z 282.2 
Da, [M+H]+); (C) MS identification of Abz half of cleaved substrate (β-Cyclohexyl-Ala-Gly-
Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH2) tR 2.68 minutes (
m/z 815.4 Da, [M+H]
+). 
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Figure III.14: Cleavage of substrate M-2055 by recombinant MMP-10, detected by 
LCMS: (A) LC of MMP-10 mediated cleaved metabolites, (tR 1.77 and 2.68 minutes); (B) 
MS identification of Dnp half of cleaved substrate (Dnp-Pro), tR 1.77 minutes (
m/z 282.2 
Da, [M+H]+); (C) MS identification of Abz half of cleaved substrate (β-Cyclohexyl-Ala-Gly-
Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH2) tR 2.68 minutes (
m/z 815.4 Da, [M+H]
+). 
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III.4.5 Flexible-ligand docking of substrate M-2110 and MMPs 
When considering the interaction between M-2110 and stromelysins (the selective 
substrate for this MMP subfamily)221 individually, it was observed that zinc ion 
coordinates strongly with the carboxylate between the Glu- Nva (Norvaline) bond, 
the known cleavage site according to Nagase et al.221 The interatomic zinc 
distance in MMP-3 is 1.9 Å and that in mmp-10 is 2.1 Å. The Glu forms the P1 
subsite and makes significant contributions to the substrate binding energy. The 
Nva side chain of the P1’ subsite is inserted into the S1’ pocket of both 
stromelysins, and is further coordinated by the wall-forming segment residues (at 
distances of 2.1 to 2.3 Å). The side chains of Leu223 and Leu229 in MMP-3 and; 
the side chains of Phe212, Leu213, Leu234 and Phe248 in MMP-10 make the 
hydrophobic cluster at the bottom of the pocket. The complete binding energies of 
M-2110 – MMP-3 and M-2110 – MMP-10 docked complexes are 591 kcal/mol and 
522 kcal/mol, respectively (Figure III.15).  
Whereas, the interaction between M-2110 and MMP-9 is nearly five times weaker 
(binding energy = 102 kcal/mol) than the M-2110 and MMP-10 complex. In this 
case, the carboxylic acid between proline-valine, which forms the P1-P1’ subsite, 
chelates the zinc ion (3.6 Å) and it is also involved in a weak polar interaction with 
the carboxylate O of Glu402. Arg424 possesses a weak interaction (4 Å) with P1’ 
residue, that is inserted into the enclosed S1’ pocket. The remaining substrate 
residues have weak binding interactions (3.5 to 4.1 Å) with the bulge-edge 
segment molecules. On the other hand, the docking of M-2110 and MMP-2 
revealed negative binding energy. Although proline-valine formed the P1-P1’ 
subsite, the catalytic zinc of MMP-2 was unable to interact with the peptide 
residues of M-2110 (Figure III.16.  
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Figure III.15: (Left) Stereo view of the docked complexes of M-2110 substrate (white 
sticks) and the catalytic domain of human MMP-3 (PDB ID: 1CIZ) and MMP-10 (PDB ID: 
1Q3A). Catalytic and structural zinc ions are shown as purple spheres. Active-site cleft 
residues (the αβ-helix loop and the specificity loop) of MMP-3 and MMP-10 are shown in 
orange and blue respectively. (Right) Schematic representation of M-2110: active site 
binding interaction in human MMP-3 and MMP-10. MMP-3 and MMP-10 enzyme binding 
pockets are shown in orange and blue respectively. Substrate chemical structure and its 
scissile bond is shown in black. The zinc ion coordinated by histidine is indicated in blue.  
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Figure III.16 (Left) Stereo view of the docked complexes of M-2110 substrate (white 
sticks) and the catalytic domain of human MMP-2 (PDB ID: 1GKC) and MMP-9 (PDB ID: 
1GKC). Catalytic and structural zinc ions are shown as purple spheres. Active-site cleft 
residues (the αβ-helix loop and the specificity loop) of MMP-2 and MMP-9 are shown in 
pink and cyan respectively. (Right) Schematic representation of M-2110: active site 
binding interaction in human MMP-2 and MMP-9. MMP-2 and MMP-9 enzyme binding 
pockets are shown in red and green respectively. Substrate chemical structure and its 
scissile bond is shown in black. The zinc ion coordinated by histidine is indicated in blue. 
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III.4.6 Experimental validation of M-2110 and MMP binding 
In vitro biochemical assessment further validated the predictability of this model 
and confirmed the cleavage of positions of M-2110 by respective MMPs. The 
hydrolysis of the substrate by recombinant MMPs was assessed over 12 h period 
and the resultant products were assessed by LCMS using a reverse phase 
gradient system to separate the substrate and proteolytic products. The 
identification of these species was confirmed by retention time and mass 
spectrometry (MS) data. M-2110 was detected at tR 4.15 minutes (Figure III.17). 
The rapid cleavage by stromelysins at the Glu-Nva bond was confirmed by two 
peaks corresponding to Mca-Arg-Pro-Lys-Pro-Val-Glu at tR of 2.8 minutes (m/z 
940.5Da, [M+H]+) and Nva-Trp-Arg-Lys(Dnp)-NH2 at tR of 2.5 minutes (
m/z 751.4 
Da, [M+H]+) (Figures III.18, III.19 and III.20).  
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Figure III.17: Detection of M-2055 at tR 4.152 minutes (
m/z 1673.8 Da, [M+H]
+), confirmed 
by LC-MS  
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Figure III.18. Schematic representation of the cleavage of M-2110 substrate by 
recombinant MMP-3 and MMP-10 enzymes at Glu-Nva bond.  
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Figure III.19: Cleavage of substrate M-2110 by recombinant MMP-3, detected by 
LCMS: (A) LC of MMP-3 mediated cleaved metabolites, (tR 2.5 and 2.8 minutes); (B) MS 
identification of Dnp half of cleaved substrate (Nva-Trp-Arg-Lys(Dnp)-NH2), tR 2.5 minutes 
(m/z 751.4 Da, [M+H]
+); (C) MS identification of Mca half of cleaved substrate (Mca-Arg-
Pro-Lys-Pro-Val-Glu) tR 2.8 minutes (
m/z 940.5 Da, [M+H]
+). 
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Figure III.20: Cleavage of substrate M-2110 by recombinant MMP-10, detected by 
LCMS: (A) LC of MMP-10 mediated cleaved metabolites, (tR 2.5 and 2.8 minutes); (B) MS 
identification of Dnp half of cleaved substrate (Nva-Trp-Arg-Lys(Dnp)-NH2), tR 2.5 minutes 
(m/z 751.4 Da, [M+H]
+); (C) MS identification of Mca half of cleaved substrate (Mca-Arg-
Pro-Lys-Pro-Val-Glu) tR 2.8 minutes (
m/z 940.5 Da, [M+H]
+). 
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Whereas, the slow hydrolysis of M-2110 by MMP-9 at the Pro-Val bond was 
confirmed by two peaks corresponding to Mca-Arg-Pro-Lys-Pro tR 2.4 minutes (
m/z 
712.4 Da, [M+H]+) and Val-Glu-Nva-Trp-Arg-Lys(Dnp)-NH2 tR 2.87 minutes (
m/z 
977.5 Da, [M+H]+) (Figures III.21 and III.22). As expected, with MMP-9 cleavage, a 
parent peak of M-2110 was also detected at tR 4.15 minutes (
m/z 1674.8 Da, 
[M+H]+), suggesting that MMP-9 metabolised M-2110 at a slower rate than 
stromelysins (Figures III.19 and III.20). The differential cleavage of M-2110 by 
stromelysins and MMP-9 occurred exactly at the predicted subsites (Figures 
III.16). Furthermore, MMP-2 did not display any experimental cleavage of M-2110, 
reflecting the negative or weak in silico binding of MMP-2 and M-2110 (Figure 
III.21). 
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Figure III.21 Schematic representation of the cleavage of M-2110 substrate by 
recombinant MMP-9 at Pro-Val bond, whereas no cleavage was detected with 
recombinant MMP-2.  
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Figure III.22: Cleavage of substrate M-2110 by recombinant MMP-9, detected by 
LCMS: (A) LC of MMP-9 mediated cleaved metabolites, (tR 2.4 and 2.87 minutes); (B) MS 
identification of Mcs half of cleaved substrate (Mca-Arg-Pro-Lys-Pro), tR 2.4 minutes (
m/z 
712.4 Da, [M+H]+); (C) MS identification of Mca half of cleaved substrate (Val-Glu Nva-
Trp-Arg-Lys(Dnp)-NH2) tR 2.87 minutes (
m/z 977.5 Da, [M+H]
+). 
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III.5 Discussion 
Difficulties in identifying substrate preferences within MMP subfamilies are a major 
hindrance for progressive design and development of therapeutics exploiting 
specific MMPs. A major requirement for prodrug or theranostic approaches is 
MMP-selectivity through incorporation of MMP subtype unique peptide sequences 
and subsequent disease-selective activation. Thus, determination of the optimum 
peptide sequence to enable biochemical activity through selective cleavage by the 
targeted MMP, in conjunction with pharmacological stability of the un-activated 
molecule, is crucial for the design and development of disease-selective probes 
and therapeutics.204, 205 This chapter was aimed at rationalising the functional 
similarity and substrate cleavage preferences between the members of the MMP 
subfamily. The utilisation of in silico proteolytic docking of MMP-selective 
substrates within the active site of MMPs, coupled to in vitro biochemical 
assessment provided a robust tool for identifying MMP-subtype specific substrates 
and progress towards subsequent development of MMP-selective therapeutic 
approaches. 
The molecular dynamics suite, Discovery Studio, was utilised for in silico studies. 
This application supports authentic and comprehensive molecular dynamics 
simulations tools for multidisciplinary research. Molecular dynamics simulations 
can help in the study of protein folding and stability, molecular recognition, 
conformational changes and developing new ligands selective to the protein of 
interest. In order to successfully utilise MD simulations, its mathematical 
parameters, collectively termed as force field, were first assigned and optimised to 
the input molecule. The availability of widely used force fields such as CHARMM, 
MMFF and CFF within this application allowed for systematic selection of suitable 
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force field for simulation studies.272 The aim of force field optimisation study was to 
select a correct force field for complete energy minimisation that can be applied for 
structure-based drug design approaches. The in silico evidence is presented, 
showing the application of various force fields for complete energy minimisation of 
MMP-selective substrate, M-2055. CHARMM demonstrated complete energy 
minimisation of the substrate and the molecule acquired a flexible α-helix 
conformation. The complete energy minimisation of the substrate structure was 
not observed with MMFF and CFF force fields. The final energy of the molecule 
with MMFF and CFF force fields were relatively higher and the molecule 
demonstrated rigid conformations compared to CHARMM. Therefore, CHARMM 
was chosen as the suitable force field for energy minimisation and conformation 
studies. CHARMM minimised geometries of substrates were employed throughout 
this study for validation of the in silico flexible-ligand docking model.  These force 
fields have unique parameters to support the simulation of many organic 
molecules. For instance, class-I force fields such as CHARMM has the broadest 
coverage for organic molecules amongst all the forcefields available in this 
application.  CHARMM has a large collection of general parameters for majority of 
organic molecules, including non-standard nucleic acid bases, non-standard 
amino acids, and co-factors; and even has optimised parameters for proteins and 
nucleic acids. It has parameter coverage for all the physiologically relevant ions 
and is able to assess the missing parameters based on the local chemical 
environment of the atom. The CHARMM force field can be used for simulations 
with different solvent models, including explicit solvents and generalised implicit 
solvent models. It also has adequate accuracy for energy minimisation of small 
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molecules; and studying protein-ligand and protein-protein interactions, a feature 
that is not observed in class-II forcefields such as MMFF and CFF.273, 274 
Class-II force fields such as CFF and MMFF are general purpose force fields with 
good parameter coverage for many organic molecules. CFF has additional cross 
terms in its potential energy function, compared to class-I force fields. MMFF is 
derived from ab initio calculations and experimental data. It was designed to be a 
transferable force field for pharmaceutical compounds that accurately treats 
conformational energetics and non-bonded interactions. The two force fields have 
wide coverage for all organic molecules, allowing for a large number of 
compounds to be tested for database screening in drug design.273, 274  
While they are highly successful with general organic molecules, class-II force 
fields are considered to be less accurate for protein simulations in explicit solvent 
models when compared with CHARMM. To remedy this deficiency, structural 
restraints are applied on protein molecules when simulating protein-ligand 
complexes. They have not been adequately tested or validated for working with 
implicit protein models and cannot be run with simulations in parallel mode. CFF 
and MMFF force fields do not possess adequate accuracy for studying protein-
ligand and protein-protein interaction when compared to CHARMM.272-274 
The next step in this study was to review how the 3D-structure of MMPs can be 
used as a guide to rationalise functional similarity between MMP catalytic 
domains.  The 3D-strutures of closely related MMP sub-families: Gelatinases 
(MMP-2 and MMP-9) and Stromelysins (MMP-3 and MMP-10) and their flexible 
docked complexes with MMP-substrates, provided valuable insights into the 
structural determinants of substrate selectivity of a particular MMP. According to 
literature, M-2110 is hydrolysed rapidly by Stromelysins and very slowly by MMP-
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9; whereas M-2055 is hydrolysed rapidly by MMP-9 and very slowly by Gelatinase 
B (MMP-2) and Stromelysins. The cleavage pattern reported in the literature222 
and observed via 3-D molecular docking (current study), demonstrated that MMP-
9 strongly interacts with M-2055 at the Gly-Cys(Me) bond, and the present study 
confirmed this finding. However, the cleavage of this substrate by MMP-2 and 
Stromelysins is unknown. Based on 3-D molecular modelling and the respective 
zinc-chelation sites, it was predicted that MMP-2 interacts with the substrate at 
Gly-Cys(Me) bond and Stromelysins interacts at Pro-β-cyclohexyl-Ala bond. This 
prediction data was experimentally confirmed by incubating M-2055 substrate with 
recombinant MMPs and analysing the cleaved metabolites via LCMS. 
The cleavage of M-2110 reported in the literature221 and observed in our 3-D 
molecular modelling indicated that stromelysins strongly interact with M-2110 at 
the Glu-Nva bond, which was confirmed by the in vitro cleavage assay. Again, as 
for the non-selective use of M-2110, the cleavage pattern of this substrate by 
MMP-9 is unknown/unreported. Based on 3-D molecular modelling and the 
respective zinc-chelation sites, it was predicted that MMP-9 interacts with the 
substrate at the Pro-Val bond. This prediction was also experimentally confirmed 
highlighting that a suitable predictive model has been created for the determination 
of substrate cleavage sites by these MMPs.  
Most members of the MMP family share a similar catalytic domain constituted by 
about 170 residues. The domain contains a catalytic zinc ion and a chelated 
histidine complex, which is responsible for the peptide hydrolysis reaction. MMP 
catalytic sites share a marked sequence similarity, where the percentage of similar 
residues ranges from 33% (between MMP-21 and MMP-23) to 86% (between 
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MMP-3 and MMP-10).271 The successful validation of the in silico proteolytic 
docking coupled to in vitro biochemical assessment provided significant 
knowledge about the subtle differences in substrate binding efficiencies between 
the closely related MMP subfamilies studied.  
The key observed differences between the binding affinity of MMP-2 and MMP-9 
with M-2055 are (Figure III.23): 
In MMP-2 the S1 subsite is located near the bulge-edge segment and; the S2 and 
S3 subsites are located in the helix αβ segment. In MMP-9, the S1 and S3 
subsites are located in the helix αβ segment and the S2 subsite is located near the 
bulge-edge segment. Furthermore, the S1 and S3 subsites in MMP-2 have deeper 
cavity than MMP-9, suggesting that MMP-2 can accommodate longer side chains 
then MMP-9. The presence of small chain Ala165 residue in MMP-2 S1 subsite 
accounts for bigger hydrophobic pocket, whereas Glu402 residue in MMP-9 
causes the S1 pocket to become shallow in comparison. Similarly, the presence of 
Gly204 in MMP-2 at S3 subsite accounts for a large neutrally charged pocket. On 
the contrary, Asp410 present at the bottom of the S3 subsite in MMP-9 accounts 
for a small pocket. It was also observed that both these MMPs consisted of large 
S2 pockets with a difference in polarity. His205 in MMP-2 αβ-Helix loop makes the 
S2 pocket charged in nature and could potentially accommodate acidic residues. 
Whereas, the presence of Phe192 residue in MMP-9 account for a hydrophobic S2 
pocket.  
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The key observed differences between the binding affinity of MMP-3 and MMP-10 
with M-2110 are (Figure III.23): 
In spite of identical substrate selectivity of MMP-3 and MMP-10, there were subtle 
but significant binding differences between the two. As previously detailed, the S1’ 
pocket of MMP-10 is wider in comparison to MMP-3. The difference in S2 and S3 
pockets may hold the key in rationalising the substrate selectivity between the two 
stromelysins. Ser179 and Leu180 are present on either sides of the S2 pocket in 
MMP-10, suggesting that it can accommodate both hydrophobic and hydrophilic 
residues. Whereas, the presence of Ile203 in MMP-3 makes the S2 pocket 
hydrophobic in nature. Similarly, the presence of Ala229 and His227 on either side 
of the S3 pocket of MMP-10 suggests that it can accept both polar and non-polar 
residues. On the other hand, the S3 pocket of MMP-3 contains His166 and is 
smaller in comparison to MMP-10. 
Using the X-ray structure of MMPs published on the RSCB Protein Data Bank in 
silico model was developed which described the binding of selective MMP 
substrates into the active sites gelatinases and stromelysins. This showed the 
binding mode of M-2055 and M-2110 in both MMP families, with the modelling 
results confirmed by in-vitro cleavage studies. This study demonstrated that it is 
possible to accurately predict the substrate binding within these systems without a 
substrate ‘small molecule’ crystal structure to guide molecular binding 
conformation. In conclusion, such a strategy would be applicable, and valuable, in 
the development of prodrug approaches to selectively target tumours with MMP 
overexpression. 
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Figure III.23: Rationalised differences between the substrate residues binding 
preferences of the studied MMPs. To indicate the type of residues preferred, amino acid 
side chains are suggested as examples. 
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Chapter 4: Design, synthesis and preclinical screening of MMP-
targeted prodrugs 
 
One of the most significant problems with standard chemotherapeutic agents is 
their lack of selectivity for tumour tissue. Targeted cancer therapies offer the 
potential of reduced side effects along with benefits of prolonging drug exposure to 
cancerous tissues, enabling improved tumour response and survival rates. 
Harnessing the elevated enzymatic activity of MMPs within the tumour 
microenvironment to selectively convert a non-toxic prodrug into a potent 
chemotherapeutic agent is one such approach with significant therapeutic 
scope.200, 203-205 Chapter 3 demonstrates the feasibility of utilising in silico 
approaches coupled to in vitro biochemical assessment for rationalising the 
differences in catalytic domain of MMPs and validating the 3D-docking model, thus 
enabling progress towards development of MMP-targeted prodrugs. Whilst  linking 
a peptide sequence to a number of cytotoxic agents renders them inactive, the 
most crucial and challenging step in the design of prodrugs is determining an 
amino acid sequence which allows for selective cleavage only by the MMPs, or 
indeed, specific members of the MMP family.205 This chapter aims to build on 
previous computational modelling studies, exploiting the binding site preferences 
between MMPs and rationally design peptide prodrugs selectively activated by 
specific MMP subfamily members.  
IV.1 Identification of MMP-selective peptide sequences 
Determining the in vivo substrate degradome of proteases is a challenging task 
but, one that has made significant progress in the last few years. Protease 
degradome account for 1.7% of the human genome and is essential for dynamic 
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regulation of virtually every biological process, suggesting the elucidation of 
protease substrates is essential.194, 275 There are a number of approaches which 
have been employed to identify in vivo and in vitro protease substrates and 
cleavage subsites, an area which is collectively known as ‘protease 
degradomics’.275, 276 Such techniques include the application of large series of 
synthetic peptides based on natural substrates, phage display libraries, activity-
based probes and mixture-based libraries.277  
If the protease substrate is defined as …P3-P2-P1~P1’-P2’-P3’… where P is any 
specific amino acid, cleavage of the substrate (by a protease) occurs between P1 
and P1’ amino acids (Figure IV.1).  
 
Figure IV.1: Protease binding sites (P) directly contact the substrate binding sites (S) of 
the substrate. The S-sites nomenclature is concordant with the P sites. Sn sites are amino 
terminal to the scissile bond, and the Sn’ sites are carboxy-terminal to the scissile bond. 
 
Utilising a mixture-based peptide library and recombinant MMPs to identify MMP 
cleavage motifs, a MMP cleavable substrate sequence was identified containing a 
Pro at P3 position,  small residues particularly Ser at P1 position and hydrophobic 
Scissile bond
S1
S2
S3
S1’ S3’
S2’
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amino acids such as Leu/Met at P1’ position.278 This study also identified for the 
first time the binding preference of MMPs for substrate residues outside of the P1-
P1’ cleavage subsite.278 Although a number of cleavage motifs have been 
identified that are common to all MMPs, certain differences have also been 
observed that can distinguish the substrate specificity of MMPs. The difference in 
substrate recognition by MMP-3 and MMP-7 was found to depend heavily on the 
type of amino acids at the P2 and P1’ positions. While both enzymes favoured Pro 
at P3 position, the substitution of Leu for Met at P1’ resulted in a modest increase 
in MMP-3 activity but decreased MMP-7 activity by eightfold. The substitution of 
Leu for Phe at P2 resulted in a threefold decrease in MMP-3 activity but increased 
MMP-7 activity by threefold.279 Collagen-sequence based synthetic peptides have 
also been used to provide a number of important insights into the differences and 
similarities in subsite requirement among MMPs. This study observed that 
aliphatic side chains at P1’ position provided good substrates for all MMPs. The 
catalytic efficiency of MMPs is dependent upon the length of the peptide substrate. 
For example, MMP-3 preferred extended peptide for enhanced catalytic activity 
compared to a peptide containing only three residues or two residues in the P’ 
subsite.279, 280  
P2’ position also showed marked influence in specificity. The study of crystal 
structures of MMPs with peptide inhibitors indicated that the side chain at the P2’ 
site points away from the enzyme surface and bulky side chains such as Leu is 
preferred compared to Ala. Substitution of the P1 position for Gly also produced 
reasonable substrates for certain MMPs. Ala was found to be well tolerated by 
collagenases, stromelysins and gelatinases. Glu at this position was well tolerated 
by MMP-3 and MMP-8. Val substitution made the peptide a poor substrate for 
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most of the MMPs except MMP-3. Bulky aliphatic chains were not favoured by 
MMP-2 and MMP-9 at P1 position.281-283  
MMP-3 (Stromelysin-1) and MMP-10 (Stromelysin-2) share a marked sequence 
similarity and substrate specificity. The crystal structure of MMP-3 bound to 
endogenous inhibitors has been studied more extensively to reveal the structural 
basis of MMP-TIMP interaction. MMP-10 has been less thoroughly characterised 
but, with 86% amino acid residue identity to MMP-3 throughout the catalytic 
domain and with similar macromolecular substrates, has been predicted to 
possess similar biochemical properties and substrate cleavage specificities.134, 271 
Substrate recognition by stromelysin was proposed to depend heavily on the P1, 
P2 and P1’ residues. MMP-3 was found to selectively cleave fluorogenic substrate 
containing charged residues at P1 position and hydrophobic residues at P2 
position. The P1’ position in MMP-3 was able to tolerate aliphatic chains rather 
than bulky aromatic residues.221 Selective modification of the binding subsites 
increased the substrates selectivity for stromelysin family, over MMP-1, MMP-2 
and MMP-9. Multiplexed iTRAQ-based Terminal Amine Isotopic Labelling of 
Substrates (TAILS) have also been employed to refine the substrate specificity of 
MMP-10. This study revealed for the first time the preference of MMP-10 for 
glutamic acid at P1 position on the substrates.284 However, this substrate was also 
cleaved by MMP-3, the closest homologue of MMP-10, but lacked selectivity for 
MMP-9. This preference reinforced the suggestion that MMP-10, similar to MMP-3, 
preferred substrates with charged residues at P1, the basis for several commercial 
stromelysin-selective substrates.221, 284 However, since MMP-10 has been mostly 
neglected in the quest for new peptide substrates, it remains to be elucidated if 
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there are any specific differences in the binding subsites and amino acid 
preferences compared to MMP-3 and gelatinases. 
IV.2 MMP-10 targeted therapeutics 
Although MMP-10 is closely related to MMP-3 with respect to structure and 
substrate specificity, differences in activity and cellular distribution exist, 
suggesting distinct roles of MMP-3 and MMP-10.155 Unlike several other MMPs 
that are localised predominantly in tumour stroma, the tumour cells themselves 
overexpress MMP-10.155 Overexpression of MMP-10 has been validated in several 
human tumours of epithelial origin including, head and neck, oesophageal and oral 
squamous cell carcinoma (SCC) and non-small cell lung carcinoma (NSCLC). 
MMP-10 has also been found to possess distinct roles (compared to MMP-3) in 
cancers, including lung cancer, lymphoma, and head and neck cancer.155, 223-225, 
227-229, 232 As demonstrated in Chapter-2, the overexpression and elevated 
proteolytic activity of MMP-10 in human glioblastoma samples and cell lines 
relative to normal brain tissues, suggests MMP-10 as a potential therapeutic target 
for selective drug activation. As outlined in sections I.13 and I.14 (Chapter 1), a 
number of studies relating to the targeting of MMPs only assessed the feasibility of 
targeting gelatinases and MT-MMPs with peptide prodrugs. The peptide 
sequences of stromelysin selective fluorogenic substrates (M2110) however, are 
unlikely to represent MMP-10 selective sequence since it also has broad 
selectivity by other MMPs including MMP-3 and MMP-9. Cleavage of the linker by 
other MMPs expressed in non-diseased tissues would lead to non-specific release 
of drug causing systemic side effects.205 Several studies have shown that most 
peptide prodrugs are cleaved by multiple MMPs, which may not be important but 
when a target and anti-target both cleave a particular sequence, the MMP-
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selective drug activation system will fail. Thus, it is apparent that the MMPs, 
particularly stromelysin subfamily, are underutilised targets for anticancer drug 
delivery. 
IV.3 Aims and objectives 
The overall aim was to develop prodrugs of doxorubicin and the analogues of 
colchicine (azademethlycolchicine) to be preferentially cleaved by MMP-10. 
Chapter 2 demonstrates the overexpression of MMP-10 in high grade glioma 
relative to histologically normal brain tissue, indicating that this enzyme is a 
potential drug target. Since MMP-10 participates in angiogenesis and is 
proteolytically expressed by tumour tissue, targeting prodrugs to MMP-10 should 
allow for activation of the agent selectively in the tumour microenvironment. MMP 
subfamily activated peptide-prodrugs were rationally designed and synthesised by 
coupling MMP-cleavable peptides to antitumour agents, to selectively target 
doxorubicin (Dox) and azademethylcolchicine to tumour tissue.   
Specific objectives include: 
1. To exploit the substrate binding selectivity between closely related MMPs 
2. To rationally design prodrugs selectively activated by specific MMPs over a 
close family homologue i.e. MMP-2 and MMP-10 but not by MMP-9 and 
MMP-3. 
3. To assess specificity of prodrug cytotoxicity utilising MMP positive and 
negative preclinical tumour models. 
4. To assess metabolism of prodrugs in tissues such as human tumour, 
mouse liver, mouse kidney and blood plasma ex vivo. 
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5. To rationally design prodrugs cleaved selectively by MMP-10 relative to 
other MMP family members, MMP-2, MMP-9 and MMP-3. 
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IV.4 Materials and methods 
IV.4.1  Synthesis of MMP-targeted peptide conjugates 
Custom designed peptide sequences with Cbz (Benzyloxycarbonyl) as the 
chemical endcap were purchased from Bachem (Bubendorf, Switzerland)/ 
synthesised using solid phase strategy. Activation of the pre-loaded 2-chlorotrityl 
resin was carried out in a fritted polypropylene reaction chamber. 0.1 mmol of 
resin was weighed into the reaction chamber and 2 ml of dry DCM added. The 
reaction vessel was shaken for 45 minutes. After this time, DCM removed and the 
resin washed further with DCM. Single couplings were carried out using 5 
equivalents of peptide (compared to resin), 5 equivalents of benzotriazol-1-
yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP®), 10 equivalents of 
N,N-Diisopropylethylamine (DIPEA) and 2 mL of DMF under agitation for 45 
minutes. Double peptide couplings were carried out - 2 x 45 minute couplings for 
each residue addition, the reaction drained after each coupling and fresh reagents 
added. After each set of coupling reactions, the reaction solution was drained and 
resin washed with 5 portions of 2 mL DMF. Removal of the Fmoc group was 
carried out using 5 mL of a solution of 20% piperidine in DMF for 5 under agitation. 
Piperidine solution was drained and fresh solution added for a further 10 minutes 
under agitation. Piperidine solution was drained and the resin rinsed using 5 
portions of 2 mL DMF. Peptide-resin was treated with a solution of 20% 
hexafluoroisopropanol in DCM for 1 h. The resin was removed by filtration and the 
solvent removed from the filtrate under reduced pressure before precipitation 
using diethyl ether and decanting of the liquid (followed by subsequent ether 
washes). The resulting solid peptide (with free COOH-terminus) was dissolved in 
deionized water and acetonitrile mix and lyophilized. Purification of peptides was 
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carried out using Perking Elmer HPLC. Samples were injected into a column and a 
gradient of 0-100% solvent B (solvent A= 95% H2O, 5% MeCN, 0.01% TFA, 
solvent B = 95% MeCN, 5%H2O, 0.01% TFA) over 95 minutes with a flow rate of 
2.0 ml/min. Doxorubicin/azademethylcolchicine was conjugated to the peptide C-
terminus as follows: Doxorubicin.HCl or azademethylcolchicine (0.0012 g, 0.002 
mol, 1 equiv.), peptide (0.0022 g, 0.002 mol, 1 equiv.), PyBOP® (0.0015 g, 0.003 
mol, 1.3 equiv.), and hydroxybenzotriazole hydrate (0.0073 g, 0.0054 mol, 2.6 
equiv.) were added together under nitrogen in anhydrous DMF (2 mL). DIPEA (8 
equiv., 0.016 mol) was added and the reaction mixture was stirred overnight in the 
absence of light. Solvent was removed in vacuo and the mixture triturated with 
cold Et2O (5 mL) to precipitate the crude peptide which was then obtained through 
centrifugation to obtain the crude solid peptide conjugate. The product was then 
purified using a C18 column and reverse phase HPLC (H2O/MeCN) gradient 
system using  mass spectrometry as confirmation of molecular mass to give a pale 
red doxorubicin peptide conjugate (0.0021 g, 70% yield) or pale yellow 
azademethylcolchicine peptide conjugate (0.0015 g, 50% yield). 
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Figure IV.2: Synthetic scheme for peptide-doxorubicin conjugates 
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IV.4.2  Development of azademethylcolchicine 
Colchicine was dissolved in 25% ammonioa solution (BDH) and stirred overnight 
at room temperature. Thin layer chromatography (TLC) was used to monitor the 
reaction and the product, azademethylcolchicine (Figure IV.3). 
 
 
Figure IV.3: Reaction of colchicine with ammonia to yield azademethylcolchicine 
 
IV.4.3 Thin Layer Chromatorgraphy (TLC) 
TLC was used to monitor the conversion of colchicine into azademethycolchicine. 
Aluminium siilca TLC sheets (silica gel 60, f254) (Merck, Darmstadt, Germany) were 
used as the solid phase whilst dichloromethane, methanol and NH2 were used in a 
10:1:0.1 ratio to form the mobile phase. TLC plates were spotted with reaction 
products approximately 1cm from the bottom of the plate and the plate placed into 
the mobile phase. After the mobile phase had migrated towards the top of the plate 
by capillary action, the plate was removed and the products viewed under a UV 
light. The migration of each product was dependent upon the polarity of the 
substance (i.e. the partition coefficient between stationary and mobile phases). 
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TLC was used to track both the disappearance of starting material and the 
appearance of product during synthesis. 
IV.4.4 Liquid Chromatography-Mass spectrometry detection of peptide 
prodrugs 
LC conditions: High-purity HPLC-grade solvents (Sigma-Aldrich), analytical grade 
chemicals (Sigma-Aldrich) and triple distilled water were used throughout. 
Reverse-phase chromatographic separation of substrates was performed using an 
Acquity UPLC comprising a BEH C18 1.7 µm column (2.1 mm x 100 mm) (Waters, 
UK). Mobile phases were as follows: Mobile Phase A consisted of 90% HPLC 
grade water, 10% HPLC grade MeCN and 0.1% HCO2H. Mobile phase B 
consisted of 40% HPLC grade water, 60% MeCN and 0.1% HCO2H. 
MS conditions: A Micromass ZMD single quadrupole electrospray MS was used in 
positive mode (Micromass, Manchester, UK) and MassLynx software was used to 
identify substrates and anticipated metabolites. MS source parameters were 
optimised to: desolvation gas 375 L/hr, cone gas 33 L/hr, capillary 2.9 kV, sample 
cone 16 V, extraction cone 5 V, fR lens 0.1 V, source block temperature 150°C 
and desolvation temperature 200°C. Parent compounds and metabolites were 
detected as singularly charged ions using selected ion readings (SIR). 
IV.4.5 Cleavage of prodrugs by recombinant MMPs 
Recombinant human MMP proteins (MMP-2, MMP-3, MMP-9 and MMP-10; R&D 
Systems, UK) were assayed for their ability to cleave peptide-prodrug conjugates. 
Reactions (100 µL) contained 20 ng recombinant protein and 10 µM prodrug in 
MMP activity buffer (100 mM Tris-HCl pH 7.6, 10 mM CaCl2, 100 mM NaCl, 0.16% 
v/v Brij-35), and incubated at 37˚C for 12 h. At T12, The sample was removed and 
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diluted 1:3 with MeCN to precipitate proteins. The sample was then centrifuged at 
10,000 x g for 3 minutes and supernatant assayed for substrate cleavage by 
LCMS. 
IV.4.6 Metabolism of prodrugs in tissues ex vivo 
Female Balb/c immunodeficient nude mice (Harlan Blackthorne) were housed in 
an air-conditioned room with regular alternating cycles of light and darkness. The 
animal model received Harlan diet and water as required. The facilities have been 
approved by the Home Office and meet all current regulations and standards of 
the United Kingdom. The mice were used between the ages of 6-8 weeks in 
accordance with institutional guidelines. All procedures were performed under a 
United Kingdom Home Office Project Licence, UKCCCR guidelines. Mice were 
subcutaneously implanted with 2-3 mm3 fragments of HT1080 tumour xenografts. 
Resultant tumours were removed, snap-frozen in liquid nitrogen and stored at -
70°C. Xenograft tissues (tumour, liver and kidney) were homogenized in MMP 
activity buffer and resultant supernatants collected by centrifugation. 
Supernatants, equivalent to 100 mg tissue/mL, were assayed for their ability to 
activate the prodrugs. Reaction aliquots were removed over a 60 min period of 
incubation at 37 °C, proteins were precipitated using MeCN and the metabolites 
analysed by LCMS.  
IV.4.7 Determination of cellular viability 
IV.4.7.1 MTT assay 
Cell viability was measured using the MTT assay. Cells seeded on 96-well plates, 
which had been incubated with varying concentrations of compound for a specific 
time frame, were treated with 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
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Bromide (MTT) (500 µg/well) (method adapted from Mosmann, 1983). Plates were 
incubated at 37°C for 4 h, allowing mitochondrial dehydrogenase in viable cells to 
metabolise MTT and produce purple crystals of formazan. Media was removed 
and 150 µL of DMSO added to each well to solubilize the formazan and produce a 
uniform colour in each well. The plate was then analysed using a plate reader (GO 
Multiskan, Thermo Life Sciences) measuring absorbance at 550 nm where the 
absorbance reading and the viable number, is directly proportional to the level of 
the formazan product created. 
IV.4.7.2 Growth curve analysis 
In order to observe the growth characteristics of the U87-MG, 1321N1 and SVG12 
cell lines, in which the cytotoxicity of peptide conjugates was to be assessed, 
growth curve analysis for each cell line was conducted in 96-well plates. Varying 
cell densities of each cell line were seeded (250, 500, 1000, 2000 and 4000 cells 
per well) and monitored for 10 days to show cell growth kinetics. On each day, the 
increase in cell number for each cell density was calculated using the MTT assay. 
The data obtained was used to produce cell growth curves for each cell line for a 
number of seeding densities. For both U87-MG and SVG-P12 cell lines, 1000 cells 
per well and for 1321N1 cell lines, 500 cells per well were chosen as the seeding 
densities during cytotoxicity assays as cells would be in the exponential phase of 
their growth cycle for the duration of the assay. 
IV.4.7.3 Assessment of compound cytotoxicity 
Cells were seeded in 96-well plates at the respective chosen seeding densities in 
a total volume of 200 µL culture medium and allowed to adhere to the plate 
overnight. Following a 24 h incubation, media was removed and fresh media 
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added containing specific concentration of the compound of choice (Doxorubicin 
prodrug, azademethylcolchicine prodrug, doxorubicin alone or 
azademethylcolchicine alone, dissolved in DMSO) over a selected concentration 
range for a specific time period. For doxorubicin prodrugs and doxorubicin alone, 
concentrations ranged from 100 µM to 10 pM produced by serial dilutions whilst for 
azademethylcolchicine prodrugs and azademethylcolchicine alone, concentrations 
ranged from 100 µM to 1 pM. Control lanes included a DMSO control containing 
the same concentration of DMSO as the highest drug concentration (0.1% 
DMSO), one lane containing no drug treatment and one lane containing no cells. 
For each compound, plates were set up for drug exposures of 48 h and 96 h. After 
incubation, viable cell number was calculated using the MTT assay. 
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IV.5 Results 
IV.5.1  Flexible-ligand docking of “Standard prodrug” and MMPs 
Following successful validation of the in silico model for the peptide substrates 
(Chapter 3) a known pan-MMP-targeted peptide conjugated doxorubicin prodrug 
was evaluated as a basis for further drug design. This prodrug is known to be 
cleaved by MMP-2, 9 and 14,207, 285 presenting an excellent model for further 
modification. 
When considering the in silico interaction of the peptide fragment of the ‘Albright 
prodrug’ with MMP-2 and MMP-9, the zinc ions are chelated by the carboxylate 
between Gly-Ser(O-Benzyl) bond at interatomic distances of 2.6 Å and 2.8 Å 
respectively (the known cleavage site). The peptide aligns tightly into the active 
site of the MMPs as determined by their interatomic zinc distances and binding 
energies (555 kcal/mol and 492 kcal/mol) in MMP-2 and MMP-9 respectively 
(Figure IV.4).  
The in silico interaction of Albright prodrug sequence with MMP-3 and MMP-10 
shows the chelation of zinc ions by the carboxylate between Ser(O-Benzyl)-Tyr 
bond (3.4 Å and 3.6 Å respectively), the unknown cleavage site by stromelysins. 
The interaction of the peptide in the active site of MMP-3 and MMP-10 is nearly 
eight times weaker (70 kcal/mol and 66 kcal/mol) than gelatinases. The P1 and 
P1’ residues align tightly into the S1 and S1’ subsite of stromelysins (2.2 Å), 
whereas other residues demonstrated weaker binding (3.8 Å), resulting in 
decreased overall binding (Figure IV.5).  
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Figure IV.4: (Left) Stereo view of the docked complexes of ‘Albright prodrug’ (white sticks) 
and the catalytic domain of human MMP-2 (PDB ID: 1GKC) and MMP-9 (PDB ID: 1GKC). 
Catalytic and structural zinc ions are shown as purple spheres. Active-site cleft residues 
(the αβ-helix loop and the specificity loop) are represented by ribbons. (Right) Schematic 
representation of ‘Albright prodrug’: active site binding interaction in human MMP-2 and 
MMP-9. MMP-2 and MMP-9 enzyme binding pockets are shown in red and green 
respectively. Substrate chemical structure and its scissile bond is shown in black. The zinc 
ion coordinated by histidine is indicated in blue.  
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Figure IV.5: (Left) Stereo view of the docked complexes of ‘Albright prodrug’ (white sticks) 
and the catalytic domain of human MMP-3 (PDB ID: 1CIZ) and MMP-10 (PDB ID: 1Q3A). 
Catalytic and structural zinc ions are shown as purple spheres. Active-site cleft residues 
(the αβ-helix loop and the specificity loop) of MMP-3 and MMP-10 are shown in orange 
and blue respectively. (Right) Schematic representation of Albright prodrug: active site 
binding interaction in human MMP-3 and MMP-10. MMP-3 and MMP-10 enzyme binding 
pockets are shown in orange and blue respectively. Substrate chemical structure and its 
scissile bond is shown in black. The zinc ion coordinated by histidine is indicated in blue.  
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IV.5.2 Development of MMP-targeted “Standard prodrug” 
To experimentally validate the predictability of in silico model, the ‘Albright prodrug’ 
was synthesised in order to endcap the peptide sequence. The peptide sequence 
of prodrugs was conjugated between Dox warhead and a Cbz 
(Benzyloxycarbonyl) non-polar endcap protecting group, and purified as described 
in materials and methods (Section IV.4.1) (Figures IV.6 and IV.7).  
 
 
Figure IV.6: Synthetic scheme for peptide-doxorubicin conjugates 
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(Crude) 
Mobile phase A: 90:10 H2O:MeCN
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Figure IV.7: Detection of MMP-targeted prodrug (reference compound at retention time 
(tR) of 3.63 minutes (m/z 1525.8 Da, [M+H]
+), confirmed by LC-MS  
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IV.5.3  Analysis of “Albright prodrug” cleavage by recombinant MMPs 
To confirm the in vitro cleavage site and validate the in silico prediction, lysis was 
performed with recombinant MMP-2 and MMP-9 in the presence of the ‘Albright 
prodrug’ and results analysed by LC-MS (reverse phase) over a 12 h period. The 
‘Albright prodrug’ (Cbz-Glu-Pro-Leu-Gly-Ser(O-Benzyl)-Tyr-Leu-Doxorubicin), was 
identified (tR) 3.63 minutes (
m/z 1525.8 Da, [M+H]
+, Figure IV.7) and cleavage of by 
both MMP-2 and MMP-9 at Gly-Ser(O-Benzyl) bond was confirmed by LCMS, 
Cbz-Glu-Pro-Leu-Gly at tR  2.87 minutes (
m/z 547.2 Da, [M+H]
+) and Ser(O-
Benzyl)-Tyr-Leu-Doxorubicin at tR 3.23 minutes (
m
/z 997.4, [M+H]
+). (Figures IV.8, 
IV.9 and IV.10).  
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Figure IV.8: Schematic representation of the cleavage of Albright prodrug by recombinant 
MMP-2 and MMP-9 enzymes at Gly-Ser(OBenzyl) bond.  
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Figure IV.9: Cleavage of MMP-targeted prodrug (Albright prodrug) by recombinant 
MMP-2, detected by LCMS: (A) LC of MMP-2 mediated cleaved metabolites, (tR 2.87 and 
3.23 minutes); (B) MS identification of Cbz-Glu-Pro-Leu-Gly, tR 2.87 minutes (
m/z 547.2 
Da, [M+H]+); (C) MS identification of Ser(OBn)-Tyr-Leu-Doxorubicin tR of 3.23 minutes (
m/z 
997.4 Da, [M+H]+).  
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Figure IV.10: Cleavage of MMP-targeted prodrug (Albright prodrug) by recombinant 
MMP-9, detected by LCMS: (A) LC of MMP-2 mediated cleaved metabolites, (tR 2.87 and 
3.23 minutes); (B) MS identification of Cbz-Glu-Pro-L9u-Gly, tR 2.87 minutes (
m/z 547.2 
Da, [M+H]+); (C) MS identification of Ser(OBn)-Tyr-Leu-Doxorubicin tR of 3.23 minutes (
m/z 
997.4 Da, [M+H]+). 
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IV.5.4 Rationalised design of MMP-subtype selective peptide conjugates 
(MJ02) 
To discriminate MMP-2 over MMP-9 subtype modification of the ‘Albright prodrug’ 
was explored through incorporating the following modifications: Aromatic residues 
in S1 subsite; acidic side-chain in S2 subsite and a polar side-chain at the S3 
subsite and small non-polar residues were included at the S1’ subsite to create 
MJ02 (Figure IV.11). 
The flexible docking of MJ02 sequence within the active site of MMP-2 
demonstrated the interaction of catalytic zinc at the carboxylate between 
Homophenylalanine (Hof)-Leu bond (1.9 Å), indicating the predicted cleavage site. 
Residues of MMP-2 tightly bind with MJ02 as demonstrated by strong interactions 
with the bulge-edge segment molecules (Gly162 to His166) and the wall-forming 
segment molecules (Tyr223 to Thr229) with interatomic distances ranging from 1.8 
to 2.8 Å and has a predicted binding energy of 805 kcal/mol. In MMP-9 the 
predicted zinc interaction is not detectable and the binding energy is negative (-
107 kcal/mol) suggesting the modified peptide residues should give selectivity for 
MMP-2 over MMP-9 (Figure IV.12). 
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Figure IV.11: Modified ‘Albright prodrug’ residues to form MJ02, highlighting the 
modified amino acid sequence and predicted MMP-2 selectivity 
 
 
Figure IV.12: (Left) Stereo view of docked complexes of MJ02 (white sticks), catalytic 
domain of human MMP-2 (PDB ID: 1GKC) (Red) and MMP-9 (PDB ID: 1GKC) (Green). 
Catalytic and structural zinc ions are shown as purple spheres and active-site cleft 
residues (αβ-helix loop and the specificity loop) are shown as green. (Right) Schematic 
representation of MJ02: active site binding interaction in MMP-2 and MMP-9, are shown in 
red and green respectively. MJ02 chemical structure and its scissile bond is shown in 
black and zinc ion coordinated by histidine is indicated in blue.  
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Considering the catalytic differences between the stromelysins, the rational design 
of a peptide conjugate selective for MMP-10 over MMP-3 was achieved by 
incorporating residues to fit S1, S2, S3, S5 and S1’ pockets of MMP-10 which 
differ in size and polar affinity compared MMP-3. The following modifications were 
incorporated:  charged residues in S1 subsite – acidic residues preferred by 
Stromelysins;284 polar side-chain in S2 subsite; non-polar side-chains in S3 
subsite; simple side-chain residues in S5 subsite and aromatic residues in S1’ 
subsite (Figure IV.13). 
The predicted interaction between MJ02 and MMP-10 demonstrated strong 
chelation of zinc ion with the carboxylate between Glu-Hof bond (2.1 Å), indicating 
a predicted cleavage site with binding energy of 780 kcal/mol. In MMP-3 the zinc 
interaction is not detectable and the predicted binding energy is negative (-88 
kcal/mol) suggesting the modified peptide residues should give selectivity for 
MMP-10 over MMP-3 (Figures IV.14). 
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Figure IV.13: Modified ‘Albright prodrug’ residues to form MJ02, highlighting the 
modified amino acid sequence and predicted MMP-10 selectivity 
 
Figure IV.14: (Left) Stereo view of docked complexes of MJ02 (white sticks), catalytic 
domain of human MMP-3 (PDB ID: 1CIZ) (Orange) and MMP-10 (PDB ID: 1Q3A) (Blue). 
Catalytic and structural zinc ions are shown as purple spheres and active-site cleft 
residues (αβ-helix loop and the specificity loop) are shown as orange and blue. (Right) 
Schematic representation of MJ02: active site binding interaction in MMP-3 and MMP-10, 
are shown in orange and blue respectively. MJ02 chemical structure and its scissile bond 
is shown in black and zinc ion coordinated by histidine is indicated in blue.  
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IV.5.5 Development of MMP-subtype selective doxorubicin prodrug (MJ02) 
To experimentally validate the in silico prediction that MJ02 is selectively 
interacted by MMP-2 and MMP-10, the prodrug was synthesised in-house in order 
to endcap the peptide sequence. The peptide sequence of MJ02 was nested 
between doxorubicin warhead and a Cbz (benzyloxycarbonyl) non-polar 
endcapping group, as described in materials and methods (Section IV.4.1). MJ02 
was synthesised, containing the amino acids sequence Gly-Pro-Ile-Gln-Glu-Hof-
Leu which has doxorubicin at the C-terminus of the peptide and Cbz group at the 
N-terminus (Figure IV.15). 
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Figure IV.15: Synthesis route of MMP targeted doxorubicin prodrug (MJ02)  
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IV.5.6 Analytical detection of MJ02 
Using the LCMS methods described in section IV.4.4, MJ02 was detected by mass 
spectrometry as a confirmation of molecular mass. Preparative-HPLC gradient 
system (H2O/MeCN) with a C18 column was used to purify MJ02, after side chain 
deprotection, at tR 3.58 minutes (
m/z 1476.65 Da, [M]
+), to give a pale red solid 
(65% yield). 
 
Figure IV.16: LCMS detection of purified MJ02. Preparative-HPLC purified MJ02 
detection at tR 3.580 minutes (
m/z 1476.6 Da, [M]
+). 
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IV.5.7  Analysis of MJ02 cleavage by recombinant MMP-2 and MMP-10 
As the pan-MMP prodrug, Albright prodrug, demonstrated cleavage by both 
gelatinases and stromelysins, the hydrolysis of MJ02 by appropriate recombinant 
enzymes was investigated over a 12 h period and analysed by LCMS. From the 
predicted modelling earlier MJ02 should be more selectively cleaved by MMP-2 
and MMP-10 over MMP-9 and MMP-3 relative to ‘Albright prodrug’ (Figures IV.11, 
IV.12, IV.13 and IV.14). Reverse phase LC-MS identified MJ02 at tR 3.58 minutes 
(m/z 1476.6 Da, [M]
+) (Figure IV.16), which was preferentially cleaved by MMP-2 at 
Hof-Leu to give Leu-Doxorubicin tR 2.078 minutes (
m/z 657.2 Da, [M+H]
+) and Cbz-
Gly-Pro-Ile-Gln-Glu-Hof tR of 2.826 minutes (
m/z 821.4 Da, [M+H]
+) (Figures IV.17, 
IV.18, IV.19 and IV.20). MJ02 was also cleaved by MMP-10 at Glu-Hof bond to 
give Cbz-Gly-Pro-Ile-Gln-Glu tR 2.621 minutes (
m/z 661.26 Da, [M+H]
+) and Hof-
Leu-Doxorubicin tR of 2.996 minutes (
m/z 816.66 Da, [M+H]
+) (Figures IV.21, IV.22, 
IV.23 and IV.24). Conversely MMP-9 and MMP-3 did not cleave MJ02 in the same 
timeframe, indicating that MJ02 is MMP-2 and MMP-10 selective, supporting the in 
silico prediction (Figure IV.25). Using M-2055 and M-2110, as control substrates to 
verify enzyme activity, MMP-9 and MMP-3 displayed no cleavage of MJ02 over 12 
h period, whilst control substrates were efficiently cleaved (Figure II.13). 
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Figure IV.17: Schematic representation of the cleavage of MJ02 by recombinant 
MMP-2. Indicating cleavage of MJ02 at the Hof-Leu bond 
 
 
 
 
 
 
 
CBZ – Gly-Pro-Ile-Gln-Glu-Homophe Leu - Doxorubicin
MMP-2 
mediated cleavage
187 
 
 
 
Figure IV.18: Schematic representation of the cleavage of MJ02 by MMP-2 but not by 
MMP-9, indicating MMP-2 mediated cleavage at the predicted subsite. 
 
 
 
Figure IV.19: Representation of in vitro cleavage of MJ02 by MMP-2 over MMP-9  
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Figure IV.20: Cleavage of MJ02 by recombinant MMP-2, detected by LCMS: (A) LC of 
MMP-2 mediated cleaved metabolites, (tR 2.078 and 2.826 minutes); (B) MS identification 
of doxorubicin half of the prodrug, tR 2.078 minutes (
m/z 658.2 Da, [M+H]
+); (C) MS 
identification of Cbz half of the prodrug, tR 2.826 minutes (
m/z 821.4 Da, [M+H]
+). 
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Figure IV.21: Schematic representation of the cleavage of MJ02 by recombinant 
MMP-10. Indicating cleavage of MJ02 at the Glu-Homophe bond 
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Figure IV.22: Schematic representation of the cleavage of MJ02 by MMP-10 but not by 
MMP-3, indicating MMP-10 mediated cleavage at the predicted subsite. 
 
 
Figure IV.23: Representation of in vitro cleavage of MJ02 by MMP-10 over MMP-3 
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Figure IV.24: Determination of MMP-10 cleavage site in MJ02. Recombinant MMP-10 
cleavage of MJ02 at the Glu-Homophe bond, as determined by LCMS analysis. A, HPLC 
trace of MJ02 metabolism following 12h incubation with recombinant MMP-10 at 37°C, 
showing MJ02 (tR of 3.580 minutes) and cleaved metabolites, tR 2.996 and 2.621 minutes; 
B, MS detection of metabolite as m/z 661.2 Da [M+H]
+ corresponding to CBZ-Gly-Pro-Ile-
Gln-Glu; C, MS detection of metabolite as m/z 816.6 Da [M+H]
+corresponding to Homophe-
Leu-Doxorubicin; confirming cleavage at the Glu-Homophe bond.  
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Figure IV.25: A and B represents HPLC traces of MMP-9 and MMP-3 mediated 
activity on MJ02, respectively. These graphs demonstrate that both MMP-9 and MMP-3 
displayed no cleavage of MJ02 over 12 h incubation period. Whilst MJ02 was cleaved by 
MMP-10 and MMP-2, MMP-9&3 were unable to cleave this prodrug.  
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IV.5.8 Stability of MJ02 in MMP positive and MMP negative cell lines 
Using semi-quantitative RT-PCR and western blotting (Figures II.3, II.4, II.6, II.7 
and II.8), U87-MG was determined as a high MMP-10 expressing cell line and 
therefore was selected as a positive control for the metabolism of MJ02. SVG-P12 
was selected as a negative control model since this cell line demonstrated 
low/negligible expression of MMP-10 (Figures II.3, II.4, II.6, II.7 and II.8). SVG-
P12, despite being negative for MMP-10, does express MMP-2 (Figures II.3, II.4, 
II.6, II.7 and II.8). These cell lines grown in monolayer were assayed for their 
ability to metabolise MJ02 and were analysed after 24 h, 48 h and 96 h drug 
exposures, determined by LCMS. As Figure IV.26 demonstrates, MJ02 was 
rapidly metabolised by U87-MG (t½ = 40 h) with a significantly slower metabolism 
observed by SVG-P12 (t½ = 89 h). In both cell lines, the metabolism of MJ02 
resulted in production of the chemotherapeutic agent, Leu-Dox. The involvement 
of MMPs was assessed by determining the degree of MJ02 metabolism by U87-
MG cells in the presence of pan-MMP inhibitor Ilomastat (GM6001) and a MMP-10 
selective inhibitor JJH-III-012A (developed by Dr Jonathan Harburn for a parallel 
project), at non-potent concentrations of 1 µM and 500 nM, respectively. Ilomastat 
resulted in a significant decrease in metabolism of MJ02 by U87-MG (t½ = >96 h). 
In contrast, MJ02 displayed relatively faster metabolism in the presence of MMP-
10 selective inhibitor (t½ = 96 h) (inhibiting 50% of MMP-10 enzyme at 1 nM, based 
on fluorometric enzyme assay studies). It is interesting to note that there is a 
significant differential between metabolism by U87-MG alone and in the presence 
of MMP-10 inhibitor, suggesting the involvement of MMP-10 rapidly metabolising 
MJ02 in MMP-positive cells. Since MJ02 is selectively activated by both MMP-2 
and MMP-10 (Figures IV.18, IV.20, IV.22 and IV.24), the differential metabolism of 
194 
 
 
MJ02 in the presence of MMP-10 inhibitor (compared to Ilomastat) could suggest 
a selective metabolism by MMP-2, which remains uninhibited at the treated dose 
(Figure IV.26).  
IV.5.9 MJ02 stability in tumour tissue ex vivo 
Following the demonstration of selective metabolism in human tumour cell lines, 
metabolism of MJ02 by HT1080 human tumour xenograft, mouse blood plasma 
and homogenised murine liver and kidney tissues was assessed. Rapid 
metabolism of MJ02 was observed in the MMP expressing HT1080 xenograft 
homogenate (t½ = 9.8 minutes). In comparison, MJ02 was relatively stable in 
plasma (t½ >> 90 minutes), murine liver (t½ ≥ 17 minutes) and murine kidney (t½ = 
≥ 38.1 minutes) (Figure IV.27). Metabolism of MJ02 in HT1080 homogenates 
resulted in rapid production of the chemotherapeutic agent, doxorubicin. 
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Figure IV.26: Differential metabolism of MJ02 by U87-MG (high MMP expressing) 
and SVG-P12 (low MMP expressing) cell lines. Cells in monolayer were assayed for 
their ability to metabolise MJ02 over 24 h, 48 h and 96 h time points, as detected by 
LCMS. Metabolism of MJ02 by cell lines representing 1 x 104 cells, demonstrated rapid 
metabolism by U87-MG relative to SVG-P12. In contrast, MJ02 demonstrated a 
decreased metabolism by U87-MG in the presence of pan-MMP inhibitor (Ilomastat, 
GM6001) and MMP-10 selective inhibitor. Metabolism values are representative of 
average from two independent experiments. Each value of inhibition study represents the 
mean ± SE of three independent experiments. 
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Figure IV.27: Metabolism of MJ02 by HT1080 tumour relative to mouse liver and mouse 
kidney. Metabolites expressed as concentration of MJ02 remaining.  
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IV.5.10 In vitro cytotoxicity of Doxorubicin and MJ02 
The response of these human glioma cell lines (U87-MG and 1321N1) and normal 
glial (SVG-P12) cell line to Dox and MJ02 was investigated using the MTT assay. 
Responses of cell lines to Dox and MJ02 were analysed after 96 h exposures 
(Figure IV.28).  
All the cell lines were sensitive to Dox following 96 h exposure, whereas, as 
predicted, malignant human glioma cells (U87-MG and 1321N1) expressing MMP-
10, were able to metabolise the prodrug efficiently and, thus, has a significantly 
lower IC50 for MJ02 compared to SVG-P12 (MMP-10 negative) at 96 h exposures. 
The differential cytotoxicity between doxorubicin and MJ02 against glioma models 
supports the requirement of MJ02 to be activated prior to inducing its effects. 
Furthermore, MJ02 remained inactive in the presence of a pan-MMP inhibitor 
(GM6001; Ilomastat), demonstrating MMP-selective chemotherapeutic action of 
this prodrug. Whereas, in the presence of MMP-10 selective inhibitor, MJ02 
demonstrated a 20-fold weaker cytotoxicity against U87-MG suggesting MMP-10 
selective chemotherapeutic action of MJ02 (Figure IV.26).  
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Figure IV.28: Chemosensitivity of U87-MG, 1321N1 and SVG-P12 to Doxorubicin and 
MJ02. Assessed using MTT assay following 96 h drug exposure. Cell survival is 
represented as relative to solvent control and demonstrates sensitivity of U87-MG and 
1321N1 cell lines to both Doxorubicin and MJ02 whilst SVG-P12 is sensitive only to 
Doxorubicin. Potency of compounds is reported as IC50 values (the concentration of drug 
required to reduce cell viability by 50% relative to control). 
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IV.5.11  Development of MMP-subtype selective azademethylcolchicine 
prodrug (MJ03) 
The doxorubicin prodrug, MJ02, demonstrated selective activation by MMP-2 and 
MMP-10, over MMP-3 and MMP-9. The in silico docking system of MJ02 was 
rationalised based on the CHARMM minimised geometry of peptide sequence 
conjugated with doxorubicin. In order to identify whether the selectivity of peptide 
sequence would change in the presence of different chemotherapeutic drugs, we 
endeavoured to take advantage of a colchicine derivative, azademethylcolchicine, 
and its established antitumour activity.203 The peptide sequence of MJ02 
conjugated with a different warhead, azademethylcolchicine, was minimised in 
silico and docked into the active site of respective MMPs. MJ03, similar to MJ02, 
demonstrated strong and selective interaction with the active sites of MMP-2 and 
MMP-10 suggesting that the prodrug of azademethylcolchicine (derived from 
MJ02) should still provide selectivity for MMP-2 and MMP-10.  
To experimentally validate the in silico prediction that MJ03 is selectively 
interacted by MMP-2 and MMP-10, over MMP-3 and MMP-9, the prodrug was 
synthesised in-house in order to endcap the peptide sequence. The peptide 
sequence of MJ03 was conjugated between azademethylcolchicine warhead 
(Section IV.4.2) and a Cbz non-polar endcapping group, as described in materials 
and methods (Section IV.4.1). MJ03 was synthesised, containing the amino acids 
sequence Gly-Pro-Ile-Gln-Glu-Hof-Leu which has azademethylcolchicine at the C-
terminus of the peptide and Cbz group at the N-terminus (Figure IV.29). 
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Figure IV.29: Synthesis route of MMP-targeted Azademethylcolchicine prodrug 
(MJ03)  
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IV.5.12 Analytical detection of MJ03 
Using the LCMS methods described in section IV.4.4, MJ03 was detected by mass 
spectrometry as a confirmation of molecular mass. Preparative-HPLC (reverse 
phase) used to purify MJ03, tR  3.68 minutes (
m/z 1317.6 Da, [M]
+) (Figure IV.30), 
to give a pale yellow solid (55% yield).  
 
Figure IV.30: LCMS detection of purified MJ03. Preparative-HPLC system was used to 
purify MJ03 tR 3.68 minutes (
m/z 1317.6 Da, [M]
+). 
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Figure IV.31: Schematic representation of the cleavage of MJ03 by recombinant 
MMP-2. Indicating cleavage of MJ03 at the Homophe-Leu bond 
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Figure IV.32: Determination of MMP-2 cleavage site in MJ03. Recombinant MMP-2 
cleavage of MJ03 at the Homophe-Leu bond, as determined by LCMS analysis. A, HPLC 
trace of MJ03 metabolism following 12 h incubation with recombinant MMP-2 at 37°C, 
showing MJ03 (tR of 3.68 minutes) and cleaved metabolites, tR 2.377 and 2.778 minutes; 
B, MS detection of metabolite as m/z 498.22 Da [M]
+ corresponding to Leu-MB2; C, MS 
detection of metabolite as m/z 820.4 Da [M]
+ corresponding to CBZ-Gly-Pro-Ile-Gln-Glu-
Homophe; confirming cleavage at the Homophe-Leu bond.   
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Figure IV.33: Schematic representation of the cleavage of MJ03 by recombinant 
MMP-10. Indicating cleavage of MJ03 at the Glu-Homophe bond 
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Figure IV.34: Determination of MMP-10 cleavage site in MJ03. Recombinant MMP-10 
cleavage of MJ03 at the Glu-Homophe bond, as determined by LCMS analysis. A, HPLC 
trace of MJ03 metabolism following 12 h incubation with recombinant MMP-10 at 37°C, 
showing MJ03 tR 3.68 minutes and cleaved metabolites, Rt 2.469 and 2.543 minutes; B, tR 
2.469 minutes, MS detection of metabolite (m/z 658.9 Da, [M]
+) corresponding to 
Homophe-Leu-MB2; C, tR 2.543 minutes, MS detection of metabolite (
m/z 661.2 Da, [M]
+) 
corresponding to CBZ-Gly-Pro-Ile-Gln-Glu; confirming cleavage at the Glu-Homophe 
bond.  
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Figure IV.35: A and B represents HPLC traces of MMP-9 and MMP-3 mediated 
activity on MJ03, respectively. These graphs demonstrate that both MMP-9 and MMP-3 
displayed no cleavage of MJ02 over 12 h incubation period. 
 
 
 
 
 
  
A 
B 
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IV.5.13 Stability of MJ03 in MMP positive and MMP negative cell lines 
Similar to the stability studies of MJ02 (Section IV.5.7), the selectivity of MJ03 was 
also tested in the two cell models i.e. U87-MG (MMP-positive) and SVG-P12 
(MMP-negative) cells. These cell lines grown in monolayer were assayed for their 
ability to metabolise MJ03 and were analysed after 24 h, 48 h and 96 h drug 
exposures, determined by LCMS. As Figure IV.36 demonstrates, MJ03 was 
rapidly metabolised by U87-MG (t½ = 38 h) with a significantly slower metabolism 
observed by SVG-P12 (t½ = 86 h). In both cell lines, the metabolism of MJ03 
resulted in production of the chemotherapeutic agent, azademethylcolchicine. The 
involvement of MMPs was assessed by determining the degree of MJ03 
metabolism by U87-MG cells in the presence of pan-MMP inhibitor Ilomastat 
(GM6001) and the MMP-10 selective inhibitor JJH-III-012A (developed by Dr 
Jonathan Harburn for a parallel project), at non-potent concentrations of 1 µM and 
500 nM, respectively. Ilomastat resulted in a significant decrease in metabolism of 
MJ03 by U87-MG (t½ = >96 h). In contrast, MJ03 displayed relatively faster 
metabolism in the presence of MMP-10 selective inhibitor (t½ = 71 h) (inhibiting 
50% of MMP-10 enzyme at 1nM). It is interesting to note that there is a significant 
differential between the metabolism by U87-MG alone and the one in the presence 
of MMP-10 inhibitor, suggesting the involvement of MMP-10 enzyme to rapidly 
metabolise MJ03 in MMP-positive cells. Since MJ03 is selectively activated by 
both MMP-2 and MMP-10 (Figures IV.32 and IV.34), the differential metabolism of 
MJ03 in the presence of MMP-10 inhibitor (compared to Ilomastat) could suggest 
a selective metabolism by MMP-2 (Figure IV.36), which remains uninhibited at the 
treated dose.  
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Figure IV.36: Differential metabolism of MJ03 by U87-MG (high MMP expressing) 
and SVG-P12 (low MMP expressing) cell lines. Cells in monolayer were assayed for 
their ability to metabolise MJ03 over 24 h, 48 h and 96 h time points, as detected by 
LCMS. Metabolism of MJ03 by cell lines representing 1 x 104 cells, demonstrated rapid 
metabolism by U87-MG relative to SVG-P12. In contrast, MJ03 demonstrated a 
decreased metabolism by U87-MG in the presence of pan-MMP inhibitor (Ilomastat, 
GM6001) and MMP-10 selective inhibitor (JJH-III-012A). Metabolism values are 
representative of average from two independent experiments. Each value of inhibition 
study represents the mean ± SE of three independent experiments. 
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IV.5.14 In vitro cytotoxicity of Azademethylcolchicine and MJ03 
The response of these human glioma (U87-MG and 1321N1) and normal glial 
(SVG-P12) cell lines to azademethylcolchicine and MJ03 was investigated using 
the MTT assay. Responses of the cell lines to azademethylcolchicine and MJ03 
were analysed after 96 h exposures (Figure IV.37).  
All the cell lines were sensitive to azademethylcolchicine following 96 hexposure, 
whereas, as predicted, malignant human glioma cells (U87-MG and 1321N1) 
expressing MMP-10, were able to metabolise the prodrug efficiently and thus has 
a significantly lower IC50 for MJ03 compared to SVG-P12 (MMP-10 negative) at 96 
h exposures. The differential cytotoxicity between azademethylcolchicine and 
MJ03 against glioma models supports the requirement of MJ03 to be activated 
prior to inducing its effects. Furthermore, MJ03 remained inactive in the presence 
of a pan-MMP inhibitor (GM6001; Ilomastat), demonstrating MMP-selective 
chemotherapeutic action of this prodrug (Figure IV.37). Whereas, in the presence 
of MMP-10 selective inhibitor (Figure IV.37), MJ03 demonstrated a 30-fold weaker 
cytotoxicity against U87-MG suggesting MMP-10 selective chemotherapeutic 
action of MJ03.  
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Figure IV.37: Chemosensitivity of U87-MG, 1321N1 and SVG-P12 to MB2 and MJ03. 
Assessed using MTT assay following 96 h drug exposure. Cell survival is represented as 
relative to solvent control and demonstrates sensitivity of U87-MG and 1321N1 cell lines 
to both MB2 and MJ03 whilst SVG-P12 is sensitive only to MB2. Potency of compounds is 
reported as IC50 values (the concentration of drug required to reduce cell viability by 50% 
relative to control). 
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IV.5.15 Rationalised design of MMP-10 selective peptide conjugates 
(MJ04) 
Following the success of in silico model for rationalised development of MMP-
subtype selective prodrugs of doxorubicin (MJ02) and azademethylcolchicine 
(MJ03), we further attempted to modify the peptide sequence in an effort to make 
the prodrugs more specific for MMP-10, and to eliminate or reduce metabolism by 
its close family homologues i.e. MMP-3 and gelatinases. MJ04 was designed 
based on the MMP-docked models of M-2110 substrate.221 M-2110 substrate is a 
stromelysin-selective substrate and has been shown to be rapidly cleaved by both 
MMP-3 and MMP-10. The in silico models of M-2110 substrate (Chapter 3; 
Figures III.15 and III.18) demonstrated effective catalytic binding with the active 
sites of MMP-3 and MMP-10, and thus provided a suitable model to rationally 
exploit the differences in stromelysin binding sites.  MJ04 sequence consisted of 
the following modifications: branched non-polar residues in S2 subsite; basic 
residues in S1’ subsite and branched non-polar residues in S2’ subsite (Figure 
IV.38).  
 
Figure IV.38: Modification of M-2110 peptide residues to achieve MMP-10 selectivity 
over MMP-3 and gelatinases, indicating predicted selectivity of MMP-10 at Glu-His bond 
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212 
 
 
IV.5.16 Flexible-ligand docking of MJ04 and MMPs 
The in silico interaction between MJ04 peptide sequence and MMP-10 
demonstrated the strong chelation of zinc ion with the carboxylate between Glu-
His bond (1.5 Å), indicating the predicted cleavage site (Figure IV.39). The zinc 
interaction here is stronger than the MJ02 and MMP-10 docked complex (2.1 Å, 
section IV.5.3). The ligand interactions with the binding residues of MMP-10 were 
similar to the interactions observed with MJ02 (Section IV.5.3). The Glu at P1 
position is strongly coordinated by Ala181 and His182 of the bulge-edge segment 
(1.4 Å). The Leu inserted into the S2 pocket is able to interact with Leu180 residue 
and the D-Pro at P3 position is strongly coordinated by Ala183 in MMP-10 (2.1 Å). 
The side-chain of His is inserted into the S1’ pocket; and is further interacted by 
Glu218 (2.0 Å), wall-forming segments (2.2 Å to 2.4 Å) and the hydrophobic 
cluster of Phe and Leu at the bottom of the pocket (1.8 Å). The docked complex of 
MJ04 and MMP-10 has an overall binding energy of 1012 kcal/mol (Figure IV.39).  
However, the docked complexes of MMP-2, MMP-3 and MMP-9 demonstrated 
weak catalytic interaction with MJ04. The zinc interactions were not detectable and 
the predicted binding energies of MJ04 were -212 kcal/mol, -77 kcal/mol and -176 
kcal/mol, with MMP-2, MMP-9 and MMP-3, respectively. The prediction model of 
MJ04 and MMPs suggests that the peptide residues should give selectivity for 
MMP-10 over MMP-3 and gelatinases (Figure IV.40). 
 
 
 
213 
 
 
 
Figure IV.39: (Above) Stereo view of docked complexes of MJ04 (white sticks) and 
catalytic domain of human MMP-10 (PDB ID: 1Q3A) (Blue). Catalytic and structural zinc 
ions are shown as purple spheres and active-site cleft residues (αβ-helix loop and the 
specificity loop) are shown as blue. (Below) Schematic representation of MJ04: active site 
binding interaction in MMP-10, are shown in blue, respectively. MJ04 chemical structure 
and its scissile bond is shown in black and zinc ion coordinated by histidine is indicated in 
blue. 
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Figure IV.40: (Left) Stereo view of docked complexes of MJ04 (white sticks) within 
catalytic domain of human MMP-2 (PDB ID: 1QIB) (Pink), MMP-3 (PDB ID: 1CIZ) 
(Orange), MMP-9 (PDB ID: 1GKC) (Cyan). (Right) Schematic representation of MJ04 and 
its active site binding interactions in MMP-2, MMP-3 and MMP-9. MJ04 demonstrates 
negligible chemical interaction with MMP-3 and gelatinases (MMP-2 and MMP-9), relative 
to strong interaction with MMP-10 
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IV.5.17 Development of MMP-subtype selective doxorubicin prodrug 
(MJ04) 
To experimentally validate the in silico prediction that MJ04 is selectively 
interacted by MMP-10, the prodrug was synthesised in-house in order to endcap 
the peptide sequence. The peptide sequence of MJ04 was conjugated between 
doxorubicin warhead and a Cbz (benzyloxycarbonyl) non-polar endcapping group, 
as described in materials and methods (Section IV.4.1). MJ04 was synthesised, 
containing the amino acids sequence Pro-Lys-DPro-Leu-Glu-His-Leu which has 
doxorubicin at the C-terminus of the peptide and Cbz group at the N-terminus 
(Section IV.4.1). 
IV.5.18 Analytical detection of MJ04 
Using the LCMS methods described in section IV.4.4, MJ04 (Figure IV.41) was 
detected by mass spectrometry as a confirmation of molecular mass. Preparative-
HPLC gradient system (H2O/MeCN) with a C18 column was used to purify MJ04 at 
retention time (tR) of 4.10 minutes (m/z 1491.7 Da, [M]
+) (Figure IV.42), to give a 
pale red solid (60% yield). 
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Figure IV.41: Chemical structure of MMP-10 targeted doxorubicin prodrug.  
Sequence: Cbz – Pro-Lys- D-Pro -Leu-Glu-His-Leu – Doxorubicin 
 
 
Figure IV.42: LCMS detection of purified MJ04. Preparative-HPLC purified MJ04 
detection at tR 4.10 minutes (
m/z 1491.7 Da, [M]
+). 
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IV.5.19 Analysis of MJ04 cleavage by recombinant MMP-10 
Rationalised computational-aided development of MJ02 (prodrug of doxorubicin) 
and MJ03 (prodrug of azademethylcolchicine) prodrugs demonstrated cleavage by 
both MMP-2 and MMP-10, over MMP-3 and MMP-9. It was predicted in silico that 
by rationalised alteration of M-2110 substrate amino acid sequence, MJ04 should 
be more selectively cleaved by MMP-10 over its close family homologue MMP-3 
and gelatinases; relative to ‘Albright prodrug’, MJ02 and MJ03. To experimentally 
validate the predictability of the in silico model, and confirm the in vitro cleavage 
position of MJ04, hydrolysis of the prodrug by appropriate recombinant MMPs 
were investigated over a 12 h period and analysed by LCMS. As figures IV.43 and 
IV.44 show, MMP-10 cleaved MJ04 at the Glu-His bond, as predicted.  Reverse 
phase HPLC identified MJ04 at tR 4.10 minutes (Figure IV.42). MJ04 was 
preferentially cleaved by MMP-10 at the Glu-His bond and two peaks identified; 
corresponding to Cbz-Pro-Lys-DPro-Leu-Glu at tR 2.85 minutes (
m/z 716.4 Da, 
[M+H]+) and Cbz-Gly-Pro-Ile-Gln-Glu-Hof at tR 3.07 minutes (
m/z 793.3 Da, [M+H]
+) 
(Figure IV.44). Conversely MMP-2, MMP-3 and MMP-9 did not cleave MJ04 in the 
same timeframe, indicating that MJ04 is MMP-10 selective, thus, supporting the in 
silico prediction (Figure IV.45). 
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Figure IV.43: Schematic representation of the cleavage of MJ04 by recombinant 
MMP-10. Indicating cleavage of MJ04 at the Glu-His bond. 
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Figure IV.44: Determination of MMP-10 cleavage site in MJ04. Recombinant MMP-10 
cleavage of MJ04 at the Glu-His bond, as determined by LCMS analysis. A, HPLC trace 
of MJ04 metabolism following 12 h incubation with recombinant MMP-10 at 37°C, showing 
MJ04 (tR of 4.10 minutes) and cleaved metabolites, tR 2.85 and 3.07 minutes; B, MS 
detection of metabolite as m/z 716.4 Da [M+H]
+ corresponding to Cbz-Pro-Lys- D-Pro -Leu-
Glu; C, MS detection of metabolite as m/z 793.3 Da [M+H]
+, corresponding to His-Leu-
Doxorubicin; confirming cleavage at the Glu-His bond.  
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Figure IV.45: MJ04 did not demonstrate cleavage by recombinant MMP-2, MMP-3 
and MMP-9. A, B and C represents HPLC traces of MMP-2, MMP-3 and MMP-9 
mediated activity on MJ04, respectively. The MS confirmation of non-cleaved MJ04 
(parent, m/z 1491.7 Da [M]
-) is shown in graph D. These graphs demonstrate that whilst 
MJ04 was cleaved by MMP-10; MMPs -2, -3 and -9 were unable to cleave this prodrug 
over 12 h incubation period.  
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IV.5.20 Stability of MJ04 in MMP positive and MMP negative cell lines 
Similar to the stability of MJ02 and MJ03 described in sections IV.5.7 and IV.5.12, 
the selective metabolism of MJ04 was tested in two cell models i.e. U87-MG and 
SVG-P12 cell lines. These cell lines grown in monolayer were assayed for their 
ability to metabolise MJ04 and were analysed after 24 h, 48 h and 96 h drug 
exposures, determined by LCMS. As figure IV.46 demonstrates, MJ04 was rapidly 
metabolised by U87-MG (t½ = 40 h) with a significantly slower metabolism 
observed by SVG-P12 (t½ = >96 h). The exposure of MJ04 in MMP-10 negative 
cell line, SVG-P12, resulted in significantly decreased metabolism of the prodrug 
compared to MJ02 (t½ = 89 h) and MJ03 (t½ = 86 h) metabolism in SVG-P12. In 
SVG-P12 cells, the disappearance of parent MJ04 post 96 h exposure was nearly 
2-fold slower (85% of MJ04 remaining at 96 h), when compared to MJ02 (45% of 
MJ02 remaining at 96 h) and MJ03 (40% of MJ03 remaining at 96 h) (Figures 
IV.46, IV.47 and IV.48). In both cell lines, the metabolism of MJ04 resulted in the 
production of the chemotherapeutic agent, Leu-Dox. The involvement of MMPs 
was assessed by determining the degree of MJ04 metabolism by U87-MG cells in 
the presence of pan-MMP inhibitor Ilomastat (GM6001) and the MMP-10 selective 
inhibitor JJH-III-012A (developed by Dr Jonathan Harburn for a parallel project), at 
non-potent concentrations of 1 µM and 500 nM, respectively . Ilomastat resulted in 
a significant decrease in metabolism of MJ04 by U87-MG (t½ >96 h). Interestingly, 
MJ04 also displayed significantly slower metabolism in the presence of MMP-10 
selective inhibitor (t½ = >96 h), when compared to the metabolism of MJ02 and 
MJ03 in the presence of this inhibitor (Figures IV.46, IV.47 and IV.48).  
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Figure IV.46: Differential metabolism of MJ04 by U87-MG (high MMP expressing) 
and SVG-P12 (low MMP expressing) cell lines. Cells in monolayer were assayed for 
their ability to metabolise MJ04 over 24 h, 48 h and 96 h time points, as detected by 
LCMS. Metabolism of MJ04 by cell lines representing 1 x 104 cells, demonstrated rapid 
metabolism by U87-MG relative to SVG-P12. In contrast, MJ04 demonstrated a 
decreased metabolism by U87-MG in the presence of pan-MMP inhibitor (Ilomastat, 
GM6001) and MMP-10 selective inhibitor (JJH-III-012A). Metabolism values are 
representative of average from two independent experiments. Each value of inhibition 
study represents the mean ± SE of three independent experiments. 
 
Differential metabolism of MJ04 
by U87-MG and SVG-P12 cell lines 
Differential metabolism of MJ04 by U87-MG 
in the presence of Ilomastat (GM6001) 
Differential metabolism of MJ04 by U87-MG 
in the presence of MMP-10 selective inhibitor 
Selectivity of MMP-10 inhibitor 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100
%
 M
J
0
4
 r
e
m
a
in
in
g
Time (hours)
U87-MG
U87-MG + GM6001
Media + GM6001 t½ = > 96h
t½ = > 96h
t½ = 40h
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100
%
 M
J
0
4
 r
e
m
a
in
in
g
Time (hours)
U87-MG
U87-MG + MMP-10 inhibitor
Media + MMP-10 inhibitor
t½ = > 96h
t½ = > 96h
t½ = 40h
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100
%
 M
J
0
4
 r
e
m
a
in
in
g
Time (hours)
U87-MG
SVG-P12
Media
223 
 
 
 
Figure IV.47: Differential MMP selectivity of rationally designed prodrugs of doxorubicin, 
MJ02 and MJ04. 
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Figure IV.48: Comparison between metabolism of MJ02 and MJ04 in human glioma 
(U87-MG) and normal glial (SVG-P12) cell lines. MJ04 showed improved selective 
metabolism by U87-MG. Whereas, SVG-P12 demonstrated significantly lower metabolism 
of MJ04 than MJ02. Compared to MJ02, MJ04 was relatively stable in the presence of 
MMP-10 selective inhibitor (JJH-III-012A) demonstrating MMP-10 selective action of MJ04 
to selectively release the chemotherapeutic Leu-dox within the human glioma cells. 
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Figure IV.49: Chemosensitivity of U87-MG, 1321N1 and SVG-P12 to Doxorubicin and 
MJ04. Assessed using MTT assay following 96 h drug exposure. Cell survival is 
represented as relative to solvent control and demonstrates sensitivity of U87-MG and 
1321N1 cell lines to both Doxorubicin and MJ04 whilst SVG-P12 is sensitive only to 
Doxorubicin. Potency of compounds is reported as IC50 values (the concentration of drug 
required to reduce cell viability by 50% relative to control). 
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IV.6 Discussion 
Identification of endoproteases overexpressed in human tumours relative to 
normal tissues represent promising drug targets for development of specific 
inhibitors and proteolytically activated antitumour prodrugs. A crucial requirement 
for the design of peptide prodrugs is the recognition of amino acid sequence 
selectively cleaved by the protease to which it is targeted. Since Chapter-2 
demonstrated a statistically significant overexpression of MMP-10 in preclinical 
and clinical tissues of glioma relative to normal brain, this section of work focussed 
on utilising the learning from in silico modelling, exploiting the differences between 
the MMP substrate binding sites and the rational design of anticancer prodrugs 
selectively activated by MMP-10.  
Anticancer prodrugs selectively activated due to elevated endoproteases activity 
within the tumour microenvironment relative to surrounding normal tissues, are 
composed of three components; a potent chemotherapeutic drug (effector), a 
peptide sequence which inactivates the effector and possesses a cleavage site for 
the endoprotease of choice and a chemical endcap to prevent non-specific 
metabolism by exoproteases.203 In this study, in silico proteolytic docking coupled 
to in vitro biochemical assessment have been applied to enable development of 
anticancer peptide prodrugs selectively activated by MMPs within the tumour, 
resulting in improved release of chemotherapeutic drug at the tumour site relative 
to normal tissues, thereby increasing the therapeutic index of the drug. In choosing 
the anticancer drug, we endeavoured to take advantage of the established 
antitumour activities of doxorubicin and the colchicine derivative 
(azademthylcolchicine) but avoid systemic toxicity by conjugating them to 
rationally designed MMP-cleavable peptides activated selectively at the tumour 
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site. The rational exploitation of stromelysin catalytic domains to identify the 
differences in their binding sites and design tumour selective prodrugs activated by 
MMP-10 over its close homologues, MMP-3 and gelatinases, is a novel and 
unreported approach to cancer treatment. 
To achieve differential selectivity between structurally homologous MMPs, the 
initial efforts focused on developing MMP-subtype selective prodrugs. Considering 
a very similar catalytic structural homology between MMPs, it would be beneficial 
to differentiate between catalytic binding subsites and further attain better 
selectivity. The most crucial step in developing peptide prodrugs is the 
development of an amino acid sequence which allows for selective cleavage only 
by specific MMPs. But more often than not, the peptide sequence is also selective 
for non-specific homologous MMPs, rendering the drug targeting system 
ineffective. For this purpose, the ‘Albright prodrug’ sequence possessing pan-MMP 
selectivity was utilised as the template sequence.207, 285 Derived from ‘Albright 
prodrug’, the modified MJ02 sequence consisted of amino acids which would 
selectively align into the active sites of MMP-2 and MMP-10, over MMP-3 and 
MMP-9. Using the MMP-2/MMP-9 cleavage site, Gly-Ser(OBenzyl), of the “Albright 
prodrug”; the replacements of the P1 Gly with a Hof residue, P2 Leu with a Glu 
residue and P3 Pro with a Gln residue, were induced to achieve MMP-2 selectivity 
over MMP-9. In terms of binding affinity, it was observed that the S1 and S3 
subsites in MMP-2 have deeper cavity than MMP-9, suggesting MMP-2 can 
accommodate longer side chains than MMP-9 (Figures IV.50 and IV.51). The 
presence of small chain Ala165 residue in MMP-2 S1 subsite showed affinity for 
large aromatic residues, whereas Glu402 residue in MMP-9 causes the S1 pocket 
to become shallow in comparison. Therefore, Hof was able to tightly fit into S1 
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pocket of MMP-2 as demonstrated by strong hydrophobic interaction with Ala165 
(Figures IV.50 and IV.51). However, Hof was unable to align into the shallow S1 
pocket of MMP-9. Similarly, the presence of Gly204 residue in MMP-2 at S3 
subsite accounts for a large neutrally charged pocket. Therefore the S3 pocket of 
MMP-2 was able to accommodate Gln residue at P3 position. Conversely, Asp410 
present at the bottom of S3 subsite in MMP-9 accounted for a smaller pocket and 
was therefore unable to accept Gln at this subsite (Figures IV.50 and IV.51). 
Furthermore, MMP-2 and MMP-9 consisted of large S2 pockets with a difference 
in polarity. His205 in MMP-2 made the S2 pocket charged in nature and had 
affinity for acidic residues. Whereas, Phe192 residue in the S2 pocket of MMP-9 
was hydrophobic in nature and possessed affinity for hydrophobic residues. 
Therefore, Glu residue at P2 position was able to strongly align into the S2 subsite 
of MMP-2, but not into MMP-9 (Figures IV.50 and IV.51). It is suggested that 
MMP-9 prefers an Arg at P2 whilst MMP-2 more efficiently cleaves small chain 
residues such as Leu.286-288 In this study, however, the addition of Leu at P2 
position caused relatively stronger interaction with MMP-9 when compared to Glu 
at this position.  It was observed that the S1’ specificity pocket of MMP-2 was 
larger in comparison to MMP-9. In MMP-2, the external wall of the S1’ cavity if 
largely formed by Thr227 – Phe232 specificity residues, creating a deeper pocket. 
Whereas, Arg424 in MMP-9 is present at the bottom of S1’ pocket and closes off 
the end, leading to a relatively smaller cavity.134, 269 Despite, the affinity of S1’ 
pocket in MMP-2 to accommodate long hydrophobic residues, small non-polar 
residue, Leu, was included at P1’ position instead. This was due to longer residues 
leading to a negative effect on the predicted binding affinity, due to conformational 
change. The S1’ cavity of MMP-9 was unable to accommodate Leu due to 
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steric/charge hindrances imposed by S1, S2 and S3 subsites of MMP-9 towards 
the MJ02 residues.  
 
Figure IV.50: MMP-2 binding subsite demonstrates strong preference for MJ02 
peptide residues 
 
 
Figure IV.51: MMP-9 binding subsites do not show preference for MJ02 residues 
due to steric/charge hindrances, relative to MMP-2  
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Similarly, based on the MMP-3/MMP-10 cleavage site, Ser(OBenzyl)-Tyr, in the 
‘Albright prodrug’ the replacements of the P1 Ser(OBenzyl) with a Glu residue, P2 
Gly with a Gln residue, P5 Glu with a Gly residue and P1’ Tyr with a Hof residue, 
were induced to achieve MMP-10 selectivity over MMP-3. In spite of identical 
substrate selectivity of MMP-3 and MMP-10, there were subtle but significant 
binding differences between the two. The difference in S2 and S3 pockets were 
important in rationalising the peptide selectivity between the two stromelysins. 
Ser179 and Leu180 residues, present on either sides of the S2 pocket in MMP-10 
demonstrated affinity for both hydrophobic and hydrophilic residues. Whereas, the 
presence of Ile203 in MMP-3 caused the S2 pocket hydrophobic in nature. 
Therefore, the Gln at P2 position inserted into the S2 pocket was strongly 
coordinated by Ser179 and Leu180 residues present on either side of MMP-10 
pocket (Figure IV.52). In MMP-3 however, the hydrophobic nature of S2 pocket 
demonstrated weaker affinity for Gln at this position. Similarly, Ala229 and His227 
residues present on either side of the S3 pocket of MMP-10 demonstrated affinity 
for both polar and non-polar residues (Figure IV.52). On the other hand, the S3 
pocket of MMP-3 contained His166 and was smaller in comparison to MMP-10. 
Therefore, the replacement of Ile at P3, was strongly coordinated by Ala 229 in 
MMP-10, but demonstrated weaker affinity for MMP-3. The small hydrophilic S3 
pocket of MMP-3 possessed weaker interaction with the hydrophobic Ile residue. It 
was suggested that a peptide sequence must possess Glu at P1 position, for it to 
be selectively cleaved by stromelysins.221, 284 Therefore, Glu was inserted at P1 
position and its acidic nature indeed made significant contributions to the MJ02 
binding energy. The presence of histidine-zinc complex in MMP-10, coordinated 
strongly with the Glu at P1 position.  The Hof side-chain at P1’ position was 
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inserted into the S1’ pocket of MMP-10 and further coordinated by the wall-forming 
segment residues (at interatomic distances of 2.3 Å to 2.5 Å). The side-chains of 
Phe212, Leu213, Leu234 and Phe248 in MMP-10 make the hydrophobic cluster at 
the bottom of the pocket, suggesting a strong binding affinity towards MMP-10 
compared to MMP-3.271  
 
 
Figure IV.52: MMP-10 binding subsites demonstrating string preference for MJ02 
peptide residues 
 
This is the first study, to our knowledge, to detail the critical binding determinants 
of gelatinases and stromelysins. It has been suggested that the main functional 
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MMP-10 suggested that the experimental cleavage must occur at these subsites 
by respective MMPs. It is proven that the catalytic zinc complex consisting of three 
histidine residues are responsible for efficiency of binding and hydrolysis by 
specific enzymes.134 In agreement with the in silico prediction, the MMP-2 and 
MMP-10 targeted prodrug of doxorubicin, MJ02, displayed preferential cleavage 
by recombinant MMP-2 at the Hof-Leu bond and by recombinant MMP-10 at the 
Glu-Hof bond. This was an encouraging result because the utilisation of in silico 
approaches to exploit the differences in MMP binding sites, successfully lead to 
the development of MMP-subtype selective prodrugs.  
Furthermore, MJ02 demonstrated relative stability in mouse liver homogenate, 
mouse plasma and mouse kidney homogenates whilst being rapidly metabolised 
by the HT1080 tumour homogenate to release free Dox. In order to assess the 
MMP-metabolism of MJ02 in preclinical models, the U87-MG human glioma cell 
line was selected as a positive control based on its expression of both MMP-2 and 
MMP-10 whilst SVG-P12 normal glial cell line was selected as a negative control 
since it demonstrated low expression of MMP-10, but does express MMP-2 at high 
levels. U87-MG demonstrated rapid metabolism of MJ02 to release Leu-Dox whilst 
relative stability of MJ02 was observed in SVG-P12 cell line. U87-MG displayed 
negligible metabolism of MJ02 in the presence of pan-MMP inhibitor (GM6001), 
strongly supporting an involvement of MMPs in the metabolism of MJ02. The 
metabolism of MJ02 by U87-MG decreased significantly in the presence of MMP-
10 selective inhibitor, JJH-III-012A, (developed by Dr. JJ Harburn in a parallel 
project) suggestive of MMP-10 selective metabolism of MJ02. However, the 
differential metabolism between GM6001 and JJH-III-012A could be suggestive of 
MMP-2 involvement in MJ02 metabolism. 
233 
 
 
Following the successful demonstration of selective MJ02 metabolism by MMP-10 
expressing preclinical model U87-MG, in vitro cytotoxicity of Dox, Leu-Dox (the 
chemotherapeutic released in preclinical cell models) and MJ02 were examined in 
U87-MG, 1321N1 and SVG-P12 cell lines. Selective cytotoxicity of MJ02 was 
observed in U87-MG and 1321N1 cell lines relative to the SVG-P12 cell line whilst 
all the cell lines demonstrated chemosensitivity to Dox. This data strongly supports 
the prodrug strategy of drug inactivation when attached to a peptide sequence, as 
demonstrated by a significantly decreased cytotoxicity of prodrug against the SVG-
P12 cell line. The lack of MJ02 cytotoxicity against U87-MG in the presence of 
GM6001 also demonstrated MMP-selective chemotherapeutic action of prodrug.  
To protect from metabolism by non-specific exoproteases, peptides were initially 
endcapped with Fmoc at the N-terminus. But the conjugation of anticancer drug at 
the C-terminus of the peptide eventually failed when the Fmoc proved to be 
chemically unstable in the presence of mild acidic conditions (data not shown). 
Therefore, Cbz non-polar group was employed as an endcap instead, providing 
improved stability during drug conjugation and in the reaction mixture.  
The demonstration of MMP-10 as a viable target for treatment of glioma and the 
successful development of rationalised MMP-subtype selective anticancer 
prodrugs led to further evaluation of peptide sequence in an effort to make MMP-
10 targeted prodrugs, and to eliminate metabolism by its close family homologues.  
Utilising the in silico docked complexes MJ02 and MMPs as a reference, we tried 
to engineer-out the MMP-2 selectivity, but it proved to be complicated. In the 
process of retaining MMP-10 selectivity, other MMP members also demonstrated 
marginal selectivity. Therefore, the focus shifted towards using the docked 
complexes of stromelysin-selective fluorescent substrate, M-2110, (discussed in 
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Chapter 3) and MMPs, as a template sequence. In agreement with the in silico 
prediction, M-2110 demonstrated preferential cleavage by MMP-3 and MMP-10 at 
Glu-Nva bond; and a relatively slower hydrolysis by MMP-9 at Pro-Val bond, 
whereas no cleavage by MMP-2 was detected. As mentioned earlier, that the 
design of peptide prodrugs selective for MMP-10, over MMP-3 (the closest MMP 
subfamily with 86% structural similarity) has not been reported.209, 271 The in silico 
docking complex of M-2110 and MMPs provided a suitable model to rationally 
exploit the difference in stromeysin binding sites. The peptide sequence of M-2110 
was modified towards MMP-10 selectivity by incorporating residues to fit the 
specificity pockets of MMP-10; but prevent binding with MMP-2, MMP-9 and MMP-
3. Using the MMP-3/MMP-10 cleavage site, Glu-Nva, of M-2110 substrate; the 
replacements of the P2 Val with a Leu residue, P3 Pro with a D-Pro residue, P1’ 
Nva with a His residue and P2’ Trp with a Leu residue, were induced to achieve 
MMP-10 selectivity over other MMPs. It was suggested that in order for a 
substrate to be selectively cleaved by stromelysin family, it must possess a Glu 
residue in the P1 position. By keeping Glu as a constant residue at P1 position, 
the sequence of M-2110 was modified based on the learning from the in silico 
docked models. Rational design of MMP-10 selective peptide conjugate was 
achieved by incorporating residues into the peptide chain to fit S2, S1’ and S2’ 
pockets of MMP-10 which differed in size, charge and polar affinity compared to 
MMP-3 The following modifications were incorporated: branched non-polar 
residues in S2 subsite; basic residues in S1’ subsite and branched non-polar 
residues in S2’ subsite. The Val in M-2110 at P2 position was substituted by Leu 
to fit a relatively larger S2 pocket in MMP-10 than in MMP-3. MMP-10 
demonstrated the lack in affinity for aromatic residues at S2’ subsite and was 
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suitable for aliphatic side-chains instead. Therefore, Trp in M-2110 at P2’ position 
was substituted by Leu to tightly fit into the pocket of MMP-10, a feature not 
observed in MMP-3 where aromatic residues are preferred. At S1’ position, Nva 
residue was substituted by His to align well into the specificity pocket of MMP-10 
but not into MMP-3. The modification of peptide sequence with His at S1’ subsite 
and to adapt well into MMP-10 binding site was an unusual finding because like 
other MMPs, MMP-10 pocket is well suited to accommodate hydrophobic residues 
that may well provide better selectivity. However, the rationale for employing His at 
S1’ subsite was that Glu218 (responsible for H2O bonding with the catalytic zinc) 
side chain is present very close to the neck of S1’ pocket in MMP-10, which further 
suggested the potential of S1’ to also accommodate charged basic residues 
(Figure IV.53). In contrast, the same Glu202 side chain in MMP-3 is facing away 
from the S1’ pocket suggesting a possibility of weaker interaction with the binding 
site in the presence of His at S1’ subsite.  
Figure IV.53: Differences possessed by the S1’ binding cavities of MMP-10 and 
MMP-3. The position of Glu residues in both MMPs determine the type of peptide residue 
preference. His peptide residue was preferred by MMP-10 because Glu is facing towards 
the pocket and interacts with His. Whereas His aligned weakly into MMP-3 S1’ pocket 
because the carboxylate side groups of Glu were facing away from the pocket. 
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In the flexible docking model the modified sequence: Pro-Lys-Pro-Leu-Glu-His-Leu 
aligned well into the MMP-10 sequence, but also showed a weaker selectivity 
towards MMP-3. His residue at P1’ position was able to loosely fit into the S1’ 
pocket of MMP-10 whereas in MMP-3 Pro~Lys residues formed the P1-P1’ 
subsites, as determined by the presence of catalytic zinc ions. In order to 
engineer-out catalysis by MMP-3, the Pro at P3 position was replaced by its D-
isomer, D-Pro; such that the peptide sequence adapted a moderate 
conformational change enough to eliminate its selectivity at Pro~Lys bond by 
MMP-3. The rationally designed peptide sequence Pro-Lys-DPro-Leu-Glu-His-Leu 
was further minimised and docked into the active sites of stromelysins and 
gelatinases. 
The newly modified sequence demonstrated in silico proteolytic docking into the 
active site of MMP-10, but displayed negligible/negative binding with MMP-2, 
MMP-9 and MMP-3. The strong interaction of catalytic zinc with the carboxylate 
between the Glu-His bond in MMP-10 suggested that the experimental cleavage 
must occur at these subsites by respective MMPs. The MMP-10 targeted prodrug 
of doxorubicin, MJ04, displayed preferential cleavage by recombinant MMP-10 at 
the Glu-His bond, but displayed no cleavage by recombinant MMP-2, MMP-3 and 
MMP-9; thus confirming the in silico prediction. The assessment of MJ04 
metabolism in preclinical cell models demonstrated rapid metabolism by MMP-10 
positive U87-MG cell line compared to MMP-10 negative SVG-P12 cell line. 
Crucially, using MJ04 to release Leu-Dox resulted in a greatly reduced exposure 
of SVG-P12 normal glial cell line to the Leu-Dox intermediate, thus suggesting an 
increased therapeutic index compared to MJ02. The metabolism of MJ04 was 2-
fold slower in SVG-P12 cell line compared to MJ02. Importantly, for this prodrug 
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strategy and targeted therapy of glioma, Leu-Dox was only detected after 96 h 
when dosed with MJ04 in the presence of MMP-10 selective inhibitor, which is in 
contrast to MJ02 where Leu-Dox was detected at 48 h. The positive result 
obtained with the significant decrease in MJ04 metabolism by U87-MG in the 
presence of JJH-III-012A, suggesting a total involvement of MMP-10 in 
metabolism of MJ04. Therefore, MJ04 cleavage was significantly retained in 
normal glial cells and also in the presence of MMP-10 selective inhibitor, with rapid 
cleavage demonstrated in U87-MG glioma cell line. In terms of glioma, this finding 
strongly support the development of MMP-10 activated prodrugs as a means for 
selectively delivering anticancer agents to the glioma tumour relative to normal 
brain tissue.  
In monitoring the in vitro cellular metabolism of MMP-selective doxorubicin 
prodrugs designed in this study, doxorubicin was detected as an intermediate 
species, Leu-doxorubicin. This is in agreement to the limited published studies 
where prodrugs, usually of doxorubicin, are not efficiently metabolised following 
the initial MMP-selective cleavage step to release the cytotoxic agent. The MMP 
and PSA activated prodrugs of doxorubicin are activated to release Leu-
doxorubicin and generally do not result in complete hydrolysis to produce 
doxorubicin directly.207, 209, 289-292 Leu-doxorubicin is an active chemotherapeutic 
agent in its own right and was originally developed to increase the therapeutic 
efficacy of doxorubicin.293 It is suggested that once released from the prodrug, 
Leu-doxorubicin is taken up efficiently into the cells and the Leu further removed is 
as yet an unidentified intracellular process.293 In contrast to Leu-doxorubicin as 
intermediate species, release of free azademethylcolchicine was observed in the 
metabolism of azademethylcolchicine prodrugs. This is again, in agreement with 
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the reported literature that demonstrated a rapid degradation of prodrugs in the 
panel of tumour homogenates and cell lines to release free 
azademthylcolchicine.203 
On the contrary, doxorubicin was detected as a free cytotoxic agent released after 
metabolism of MJ02 ex vivo. Despite the release of free doxorubicin, MJ02 
displayed differential and selective metabolism in tumour homogenates relative to 
normal tissues. The presence of a high proportion of both extracellular and 
intracellular proteolytic enzymes in tumour homogenates, relative to tumour cell 
models, could have resulted in the rapid degradation of MJ02 to produce free 
doxorubicin. It will be valuable in the future to determine the exact cleavage 
pattern of metabolism by significantly slowing down the reaction. 
In summary, these data indicate that it is possible to utilise in silico predictive 
approaches to rationally design prodrugs selectively metabolised by MMP-10 
expressed in glioma tumours relative to normal brain. The prodrugs demonstrated 
tumour selective drug release with a significant reduction in exposure of normal 
glial cells to the released chemotherapeutic agents, as compared to administration 
of the active agent alone.  
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Chapter 5: Development and preclinical testing of graphene oxide 
tethered prodrug conjugates 
 
V.1 Graphene oxide as a drug carrier 
The development of nanoscale drug carriers has been an important focus in 
advanced drug delivery systems.294 Recently approved drug delivery systems like 
polymer nanoparticles or liposomes, have led to many conventional drugs 
regaining the possibility of clinical use.295 Since 2004, graphene has been 
recognised as one of the most promising materials for biomedical and life science 
applications. Graphene is a two-dimensional carbon material with enhanced 
mechanical strength, conductivity and gas barrier properties. Compared to other 
carrier materials used in advanced drug delivery systems, graphene oxide (GO) 
offers a high surface to weight ratio, high drug loading efficiency, high possibility 
for surface modification and photothermal effects.296-300 Furthermore, 
functionalised GO can enter mammalian cells to deliver the therapeutic drug, 
rendering it a reasonable drug carrier.298 Unlike the common poor aqueous 
dispersion problems observed with the use of other carbon nanomaterials like 
carbon nanotubes and fullerenes, GO has good water solubility because of 
abundant hydrophilic groups on either side of the GO surface. The functional 
groups such as epoxide, carboxylic and hydroxylic groups help to maintain stability 
in physiological solutions and increase the drug carrier efficiency.301  
Currently, all the research applications of GO-drug binding are based on non-
covalent interactions. For example, π-π stacking exists between GO and 
chemotherapeutic drugs possessing aromatic structures such as doxorubicin, SN-
38 and camptothecin. This adsorption binding provide GO with high drug loading 
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efficiency.302 Chen et al. used a chemical coprecipitation method to add Fe3O4 
magnetic nanoparticles onto graphene. After linking the targeting ligand, the 
graphene selectively released doxorubicin to target breast cancer cells. Graphene 
can also be modified with polyvinyl alcohol for adsorption of doxorubicin for 
targeted anticancer delivery. Studies have also increased the GO pH-
responsiveness with sulphonic acid to improve increased drug loading and 
delivery efficiency.303  
In light of the current study, a major hindrance in the use of systemic 
chemotherapy for the treatment of glioma is the presence of the blood brain barrier 
(BBB). Therefore the clinical use of novel MMP-targeted prodrugs via systemic 
route would prove challenging for anti-glioma therapy.304  In order to selectively 
target glioma tumour, one therapeutic strategy is to harness the activity of specific 
MMPs located in the glioma microenvironment for tumour-selective release of 
potent chemotherapeutics from functionalised GO nanostructured prodrug 
implants. 
V.2 Aims and objectives  
This chapter determines the feasibility of targeting MMP-selective anticancer 
prodrugs conjugated to graphene oxide as a local drug delivery approach for 
glioblastoma.  
Specific objectives of this section include: 
1. To design graphene tethered doxorubicin prodrug, with MJ02 peptide 
sequence nested between functionalised graphene oxide and doxorubicin. 
2. To determine the selective cleavage of graphene oxide-prodrug by 
recombinant MMPs. 
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3. To assess metabolism of graphene oxide-prodrug in preclinical human 
glioma cell lines. 
4. To assess specificity of prodrug cytotoxicity in human glioma cells relative 
to normal glial cells.  
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V.3 Materials and methods 
V.3.1 Reagents and materials 
GO was purchased from ACS Materials (Pasadena, CA, USA), as a starting 
material. N-Hydroxysulfosuccinimide (Sulfo-NHS), 1-ethyl-3-(3-dimethyl-
aminopropyl) carbodiimide hydrochloride (EDC) and sodium chloroacetate 
(ClCH2COONa) were purchased from Sigma Aldrich (Missouri, USA). 
V.3.2 Preparation of graphene oxide (GO)-peptide conjugate 
The GO suspension (in H2O, ~1 mg/mL) was sonicated in a bath sonicator for 1 h. 
The resulting suspension was centrifuged at 12,000 rpm for 10 min, and the 
supernatant was taken for further carboxylation and peptide conjugation. In 
carboxylation of GO, 125 mM NaOH and 42.9 mM ClCH2COONa were added into 
1.5 mL GO suspension and bath sonicated for 1 h to convert the hydroxyl and 
epoxide groups to COOH groups. The resulting reaction mixture was neutralized 
with diluted HCl, and purified by repeated centrifugation at 100,000 rpm for 30 min 
and rinsing with distilled water. The sediment was re-dispersed in 1.5 mL 
phosphate buffer (PB) (8 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) to obtain the 
carboxylated GO suspension. In conjugation of GO with peptide, 5 mM Sulfo-NHS, 
1 mM EDC were added into the carboxylated GO suspension, and the mixture was 
bath sonicated for 1 h. After the mixture adjusted to pH 8.0 with 1 mM NaOH, 1 
mM side-chain protected MJ02 with free N-terminus, was added. The mixture was 
stirred vigorously at 37°C in the dark overnight. The product was purified by 
repeated centrifugation at 100,000 rpm for 30 min and rinsing with distilled water 
to remove unreacted peptides. The final product, GOpeptide conjugate, was 
dispersed in distilled water and stored in refrigerator at 4 ºC.  
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V.4 Results 
V.4.1 Creation of graphene oxide tethered doxorubicin prodrug  
Chapter-4 demonstrates the utilisation of in silico approaches to design anticancer 
prodrugs selectively activated by specific MMP-subtype members. In developing a 
graphene oxide (GO)-bound anticancer prodrug implant, we endeavoured to take 
advantage of MJ02’s MMP-subtype selectivity and antitumour activity by 
catalytically hydrogenating the Cbz ‘endcapping group’ with Pd/C (10 wt. %) and 
attaching the carboxylated GO to the N-terminus of MJ02 peptide-Dox that is only 
cleaved at the tumour site by MMP-2 and MMP-10. The GO-conjugated MJ02 was 
developed systematically comprising of following reaction stages and analytic 
detection at each step: Development of MJ02 with preserved side-chain protecting 
groups, catalytic hydrogenation of Cbz endcapping group and conjugation of MJ02 
peptide-Dox onto graphene oxide. 
V.4.1.1 Development of MJ02 with side-chain protecting groups 
The MJ02 peptide sequence containing a Cbz non-polar endcapping group was 
conjugated to doxorubicin warhead, as described in materials and methods 
(Chapter 4, section IV.4.4). The side chain protecting groups, Boc (tert-
butyloxycarbonyl) of Gln and OtBu (tert-butyl) of Glu, were preserved to avoid side-
chain reactions while conjugation with the GO. MJ02, with protecting groups, was 
synthesised containing the amino acid sequence Gly-Pro-Ile-Gln(Boc)-Glu(OtBu)-
Hof-Leu which has doxorubicin at the C-terminus of the peptide and Cbz groups at 
the N-terminus. 
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V.4.1.2 Analytical detection of ‘protected MJ02’ 
Protected MJ02 was analysed and its molecular mass confirmed using LCMS 
methods described in section IV.4.4 (Chapter 4). Preparative-HPLC gradient 
system with a C18 column was used to purify ‘protected MJ02’ at tR of 3.760 
minutes (m/z 1633.7 Da [M+H]
+) (Figures V.1 and V.2), to give a pale red solid. 
 
 
Figure V.1: Purified ‘Protected MJ02’. Sequence: Cbz – Gly-Pro-Ile-Gln(Boc)-
Glu(OtBu)-Hof-Leu – Doxorubicin 
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tR = 3.760 minutes
 
Figure V.2: Identification of MJ02 with side chain protecting groups at tR 3.760 
minutes (m/z: 1633.7 Da [M+H]
+) confirmed by LCMS  
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V.4.1.3 Catalytic hydrogenation of Cbz with Pd/C (10 wt. %) 
Cbz, the endcapping group, of ‘protected MJ02’ was deprotected using catalytic 
hydrogenation reaction in the presence of palladium catalyst at room temperature. 
The hydrogenation reaction of Cbz was performed based on the literature.305 It has 
been suggested that during hydrogenolysis of Cbz groups, the phenyl ring of the 
Cbz is simultaneously converted to toluene, thus cleaving from the N-terminus of 
the corresponding molecule.306 ‘Protected MJ02’ was successfully converted into a 
free N-terminus peptide-Dox conjugate devoid of Cbz protecting group, containing 
the amino acid sequence NH2-Gly-Pro-Ile-Gln(Boc)-Glu(O
tBu)-Hof-Leu which has 
doxorubicin at the C-terminus of the peptide (Figures V.3 and V.4). 
 
 
Figure V.3: ‘Protected MJ02’ with free N-terminus after catalytic hydrogenation of Cbz 
non-polar endcap. Sequence:   NH2-Gly-Pro-Ile-Gln(Boc)-Glu(O
tBu)-Hof-Leu – 
Doxorubicin 
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tR = 3.63 minutes 
 
Figure V.4: LCMS Confirmation of Cbz deprotection from MJ02, leaving the N-terminus of 
MJ02 free. The metabolite detected at tR 3.63 minutes (
m/z: 1497.8 Da [M+H]
+). At tR 3.762 
minutes, m/z 1633.7 Da [M+H]
+ (corresponds to the starting material i.e. the prodrug) 
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V.4.1.4 Development of GO-prodrug conjugate (MJ06) 
The GO-peptide conjugate was prepared based on the method described in the 
literature.307 Following its complete carboxylation, the COOH of GO was 
conjugated to free N-terminus of the peptide-Dox of MJ02. After completion of the 
GO-peptide-Dox conjugation reaction, the final product was purified by repeated 
centrifugation and rinsing with water to separate unreacted peptide-Dox (Figure 
V.5).  
The resulting GO conjugated prodrug could not be detected by LCMS (as per 
previous samples). This was because the finished product presented as a 
suspension with a large particulate size that is unable to be passed through a MS 
column. In order to prove the success of conjugation in a step-wise manner, the 
separated unreacted peptide present in the supernatant, following centrifugation, 
was detected on LCMS to prove whether the ‘N-terminus free’ MJ02 peptide-Dox 
remained intact during the conjugation reaction (Figure V.6). The centrifugation 
was repeated until the free peptide-Dox in the supernatant was undetectable on 
LCMS.  
The red-charcoal coloured GO-peptide-Dox precipitate, now potentially free of any 
unreacted peptide contaminants, was subjected to side-chain deprotection 
reaction with TFA:DCM (1:1) to selectively cleave Boc and OtBu protecting groups. 
The reaction mixture was again centrifuged and the supernatant from this reaction 
mixture was analysed to ensure that no peptide-Dox had deprotected from the GO 
(Figure V.7). When analysed by LCMS, there was no presence of free peptide-Dox 
in the supernatant of deprotection reaction mixture, suggesting that the GO was 
successfully adhered or conjugated onto the peptide-Dox (Figure V.7). 
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Figure V.5: Synthesis route of the GO-peptide-Dox conjugate (MJ06). A, 
carboxylation of GO to convert hydroxyl and epoxide groups to COOH groups. B, 
Reactions conditions required for the conjugation of ‘protected MJ02’ to the surface of 
GO. C, GO-conjugated to protected MJ02 purified by repeated centrifugation and 
deprotection of side-chain protecting groups. D, Production of purified MJ06 
ClCH2COONa
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tR = 3.63 minutes 
 
Figure V.6: LCMS detection of unreacted peptide-doxorubicin. Supernatant from the 
reaction mixture corresponding to the unreacted peptide-doxorubicin at tR of 3.63 
minutes, m/z 1497.8 Da [M+H]
+. At tR 3.762, 
m/z is 1633.7 Da [M+H]
+ corresponding to 
‘protected MJ02’. 
 
 
Figure V.7: LCMS analysis of supernatant from the TFA (50%)-DCM deprotection 
reaction mixture. Indicating the absence of unreacted peptide from the supernatant. 
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V.4.2 Analysis of MJ06 cleavage by recombinant MMP-2 and MMP-10 
MJ02 was rationally designed to be preferentially cleaved by MMP-2 and MMP-10, 
over MMP-9 and MMP-3. Following complete energy minimisation the in silico 
modelling of GO-prodrug of doxorubicin (MJ06) demonstrated rigid molecular 
conformation. The peptide sequence, in the same rigid conformation, was docked 
into the active site of respective MMPs. Similar to the MJ02 flexible docking 
presented in section IV.5.3 (Chapter 4), the rigid peptide sequence demonstrated 
selective interaction with MMP-2 and MMP-10, whereas negligible interaction was 
observed with MMP-9 and MMP-3. This suggests that MJ06 should still be 
selectively activated by MMP-2 and MMP-10. In order to validate the in silico 
prediction, MJ06, containing the amino acid sequence of MJ02, was assessed for 
its cleavage by recombinant MMPs. Considering the limitation of MJ06 detection, 
only the Dox-half of the cleaved metabolites were detected on LCMS, whereas the 
GO-conjugated half of the peptide remained precipitated along with the enzyme 
buffer and recombinant MMP proteins, prior to analysis. Therefore, only one peak 
was detected, corresponding to Dox-half of MJ06, suggesting preferential 
cleavage by a particular MMP. However, MMP-3 and MMP-9 demonstrating lack 
of cleavage of MJ06 showed undetectable metabolites when analysed by LCMS. 
MMP-2 cleaved MJ06 at the Hof-Leu bond whereas MMP-10 cleaved MJ06 at the 
Glu-Hof bond, as was predicted (Figures V.8, V.9, V.10 and V.11). MJ06 was 
preferentially cleaved by MMP-2 at Hof-Leu and one peak identified; 
corresponding to Leu-Doxorubicin at tR of 2.078 minutes (
m/z 657.2Da, [M+H]
+) 
(Figures. V.8 and V.9). MJ06 was also cleaved by MMP-10 at Glu-Hof bond and 
one peak was identified; corresponding Hof-Leu-Doxorubicin at tR of 2.996 
minutes (m/z 816.66 Da, [M+H]
+) (Figures V.10 and V.11). Conversely MMP-9 and 
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MMP-3 did not cleave MJ02 in the same timeframe, indicating that MJ06 is still 
MMP-2 and MMP-10 selective, supporting the in silico prediction (Figure V.12). 
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Figure V.8: Schematic representation of the cleavage of MJ06 by recombinant MMP-
2. Indicating cleavage of MJ06 at the Homophe-Leu bond 
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tR 2.078 minutes; peptide metabolite: Leu-Doxorubicin 
 
Figure V.9: Determination of MMP-2 cleavage site in MJ06 – Supernatant from the 
enzyme treated MJ06 mixture. Recombinant MMP-2 cleavage of MJ06 at the Homophe-
Leu bond, as determined by LCMS analysis. HPLC trace of MJ06 metabolism following 12 
h incubation with recombinant MMP-2 at 37°C, showing the cleaved metabolite at tR 2.078 
minutes and the MS detection of metabolite as m/z 658.2 Da [M+H]
+, corresponding to Leu-
Doxorubicin  
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Figure V.10: Schematic representation of the cleavage of MJ06 by recombinant 
MMP-10. Indicating cleavage of MJ06 at the Glu-Homophe bond 
 
 
 
 
 
 
 
 
 
 
 
 
 
MMP-10 
mediated cleavage
GO – Gly-Pro-Ile-Gln-Glu-Hof-Leu –Doxorubicin
GO – Gly-Pro-Ile-Gln-Glu- Hof-Leu – Doxorubicin
256 
 
 
 
tR 2.997 minutes; peptide metabolite: Hof-Leu-Doxorubicin 
 
Figure V.11: Determination of MMP-10 cleavage site in MJ06 – Supernatant from the 
enzyme treated MJ06 mixture. Recombinant MMP-10 cleavage of MJ06 at the Glu-Hof 
bond, as determined by LCMS analysis. HPLC trace of MJ06 metabolism following 12 h 
incubation with recombinant MMP-10 at 37°C, showing the cleaved metabolite at tR 2.997 
minutes and the MS detection of metabolite as m/z 817.3 Da [M+H]
+, corresponding to Hof-
Leu-Doxorubicin.  
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Incubation with MMP-9 
 
Incubation with MMP-3 
 
Figure V.12: Recombinant MMP-9 and MMP-3 do not cleave MJ06 
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V.4.3 Stability of MJ06 in MMP positive and MMP negative cell lines 
Similar to the metabolism of MMP-selective prodrugs measured in Chapter-4, the 
selectivity of MJ06 was tested in human glioma U87-MG (MMP-10 positive) and 
SVG-P12 (MMP-10 negative) cell lines. Despite being negative for MMP-10, SVG-
P12 cells do express MMP-2. These cell lines grown in monolayer were assayed 
for their ability to metabolise MJ06 and the appearance of compound Leu-Dox was 
analysed after 24 h, 48 h and 96 h prodrug exposures, determined by LCMS. In 
order to bypass the limitation of LCMS detection pertaining to parent MJ06, Leu-
Dox was used as an ‘internal standard’ in a separate cell monolayer at equipotent 
dose of MJ06 (100 µM), to calculate the appearance of compound. Figure V.13 
demonstrates that MJ06 was rapidly converted into Leu-Dox by U87-MG with a 
significantly slower conversion observed in SVG-P12. U87-MG demonstrated 
complete conversion of MJ06 at 96 h, compared to only 50% (± 3.4) of Leu-Dox 
detected in SVG-P12. 
The involvement of MMPs was assessed by determining the degree of MJ06 
metabolism by U87-MG cells in the presence of pan-MMP inhibitor Ilomastat 
(GM6001) and the MMP-10 selective inhibitor JJH-III-012A (developed by Dr 
Jonathan Harburn for a parallel project), at non-potent concentrations of 1 µM and 
500 nM, respectively . Ilomastat resulted in a significant decrease in metabolism of 
MJ06 by U87-MG, measured by slow appearance rate of Leu-Dox. There was only 
10% (±2.5) of Leu-Dox detected in the presence of Ilomastat, suggesting the 
MMP-selective action of MJ06. In contrast, MJ06 displayed relatively faster 
metabolism in the presence of MMP-10 selective inhibitor (inhibiting 50% of MMP-
10 enzyme at 1 nM) (Figure V.13). It is interesting to note that there is a significant 
differential between the metabolisms by U87-MG alone and the one in the 
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presence of MMP-10 inhibitor, suggesting the involvement of MMP-10 enzyme to 
rapidly metabolise MJ02 in MMP-positive cells. Since MJ06 is selectively activated 
by both MMP-2 and MMP-10 (Figures V.13), the differential metabolism of MJ06 in 
the presence of MMP-10 inhibitor (compared to Ilomastat) could suggest a 
selective cleavage by MMP-2, which remains uninhibited at the treated dose.  
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Figure V.13: Differential metabolism of MJ06 demonstrated by time-dependent 
release of compound Leu-Dox in U87-MG (high MMP expressing) and SVG-P12 (low 
MMP expressing) cell lines. Cells in monolayer were assayed for their ability to 
metabolise MJ06 over 24 h, 48 h and 96 h time points, as detected by LCMS. Appearance 
of Leu-Dox; demonstrating rapid metabolism of MJ06 in U87-MG relative to SVG-P12, 
and increased release of Leu-Dox. In contrast, MJ06 displayed a decreased metabolism 
by U87-MG in the presence of pan-MMP inhibitor (Ilomastat, GM6001) and MMP-10 
selective inhibitor (JJH-III-012A), evidenced by relatively slower rate of MJ06 conversion 
to Leu-Dox. Metabolism values are representative of average from two independent 
experiments. Each value of inhibition study represents the mean ± SE of three 
independent experiments. 
 
Differential metabolism of MJ06 
by U87-MG and SVG-P12 cell lines 
Differential metabolism of MJ06 by U87-MG 
in the presence of Ilomastat (GM6001) 
Differential metabolism of MJ06 by U87-MG in 
the presence of MMP-10 selective inhibitor 
Selectivity of MMP-10 inhibitor 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100
%
 L
e
u
-D
o
x
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l
Time (hours)
U87-MG
SVG-P12
Media
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100
%
 L
e
u
-D
o
x
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l
Time (hours)
U87-MG
U87-MG + GM6001
Media + GM6001
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80 90 100
%
 L
e
u
-D
o
x
 r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l
Time (hours)
U87-MG
U87-MG + MMP-10 inhibitor
Media + MMP-10 inhibitor
261 
 
 
V.4.4 In vitro cytotoxicity of GO, Doxorubicin, Leu-Dox and MJ06 
The response of the human glioma (U87-MG) and normal glial (SVG-P12) cell 
lines to the GO, doxorubicin, Leu-Dox and MJ06 was investigated using the MTT 
assay. The cytotoxicity of GO was carried out to prove their safety as a drug 
delivery vehicle. The GO sheets were dissolved in distilled H2O and delivered into 
the cells at 3 mg/ml concentration. Drug responses of cell lines were analysed 
after 96 h exposures (Figure V.14).  
All the cell lines were sensitive to doxorubicin and Leu-Dox at equipotent doses of 
doxorubicin, following 96 h exposure. In contrast, the treatment of GO into the 
cells proved to be non-toxic, verifying its application in this study as a safe drug 
carrier. As predicted, malignant human glioma cells (U87-MG and 1321N1) 
expressing MMP-10, were able to metabolise the prodrug efficiently and thus has 
a significantly lower IC50 for MJ06 compared to SVG-P12 (MMP-10 negative) at 96 
h exposures. The differential cytotoxicity between doxorubicin and MJ06 against 
glioma models supports the requirement of MJ06 to be activated prior to inducing 
its effects. Furthermore, MJ06 remained inactive in the presence of a pan-MMP 
inhibitor (GM6001; Ilomastat), again demonstrating MMP-selective 
chemotherapeutic action of this prodrug.  Whereas, in the presence of MMP-10 
selective inhibitor (JJH-III-012A), MJ06 demonstrated a 40-fold weaker cytotoxicity 
against U87-MG suggesting MMP-10 selective chemotherapeutic action of MJ06. 
Similar to the metabolism study, the differential cytotoxicity of MJ02 between the 
two inhibitors could suggest the proteolytic activity of MMP-2 in U87-MG, causing 
MJ06 to metabolise faster in the presence of JJH-III-012A relative to Ilomastat. 
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Figure V.14: Chemosensitivity of U87-MG, 1321N1 and SVG-P12 to Doxorubicin and 
MJ06. Assessed using MTT assay following 96 h drug exposure. Cell survival is 
represented as relative to solvent control and demonstrates sensitivity of U87-MG and 
1321N1 cell lines to both Doxorubicin and MJ06 whilst SVG-P12 is sensitive only to 
Doxorubicin. There is no significant difference between the MJ02 and MJ06 cytotoxicity. 
Potency of compounds is reported as IC50 values (the concentration of drug required to 
reduce cell viability by 50% relative to control). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound
U87-MG
IC50 (µM)
1321N1
IC50 (µM)
SVG-P12
IC50 (µM)
96 
hours
Doxorubicin 0.3  0.2 0.005 0.002 0.7  0.5
Leu-Dox 0.6  0.2 0.01 0.02 0.9  0.3
MJ06 2  1.8 0.1  0.32 > 100
Compound
U87-MG
IC50 (µM)
MJ06 2  1.8
MJ06 + GM6001 > 100
MJ06 + JJH-III-012A 80  7.5
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V.5 Discussion 
Therapeutic options for glioblastoma are significantly restricted by the inability of 
systemic chemotherapy to reach the tumour, due to the presence of blood-brain 
barrier, and subsequent dose-limiting toxicity against normal tissues. To improve 
the concentration of drug reaching the glioma tumour, the implantation of Gliadel 
wafers into the tumour resection cavity is a currently employed strategy to 
overcome the pathophysiological barriers within the brain and locally target the 
tumour with a DNA alkylating chemotherapeutic, BCNU. Despite the median 
survival of patients has been reported to increase by 2-4 months, Gliadel wafers 
provide insignificant clinical benefit with adverse neurological side-effects reported 
in patients. This is therefore an area of significant unmet medical need and 
improved tumour-selective therapeutics are essential for the treatment of patients 
with glioma. Since this study attempted to rationally design anticancer peptide-
prodrugs selectively activated by MMPs overexpressed in glioma relative to 
normal brain, this section of work focussed on the potential of utilising these 
tumour-selective anticancer prodrugs and converting them into nanostructured 
prodrug implants of functionalised graphene.  
The biomedical applications of graphene oxide (GO), including drug delivery; have 
been extensively explored as one of the most promising biomaterials due to their 
unique properties: possibility of surface modification, 2D-planar surface, chemical 
stability, efficiency of drug loading and photothermal effects. However, the utility of 
GO as a ‘base’ for tumour-selective drug delivery has been largely unexplored.308 
Herein, we attempted to take advantage of the superior functional and mechanical 
properties of GO and report the proof-of-principle of novel tumour-targeted 
therapeutics based on the nanoconjugate of GO and MMP-selective prodrugs. 
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Because GO as a nanocarrier can intrinsically deliver peptide fluorophores and 
chemotherapeutics, like doxorubicin, inside the cells;309, 310 the GO-conjugate of 
anticancer peptide prodrugs may be selectively activated by overexpressed MMPs 
to release the potent chemotherapeutic to glioma cells relative to normal brain 
cells. To test this hypothesis, the peptide-Dox sequence of MMP-2 and MMP-10 
selective prodrug, MJ02, was chosen and the Cbz endcap was replaced with 
nanostructured carboxylated GO.  
Essentially, GO, in this study, potentially functions as an endcap to protect from 
metabolism by non-specific exoproteases and also as a material to accommodate 
multiple peptide-Dox conjugated on single GO surface. Since GO is a material with 
large surface area, the analytic confirmation of chemical conjugation between GO 
and peptide-Dox could not be fully confirmed by LCMS. Instead, we relied on 
demonstrating the complete removal of unreacted peptide-Dox during multiple 
washes of conjugation reaction and analysing the cleavage of MJ06 by 
recombinant MMPs, thus liberating the Dox-half of the peptide for successful 
detection on LCMS. Thus, suggesting the conjugation of GO and peptide-Dox was 
potentially successful. 
Similar to MJ02, MJ06 demonstrated preferential cleavage by recombinant MMP-2 
at the Hof-Leu bond and by recombinant MMP-10 at the Glu-Hof bond, whereas 
no cleavage was detected by recombinant MMP-9 and MMP-3. MJ06 also 
displayed relative stability in SVG-P12 cells whilst being rapidly metabolised by 
U87-MG cells to release free Leu-Dox. The decreased metabolism of MJ06 in the 
presence of pan-MMP inhibitor and MMP-10 selective inhibitors demonstrated 
proof of MMPs involved in the metabolism of MJ06.  
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Following successful demonstration of selective MJ06 metabolism by MMP-10 
expressing preclinical model U87-MG, in vitro cytotoxicity of doxorubicin, Leu-Dox 
and MJ06 were examined in human glioma cells, U87-MG and 1321N1; and 
normal glial cells, SVG-P12. Selective cytotoxicity of MJ06 was observed in U87-
MG and 1321N1 cell lines relative to the SVG-P12 cell line whilst all the cell lines 
demonstrated chemosensitivity to Dox and Leu-Dox at equipotent doses. This data 
strongly proves the ability of GO to physically support the conjugated peptide-Dox 
on its functionalised surface, acting as a prodrug; and to allow selective delivery of 
chemotherapeutics into the tumour cells as demonstrated by significantly 
decreased cytotoxicity of MJ06 against SVG-P12 cell line. The lack of MJ06 
cytotoxicity against U87-MG in the presence of GM6001 also demonstrated MMP-
selective chemotherapeutic action of GO-prodrug. 
One of the limitations in this study was the failure to successfully characterise the 
chemical conjugation of the peptide-prodrug to GO surface. Despite several 
washes performed during conjugation reaction in an effort to remove unreacted 
peptides and the successful analytical detection of MMP-mediated cleaved 
metabolites, corresponding to doxorubicin-half of the prodrug not attached to GO; 
there is a possibility that a significant proportion of peptide itself was adsorbed, 
rather than conjugated, to the surface of GO. According to the published studies, 
GO-peptide conjugates were confirmed using atomic forced microscopy (AFM), 
confocal microscopy and fluorescence spectrum detection of the GO-peptide 
fragments.307, 311 Guaranteed, these detection techniques would provide the visual 
evidence of the drug carriers being loaded on to the GO surface, but does not 
prove whether the nature of encapsulation was chemical conjugation or just 
surface adsorption (through non-covalent interactions). It will be crucial in the 
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future studies to determine the nature of the conjugation between peptide and GO 
by analysing the chemical bonds using matrix-assisted laser desorption/ionisation 
(MALDI).  
The observation that MJ06 is cleaved by MMP-2 and MMP-10; and demonstrated 
glioma selective release of chemotherapeutic agent, Leu-doxorubicin, compared to 
normal glial cells; is a promising and valuable result. MJ06 contains the amino acid 
sequence of MJ02, but with the GO as the endcap. In agreement with MJ02 
cleavage, the ability of MMPs to metabolise MJ06 in a similar fashion suggests 
that molecular conformation of the peptide chain was retained causing the 
residues to fit into the active sites of MMP-2 and MMP-10, selectively. This offers 
the opportunity to further improve the GO-prodrug conjugate by the incorporation 
of GO matrix with larger surface area to accommodate several tumour-selective 
peptide prodrugs and utilisation of this superior chemotherapeutic drug as a post-
operative brain tumour implant. 
In summary, this study explored the strategy of exploiting the proteolytic activity of 
these specific endoproteases located in the glioma microenvironment for tumour 
selective-release of potent chemotherapeutics, from graphene oxide-bound 
prodrug nanostructure implants. During surgical resection, it is difficult to remove 
glioma tumours completely because these tumours infiltrate the normal brain 
tissue, and more often than not, gliomas recur at the same site in the brain, which 
further causes the increase in endoprotease activity and the vicious cycle of 
tumour angiogenesis and invasion is switched on with poor prognosis making it 
challenging for intervention by current therapies. Mechanistically, the implantation 
of GO-bound tumour-activated prodrug implants following tumour resection, are 
aimed to halt the recurrence of glioblastomas by exploring the proteolytic activity of 
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specific tumour endoproteases and safe release of the anticancer drug into the 
tumour. This therapeutic strategy will potentially improve the therapeutic efficacy of 
the drug and eliminate toxicity on normal tissues. 
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Figure V.15: Overview of therapeutic strategy. Post-operative introduction of 
Graphene-oxide ‘tethered’ MMP-activated prodrug 
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Chapter 6: Overall conclusion and discussion 
Glioblastoma is one of the most aggressive human cancers. Despite recent 
advances in cancer biology and multimodality therapies, such as surgery, 
radiotherapy and chemotherapy, the outcome of patients with high grade glioma 
remains fatal.312 A major limitation of current standard chemotherapeutics is their 
lack of tumour selectivity and consequent side effects, with inevitable glioma 
tumour recurrence within 30-32 weeks following surgery.313 Rationalised drug 
design approaches represent an attempt to address this problem. This process 
involves the identification of tumour associated molecular targets followed by the 
assessment of their drugability and finally the design of tumour-selective 
therapies.314 The main aims of this study was to assess the expression and activity 
of matrix metalloproteases in human glioma samples and preclinical glioma 
models, to examine substrate binding differences between homologues MMPs 
using in silico approaches, to rationally design anticancer prodrugs and evaluate 
MMP-mediated tumour-selective drug release, and finally to assess the 
conceivability of targeting tumour-specific MMPs with nanostructured anticancer 
prodrug implants of functionalised-graphene as a therapeutic strategy for localised 
drug delivery post glioma tumour resection.  
MMPs are a family of zinc-dependent endoproteases with a causal and central 
role in cancer.135 The overexpression and endoproteolytic activity of specific MMP 
members is a major contributor to tumour progression, invasion and metastasis, 
thus making them attractive targets for drug development. This study assessed the 
expression and activity profile of key MMPs in preclinical human glioma models; 
glioma and histologically normal brain samples. Significantly greater MMP-10 
expression was observed in the analysed clinical samples of human gliomas 
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relative to histologically normal brain. Furthermore, MMP-10 gene expression as 
determined by RT-PCR was shown to display a strong correlation with the levels 
of active MMP-10 in preclinical models, suggesting a predominant role of MMP-10 
in the growth and development of glioma tumours. Taken together, this data 
indicates that MMP-10 is overexpressed, proteolytically active and is a target for 
therapeutic intervention in human glioblastoma. Overexpression of MMP-10 has 
been shown in several malignancies including oral carcinoma, head and neck 
squamous cell carcinoma (HNSCC), skin cancer, oesophageal carcinoma and 
non-small cell lung carcinoma (NSCLC).155, 223-226 However, the expression of 
MMP-10 protein in human glioblastoma had not been previously reported. To our 
knowledge, the present study is the first to address the overexpression and 
elevated proteolytic activity of MMP-10 in preclinical models of human glioma 
relative to normal glial cells. 
Despite the involvement of MMP-10 in several human malignancies, the 
elucidation of therapeutics targeted against MMP-10 has remained unexplored 
and elusive. All MMPs share a marked structural similarity in their catalytic 
domains with MMP-3 and MMP-10 being the most homologous of the MMP family 
with 86% structural similarity.271 The similarity in binding preferences and 
substrate complexity poses a significant problem in the generation of MMP 
subfamily selective prodrugs. A requirement for success in prodrug approaches is 
MMP selectivity through incorporation of MMP subtype selective peptide sequence 
and subsequence disease activation. In order to achieve this, reiterative approach 
using in silico proteolytic docking coupled to in vitro biochemical assessment 
methodology was employed. The available MMP X-ray crystal structures were 
carefully studied in silico and the substrate binding selectivity between close MMP 
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family homologues was analysed. The rationale for using a computer-aided drug 
design approach was to evaluate its potential as a guide to rationalise functional 
similarity between MMP catalytic domains for subsequent development of novel 
MMP-targeted prodrugs.  The 3D-strutures of closely related MMP sub-families: 
gelatinases (MMP-2268 and MMP-9269) and stromelysins (MMP-3270 and MMP-
10271) and their flexible docked complexes with MMP-substrates, provided 
valuable insights into the structural determinants of substrate selectivity of a 
particular MMP. According to the literature, M-2110 is hydrolysed rapidly by 
stromelysins and very slowly by MMP-9; whereas M-2055 is hydrolysed rapidly by 
MMP-9 and very slowly by gelatinase B (MMP-2) and stromelysins. The cleavage 
pattern reported in the literature222 and observed via 3-D molecular docking 
(current study), demonstrated that MMP-9 strongly interacts with M-2055 at the 
Gly-Cys(Me) bond, and the present study confirmed this finding. However, the 
cleavage of this substrate by MMP-2 and Stromelysins is unknown. Based on 3-D 
molecular modelling and the respective zinc-chelation sites, it was predicted that 
MMP-2 interacts with the substrate at Gly-Cys(Me) bond and stromelysins 
interacts at Pro-β-cyclohexyl-Ala bond. This prediction data was experimentally 
confirmed by incubating M-2055 substrate with recombinant MMPs and analysing 
the cleaved metabolites via LCMS. 
The cleavage of M-2110 reported in the literature221 and observed in our 3-D 
molecular modelling indicated that stromelysins strongly interact with M-2110 at 
the Glu-Nva bond, which was confirmed by the in vitro cleavage assay. Again, as 
for the non-selective use of M-2110, the cleavage pattern of this substrate by 
MMP-9 is unknown/unreported. Based on 3-D molecular modelling and the 
respective zinc-chelation sites, it was predicted that MMP-9 interacts with the 
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substrate at the Pro-Val bond. This prediction was also experimentally confirmed 
highlighting that a suitable predictive model has been created for the determination 
of substrate cleavage sites by these MMPs.  
 
This promising result demonstrated that it is possible to accurately predict the 
substrate binding differences between homologous MMPs without a substrate 
‘small molecule’ crystal structure to guide molecular conformation. Furthermore, 
this approach proved to be of applicable value for the development of prodrugs to 
be selectively activated by specific MMP subtype such as MMP-10 and target 
tumours with the selective release of the chemotherapeutic agent.  
 
In order to achieve MMP subtype selectivity, a known MMP-targeted peptide-
prodrug of doxorubicin (Albright prodrug)207, 285 was utilised as a template 
sequence as it is cleaved by MMP-2 and MMP-9 at the same subsite (Gly-
Ser(OBenzyl)), presenting an excellent model for further modification. The in silico 
interaction of the Albright prodrug with MMP-2 and MMP-9 demonstrated zinc 
chelation between the known cleavage site, Gly and Ser(OBenzyl) bond, which 
was also confirmed by the in vitro cleavage assay with respective MMPs. 
However, the Albright prodrug also showed relatively weaker in silico interaction 
with MMP-3 and MMP-10 at a distinctive unknown subsite Ser(OBenzyl)–Tyr.  The 
in vitro assessment confirmed cleavage of prodrug by MMP-3 and MMP-10 at the 
predicted subsite, supporting the predictability of the in silico model of anticancer 
prodrugs and providing a suitable template for the exploitation of MMP binding 
subsites and rational modification of peptide residues to produce prodrugs 
selective for specific MMP subtypes. Initial efforts focused on exploiting the 
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differences in peptide selectivity between homologous MMPs to produce a 
prodrug, termed MJ02, selective for MMP-2 and MMP-10, over MMP-3 and MMP-
9. Based on the MMP-2/MMP-9 cleavage site, Gly-Ser(OBenzyl), rational design 
of a peptide sequence selective for MMP-2 over MMP-9 was achieved by 
incorporating residues into the peptide chain to fit S1, S2, S3 and S1’ pockets of 
MMP-2 which differed in size and polar affinity compared to MMP-9. Modifications 
such as aromatic residue homophenylalanine (Hof) in S1 subsite, acidic residue 
Glu in S2 subsite, polar side chain Gln at S3 subsite and small nonpolar residue 
Leu in S1’ subsite were incorporated. Similarly, based on the MMP-3/MMP-10 
cleavage site, Ser(OBenzyl)-Tyr, in the ‘Albright prodrug’ the replacements of the 
P1 Ser(OBenzyl) with a Glu residue, P2 Gly with a Gln residue, P5 Glu with a Gly 
residue and P1’ Tyr with a Hof residue, were induced to achieve MMP-10 
selectivity over MMP-3. In spite of identical substrate selectivity of MMP-3 and 
MMP-10,271 there were subtle but significant binding differences between the two. 
The difference in S2 and S3 pockets were important in rationalising the peptide 
selectivity between the two stromelysins. The modified peptide sequence 
demonstrated strong in silico zinc interaction with MMP-2 at the Hof-Leu bond, and 
with MMP-10 at the Glu-Hof bond, indicating the predicted cleavage sites. The 
interaction of peptide sequence was not detectable in MMP-3 and MMP-9, 
suggesting the modified peptide residues should give selectivity for MMP-2 and 
MMP-10, over MMP-3 and MMP-9. In order to confirm the in vitro prediction and 
assess the preferential MMP-selective activation, a rationally designed peptide 
conjugated prodrug, MJ02, was synthesised via solid phase chemistry with the 
chemotherapeutic drug doxorubicin conjugated to the C-terminus and the Cbz 
non-polar endcap linked to the N-terminus of the peptide. Both MMP-2 and MMP-
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10 recombinant enzymes induced cleavage of MJ02, with cleavage occurring at 
the predicted subsites. Conversely, no MJ02 activation was observed by MMP-3 
and MMP-9, indicating that MJ02 is MMP-2 and MMP-10 selective supporting the 
in silico prediction. The prodrug also displayed differentials in cytotoxicity and 
ability to metabolise between MMP positive glioma cell lines (U87-MG and 
1321N1) and MMP-negative normal glial cell line (SVG-P12). Furthermore, MJ02 
remained inactive in the presence of pan-MMP inhibitor, demonstrating MMP-
selective action of this prodrug. However, MJ02 was metabolised slowly by both 
glioma and normal brain cell lines, in the presence of MMP-10 selective inhibitor, 
suggesting the involvement of MMP-2 in MJ02 metabolism, as evidenced by high 
proteolytic activity of MMP-2 in all the brain tumour and normal brain cells. The 
successful rationalised computer-aided development of MJ02 in this project 
provided valuable understanding for the progress towards specific investigation in 
the development of MMP-10 selective prodrug (rationally designed by Dr. 
Jonathan Harburn). 
Even though strategies were directed towards MMP-10 selectivity for prodrug 
design, understanding and attainment of MMP-subtype selectivity, possessed by 
MJ02, was important because it allowed for a first-hand detailed exploitation of the 
differences within the same MMP subfamily. To achieve MMP-10 selectivity, 
efforts focused on utilising the in silico docked complexes of MJ02 and MMPs as a 
reference to engineer-out selectivity of close family homologues i.e. MMP-3 and 
gelatinases. However, in the process of retaining MMP-10 selectivity, other MMP 
members also demonstrated marginal selectivity. Therefore, focus shifted towards 
exploiting the docked complexes of M-2110 fluorescent substrate and MMPs. The 
peptide sequence of M-2110 was modified towards MMP-10 selectivity by 
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incorporating residues to fit the specificity pockets of MMP-10; but prevent binding 
with MMP-2, MMP-9 and MMP-3. Using the MMP-3/MMP-10 cleavage site, Glu-
Nva, of M-2110 substrate; the replacements of the P2 Val with a Leu residue, P3 
Pro with a D-Pro residue, P1’ Nva with a His residue and P2’ Trp with a Leu 
residue, were induced to achieve MMP-10 selectivity over other MMPs. The 
design of a peptide prodrug selective for MMP-10, termed MJ04, over MMP-3 (the 
closest MMP subfamily with 86% structural similarity) has yet been unreported and 
is the first study to our knowledge, to describe detailed differences between MMP-
10 and MMP-3 binding subsites. 
 
The MMP-10 targeted prodrug of doxorubicin, MJ04, displayed preferential 
cleavage by recombinant MMP-10 at the predicted subsite, but displayed no 
cleavage by recombinant MMP-2, MMP-3 and MMP-9; thus confirming the in silico 
prediction.  The assessment of MJ04 metabolism in preclinical cell models 
demonstrated rapid metabolism by MMP-10 positive U87-MG cell line compared to 
MMP-10 negative SVG-P12 cell line. Crucially, using MJ04 to release Leu-Dox 
resulted in a greatly reduced exposure of SVG-P12 normal glial cell line to the 
Leu-Dox intermediate, thus suggesting an increased therapeutic index compared 
to MJ02. The metabolism of MJ04 was 2-fold slower (or negligible) in SVG-P12 
cell line compared to MJ02.  
Whilst these cell lines were selected for preclinical prodrug screening based on 
their differential levels of MMP expression, it would be worthwhile undertaking a 
more extensive screen of brain tumour xenograft models to allow for the selection 
of glioblastoma model systems for drug screening. If the progress and direction of 
this project could have been predicted from the outset, it would have been of great 
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value to produce fluorescently labelled substrates of these rationally designed 
peptides where the efficiency of MMP-mediated cleavage could be analysed by 
enzyme kinetics. The MMP-10 selective prodrug could prove potentially useful in 
the selective targeting of many cancers including glioblastoma, where MMP-10 is 
overexpressed and proteolytically active relative to normal surrounding tissues. It 
could also provide a valuable template for development of MMP-10 selective 
inhibitors and peptide probes for advanced diagnostic and prognostic applications.  
With regards to glioblastoma, the systemic delivery of therapeutics has been a 
disadvantageous with poor outcome because of the limitations imposed by the 
blood brain barrier (BBB). Even with the application of localised post-surgical 
BCNU (Gliadel) wafers have proven ineffective in many cases because of lack of 
tumour-selective drug targeting with neurological side effects. In order to 
circumvent this problem, the final part of this study was aimed at developing 
nanostructured graphene oxide (GO)-tethered prodrug implants. With 
overexpression of specific MMPs in the glioma tumour microenvironment, the 
prodrugs conjugated to a stable “base” can get activated by tumour-associated 
MMPs and target the tumour selectively. This study was carried out only on a 
small scale to prove the in vitro application. The GO-conjugated prodrug (MJ06) 
was derived from MJ02 peptide sequence with GO sheets as the endcap and 
doxorubicin as the chemotherapeutic agent. MJ06 preparation underwent several 
washing steps to remove non-conjugated peptide impurities. Since the detection of 
GO material was difficult on LCMS due to size restrictions, only the 2nd half of the 
cleaved MMP-metabolites were detectable, whereas the first half linked to the GO 
was undetectable.  A promising outcome from the in vitro cleavage assay was that 
MJ06 demonstrated cleavage by both MMP-2 and MMP-10 at the predicted 
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subsites. However this study faced shortcomings in examining whether the 
prodrug was chemically conjugated to the GO as a covalent bond or was it in fact 
only adsorbed or adhered on the surface. Non-chemical linkage of prodrug on GO 
is insufficient in tumour environment because the free non-conjugated N-terminus 
of the prodrug is prone to non-selective hydrolysis by exoproteases and 
subsequence release of toxic chemotherapeutic agent targeting the normal cells. 
Therefore it would be important to convincingly elucidate the type of conjugation 
between GO and the prodrug, before evaluating its potential for glioma targeted 
therapy. Our research team believed that the characterisation and development of 
GO-prodrug implants could become part of future research projects extensively 
concentrating on localised targeted therapy of cancers such as glioblastoma.   
Following successful development and validation of GO-prodrug implants, this 
therapeutic can be implanted in the tumour resected site of glioblastoma to halt its 
recurrence. This localised prodrug-implant strategy could lead to dose 
intensification at the tumour site, avoid the accumulation of prodrug in the 
surrounding tissues, result in reduced side-effects and potentially improve the 
success rate of glioblastoma. 
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Appendix 1: Human cell line origin 
 
Cell line Tissue of origin 
Cell 
morphology 
Culture medium 
U87-MG 
Brain; Grade-IV 
glioblastoma astrocytoma 
Epithelial-like EMEM + 1% NEAA 
1321N1 Brain; Grade-II astrocytoma Glial DMEM 
SVG-P12 Brain; Foetal glial cells Fibroblasts EMEM + 1% NEAA 
H460 Lung cancer Epithelial RPMI 
MCF7 Breast cancer Epithelial RPMI 
 
Note: 10% fetal bovine serum (FBS) and 2 mM L-glutamine were added to each 
culture medium prior to supplementation 
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Appendix 2: Composition of Buffer RLT 
According to the manufacturer, the exact composition of Buffer RLT is confidential. 
Buffer RLT contains a high concentration of guanidine isothiocycanate, which 
supports the binding of RNA to the silica membrane (Qiagen, Hilden, Germany).  
Note: note that ß-mercaptoethanol should be added to Buffer RLT before use to 
effectively inactivate RNAses in the lysate (10 µl ß-Mercaptoethanol per 1 ml 
Buffer RLT). 
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Appendix 3: Composition of Buffer RW1 
According to the manufacturer, the exact composition of Buffer RW1 is 
confidential. Buffer RW1 contains a guanidine salt, as well as ethanol, and is used 
as a stringent washing buffer that efficiently removes biomolecules such as 
carbohydrates, proteins, fatty acids etc., that are non-specifically bound to the 
silica membrane. At the same time, RNA molecules larger than 200 bases remain 
bound to the column (Qiagen, Hilden, Germany). 
Note: Buffer RW1 should not be used for isolation of small RNAs, for example, 
microRNAs or fragmented RNA from formalin-fixed tissues, as these smaller 
fragments will be washed away.  Buffer RWT should be used instead. 
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Appendix 4: Composition of Buffer RPE 
 
According to the manufacturer, the exact composition of Buffer RPE is 
confidential. Buffer RPE is a mild washing buffer, and proprietary component of 
RNeasy Kits. Its main function is to remove traces of salts, which are still on the 
column due to buffers used in the protocol. Ethanol is an important ingredient of 
Buffer RPE (Qiagen, Hilden, Germany). 
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Appendix 5: Composition of 1X Master Mix 
 
 10 mM Tris-HCl 
 50 mM KCl 
 1.5 mM MgCl2 
 0.2 mM dNTPs 
 5% Glycerol 
 0.08% IGEPAL CA-630 
 0.05% Tween 20 
 25 units/ml Taq DNA Polymerase 
 pH 8.6 at 25°C 
Storage temperature: -20°C 
Provided by the manufacturer (New England Biolabs, USA) as ‘Taq 2X Master 
Mix’. 
Note: IGEPAL CA-630 is a non-ionic, non-denaturing detergent with IUPAC name 
as octylphenoxypolyethoxyethanol. 
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Appendix 6: PhD publications 
1. Jain et al., J. Med. Chem. 2017, 60, 4496-4502 
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ABSTRACT: Matrix metalloproteinases (MMPs) are central to cancer develop-
ment and metastasis. They are highly active in the tumor environment and absent
or inactive in normal tissues; therefore they represent viable targets for cancer
drug discovery. In this study we evaluated in silico docking to develop MMP-
subtype-selective tumor-activated prodrugs. Proof of principle for this therapeutic
approach was demonstrated in vitro against an aggressive human glioma model,
with involvement of MMPs confirmed using pharmacological inhibition.
■INTRODUCTION
Matrix metalloproteinases (MMPs) are zinc-dependent endo-
proteases central to digestion of extracellular matrix (ECM)
and pericellular proteins involved in regulation of many normal
physiological processes including tissue growth and embryo-
genesis.1−5 Their activity is regulated by postsecretion
zymogenic activation and inhibition by endogenous inhibitors
termed TIMPs (t issue inhibitor of metalloproteinase).6
However, dysregulation of MMP expression and unbalanced
endoproteolytic activity of specific MMPs are a major
contributor to many degradative diseases including arthritis,
cancer, cardiovascular disease, inflammatory disorders, and
neurodegeneration,5,7−9 thus making them attractive drug
targets.2,10,11
In the past 2 decades significant drug discovery effort was  
focused on inhibition of  MMPs as a strategy to prevent  tumor
invasion and subsequent tumor metastases.12 As a result, the
pharmaceutical industry produced a number of well tolerated
orally active MMP inhibitors (MMPi).13 These agents were
largely peptidomimetic zinc-binding hydroxamates, based upon
an MMP peptide substrate.2,14,15 Although many of these
inhibitors progressed to late stage clinical trials against
metastatic cancer, limited clinical success was seen due to a
lack of inhibitor MMP-subtype specificity and insufficient
knowledge about the complexity of the disease biology.2,16,17
Several additional strategies have been evaluated over recent
years, including development of inhibitors exploiting the
enzymatic transition state,2,18 inhibitors binding enzyme cavity
subsites,19 or alternative zincchelation groups.2 Generation of
MMP subfamily selective inhibitors still proves mostly elusive,
however, because of the broad structural similarity of their
active site, substrate complexity, and identification of specific
MMPs as antitargets.2,17
In  contrast to inhibition of  MMP function, exploitation    of
the MMP-mediated proteolysis within diseased tissues has also
been investigated as a diagnostic and prognostic approach.
These studies used activity-based probes comprising a “broad-
spectrum” or selective MMP-cleavable peptide labeled with a
quenched fluorophore or imaging moiety.20,21 In this approach,
elevated MMP activity in the diseased tissue results in
activation of the probe via selective cleavage of the peptide and
release of the contrast agent, facilitating imaging and
quantification of MMP activity.20,21
In  line  with  the  MMP-activated  probe-based  approaches,
elevated activity of MMPs within diseased tissue has also been
explored as a strategy for conversion of a nontoxic peptide-
conjugated prodrug into a potent therapeutic entity within the
disease site. The advantage of this approach is dose
intensification  and  reduced  systemic  drug exposure.1,22−26 A
requirement for success in activity probes, prodrugs, or
theranostic approaches is MMP selectivity through incorpo-
ration of MMP-subtype unique (e.g., MMP-2, MMP-9, or
MMP-14) peptide sequences and subsequent disease-selective
activation.
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The rationale for this study is to exploit the MMP binding
subsites and modify the substrate residues to produce a prodrug
selective for MMP-2 over MMP-9 and MMP-14 and create a
robust approach that could be exploited for development of
endoprotease-activated diagnostic probes and therapeutics.
Visualizing and quantifying binding preferences and motifs can
provide valuable insight into the structural determinants of
substrate selectivity and enable MMP-targeted drug develop-
ment.27 In order to achieve this, the following steps were
undertaken: definition of the catalytic domains within the
relevant MMPs through in silico study, docking of known
MMP-selective sequences to highlight key catalytic binding
determinants, subsequent rational design of novel MMP-
selective prodrugs, and in vitro confirmation of MMP selectivity
and therapeutic proof-of-concept. In this work a reiterative
approach using in silico proteolytic docking coupled to in vitro
biochemical assessment has been applied to enable the
development of prodrugs that are selectively activated by
MMP-2 over MMP-9, the closely related gelatinase family
members, and over MMP-14, the endogenous activator of
MMP-2. The availability of three-dimensional crystal structures
of MMPs allowed us to critically examine the differences existing
between the catalytic domains of the MMP-2 (PDB code
1QIB), MMP-9 (PDB code 1GKC), and MMP-14 (PDB
code 1BQQ).28−30 This allowed for successful development of
in silico models of MMPs. The in silico model was able to
accurately predict known cleavage sites on substrates and
prodrugs by MMPs, thus enabling rationalized design of an
MMP-2 selective peptide.
■RESULTS AND DISCUSSION
The catalytic domain of MMPs consists of five β-sheet strands
and three α-helixes. The catalytic center comprises a catalytic
zinc ion coordinated by three histidine residues and a glutamic
acid.28 The specificity loop within the catalytic site of MMPs
shows the largest stru ctural differences, as visualized for MMP-2
and MMP-9 in Figure S1 in Supporting Information. The
overall folding of MMP-2 and MMP-9 resembles those of other
MMPs, which is expected based on their structural similarity
(Figure S1) .31 The cavity of S1 ′ pockets in MMPs is well-suited
to accommodate a wide range of hydrophobic residues, with the
main functional difference between MMP subtypes lying in this
region. In MMP-9, residues 421−423 form the wall of the
binding pocket and the specificity loop is formed by the
residues 424−430. Arg424 is present at the bottom of S1 ′
pocket and closes off the end. Arg424 is therefore responsible
for making the pocket cavity smaller in MMP-9 than in MMP2
(Figure S1) , whereas in MMP-2, the external wall of the S1 ′
pocket is largely formed by Thr227-Phe232 specificity residues,
creating a deeper pocket. These differences can potentially be
exploited for rational design of MMP-selective substrates/
conjugates.
To  probe  the  selective  binding  of  potential  substrates, the
peptide sequence of the nonspecific gelatinase substrate 1 Dnp-
Pro-β-cyclohexyl-Ala-Gly-Cys(Me)-His-Ala-Lys(N-Me-Abz)-
NH2 (M-2055)
32 was input into BIOVIA Discovery Studio 4.0,
minimized with respect to its geometry, and then docked into
the MMPs. In order to validate modeling work, attempts at
crystallization of this and other substrates were undertaken to
determine the X-ray crystal structure. Crystallization experi-
ments failed to yield suitable crystals for structure determi-
nation; therefore only force field (CHARMM) minimized
geometries of the substrates were employed throughout this  
study.
Figure 1 shows the interaction of 1 peptide sequence with  
human  MMP-2  and  MMP-9.  In  both  MMPs  the  zinc   ion
interacts with the Gly and Cys(Me) bond, the known cleavage
site according to Bickett et al.32 MMP-9 is able to bind tightly
with the substrate residues compared to MMP-2, as determined
by differences in their predicted interatomic zinc distances and
overall binding energies. The substrate bound MMP complexes
provided crucial insight into the differences in their subsite
interactions, as S1 and S3 subsites in MMP-2 demonstrated
affinity to accommodate longer side chains than MMP-9. The
charged nature of the S2 subsite (presence of His205) in MMP-
2 lends affinity for acidic residues, whereas this feature is not
observed in MMP-9. In the MMP-9 structure, the carboxylic
acid between Gly and Cys(Me) chelates the zinc ion (2.1 Å)
and is involved in a strong H-bond to the carboxylate O of
Glu402. The zinc ion is further coordinated by three histidine
residues, namely, His401, His405, and His411 present in Helix
αβ segment of the protein. Only the P1 ′ amino acid is involved
in strong H-bonds with Arg424 (2.2 Å), which creates the wall-
forming segment. The strong binding of Arg424 with the P1 ′
residue is an important determinant of the specificity pocket.
Remaining substrate residues are involved in strong interactions
with the bulge-edge segment molecules (Gly186 to His190)
with interatomic distances ranging from 2.5 to 3.1 Å. The
docked complex of 1 and MMP-9 has an overall binding energy
of 706 kcal/mol (Figures 1, S2, S3, and S4).
Consideration of the interaction of 1 with the active site of  
MMP-2  shows  a  marked  reduction  in  affinity  in   energetic
Figure 1. (Top) Docked complexes of 1 substrate and the catalytic
domain of human MMP-2 (PDB code 1QIB) and MMP-9 (PDB code
1GKC). The MMP-substrate docked complexes are merged with zinc
as the same point of view. MMP-2 structure is shown in red, zinc as
purple, and 1 substrate (white sticks) docked within MMP-2 active
site. MMP-9 is shown in gray, zinc as green, and 1 substrate (thin
green sticks) docked within its active site. (Bottom) Schematic
representation of 1: active site binding interaction in human MMP-2
and MMP-9. MMP-2 and MMP-9 enzyme binding pockets are shown
in red and green, respectively. Substrate chemical structure and its
scissile bond are shown in black. The zinc ion is indicated in blue.
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terms; the predicted interaction is 7 times weaker than that of 1
and MMP-9 (binding energy of 101 kcal/mol). Gly forms the
P1 subsite and Cys(Me) forms the P1′ subsite, and the
presence of a zinc ion, chelated by the carboxylic acid between
P1 and P1 ′ residues (3.8 Å), further confirms this. The P1 ′
residue, although favorable for the MMP-2 specificity pocket, is
not involved in any significant interaction with MMP-2
residues. The remaining substrate residues have weak H-bond
interactions with wall-forming and bulge-edge segments of
MMP-2 with interatomic distances ranging from 3.1 to 5.1 Å.
This is expected as 1 residues are oriented away from further
MMP-2 binding pockets (Figures 1, S2, S3, and S4). Key
observed differences between the binding affinity of MMP-2
and MMP-9 with 1 are S1 and S3 subsites in MMP-2 that can
accommodate longer side chains than MMP-9. Charged nature
of S2 subsite in MMP-2 has affinity for acidic residues, whereas
this feature is not observed in MMP-9. Refer to Figure S5 for in
silico binding of 1 with the active site of MMP-14, also
demonstrating zincinteraction between Gly-Cys(Me) bond.
To experimentally validate the predictability of this model
and confirm the in vitro cleavage position of 1, hydrolysis of the
substrate by recombinant MMP-2 and MMP-9 was assessed
over a 12 h period. The resultant products were analyzed by
LCMS using a reverse phase gradient system to separate the
substrate 1 and proteolytic products. The identification of these
species was confirmed by retention time and mass spectrometry
(MS) data. 1 demonstrated a retention time (tR) of 2.8 min
(Figure S6), and rapid cleavage by MMP-9 at Gly-Cys(Me)
bond was confirmed by LCMS, two peaks corresponding to
Dnp-Pro-β-cyclohexyl-Ala-Gly at tR of 2.3 min (m/z 491.5 Da,
[M + H]+) and Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH2 at tRof
2.47 min (m/z 604.7 Da, [M + H]+) (Figures 2 and S7). Slow
hydrolysis of 1 by MMP-2 (compared to MMP 9) at Gly-
Cys(Me) bond was confirmed by two peaks at tRof 2.3 min and
tRof 2.47 min. MMP-2 cleavage experiments displayed a parent
peak of 1, detected at tRof 2.8 min (m/z 1077.5 Da, [M + H]+),
suggesting that MMP-2 metabolized 1 at a slower rate than
MMP-9 (Figures 2 and S8). Recombinant MMP-14 also
cleaved 1 at the Gly-Cys(Me), confirming the in silico
prediction (Figure S9) . This in vitro assessment supports the
validity of the predicted in silico model of substrate and MMP
interactions and was subsequently used for further design of
MMP-targeted therapeutics.
The next phase of the study was to design a prodrug
(substrate and warhead) that would be selectively activated by a
specific MMP over a close family homologue, i.e., cleaved by
MMP-2 and not by MMP-9 or MMP-14. A known MMP-
targeted peptide-conjugated doxorubicin prodrug33,34 was
evaluated as it is cleaved by MMP-2, MMP-9, and MMP-14,
presenting an excellent model for further modification. MMP-
targeted peptide conjugates were synthesized via solid phase
chemistry and purified by reverse phase HPLC, the chemo-
therapeutic drug doxorubicin conjugated to the C-terminus
(Scheme S10) . In silico interaction of the 2 (reference
compound) with MMP-2 and MMP-9 shows the zinc ions are
chelated by the carboxylate between Gly-Ser(O-benzyl) bond
(2.6 and 2.8 Å, respectively), the known cleavage s ite.31,32
Figure S11 shows that the binding pockets of MMP-2 are larger
and deeper than MMP-9, S1 subsite allowing for larger
aromatic residues. Compound 2 aligns tightly into the active
site of both MMPs as shown by their predicted interatomic zinc
distances and binding energies (555 and 492 kcal/mol) in
MMP-2 and MMP-9 docked complexes, respectively. Active
site residues interact with the compound in a similar way to that
previously explained. His205 in MMP-2 αβ-helix loop makes
the S2 pocket charged in nature and could potentially
accommodate acidic residues (Figures S11 and S12). Similar to
MMP-2 and MMP-9, MMP-14 also demonstrated selective
interaction with 2 (Figure S13) To experimentally validate the
in silico docking of 233,34 and confirm the in vitro cleavage site,
the lysis of this prodrug by recombinant MMP-2 and MMP-9
was assessed over a 12 h period, with the resultant products
being assessed by LCMS. HPLC (reverse phase gradient) was
used to separate 2 (Cbz-Glu-Pro-Leu-Gly-Ser(O-benzyl)-Tyr-
Leu-doxorubicin),33,34 identification confirmed by mass spec-
trometry (MS) with a retention time of 3.63 min (Figure S14).
Cleavage of 2 by MMP-2 and MMP-9 at Gly-Ser(O-benzyl)
bond was confirmed by LCMS, two peaks corresponding to
Cbz-Glu-Pro-Leu-Gly at tR of 2.87 min (m/z 547.2 Da, [M +
H]+) and Ser(O-benzyl)-Tyr-Leu-doxorubicin at tR of 3.23 min
(m/z 997.4, [M + H]+) (Figures 3, S15, and S16). A parent
peak was also detected at tRof 3.63 min (m/z 1525.8 Da, [M +
H]+). Similarly, MMP-14 also displayed hydrolysis of 2 at the
Gly-Ser(O-Benzyl) bond (Figure S17). This in vitro assessment
supports the predictability of the in silico model of anticancer
therapeutics with MMPs for further design of MMP-2 selective
prodrugs.
Rational design of a peptide conjugate selective for MMP-2  
over  MMP-9 was  achieved  by  incorporating  residues into the
peptide chain to fit S1, S2, S3, and S1 ′ pockets of MMP-2
which differ in size and polar affinity compared to MMP-9. The
following modifications were incorporated: aromatic residues in
S1 subsite; acidic side chain in S2 subsite, and a polar side chain
at the S3 subsite. Small nonpolar residues were included at the
S1 ′ subsite despite S1’s potential to accommodate longer
hydrophobicresidues. This was due to longer residues leading
Figure 2. Schematic representation of the cleavage of 1 substrate by  
recombinant MMP-2 and MMP-9 enzymes  at Gly-Cys(Me).
Figure 3. Schematic representation of the cleavage of 2 by
recombinant MMP-2 and MMP-9 enzymes at the Gly-Ser(O-Bn)
bond.
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on the basis of the peptide modifications for MMP-14
selectivity suggested in the literature,35,36 the zinc interaction
between 3 and MMP-14 was nondetectable and the binding
energy was negative (Figure S20). The hydrolysis of 3 by
recombinant MMP-2, MMP-9, and MMP-14 was assessed over
a 12 h period and analyzed by LCMS. Reverse phase HPLC
identified 3 at tR of 3.58 min (Figure S21). 3 was preferentially
cleaved by MMP-2 at Hof-Leu, and two peaks were identified
corresponding to Leu-doxorubicin at tR of 2.078 min (m/z
657.2 Da, [M +H]+) and Cbz-Gly-Pro-Ile-Gln-Glu-Hof at tRof
2.826 min (m/z 821.4 Da, [M + H]+) (Figures S22 and S23).
Conversely MMP-9 and MMP-14 did not cleave 3 in the same
time frame, indicating that 3 is MMP-2 selective supporting the
in silico prediction (Figures S22 and S24).
In order to assess activity and demonstrate  proof-of-concept
for the developing approach, the effects of 3 were assessed
against the U87-MG malignant human glioma cell line. This
cell line is derived from a highly aggressive glioma tumor and
expresses MMP-2 and MMP-9 (Figure 5) . Cytotoxicity was
observed in this cell line with doxorubicin, leucine-doxorubicin
(Leu-Dox), and 3, with IC50 values of 0.3  0.2 μM,   0.6 0.2
μM,   and   5.0    1.2   μM,   respectively.   The differential
cytotoxicity between doxorubicin and 3 supports the require-
ment for 3 to be activated prior to inducing its effects.
Furthermore, 3 remained inactive in the presence of a pan-
MMP inhibitor, (2R)-N′-hydroxy-N-[(2S)-3-(1H -indol-3-yl)-1-
(m ethylam ino) -1-oxopropan -2-yl]-2-(2-m ethylpropyl) -
butanediamide (GM6001, ilomastat/galardin),37 demonstrating
MMP-selective chemotherapeutic action of this prodrug.
In order to further determine the tumor-selective activation
of 3, its metabolism was studied ex vivo using MMP-expressing
HT1080 human tumor xenograft,33 mouse plasma, and
homogenized murine liver and kidney tissues (Figure S25).
Rapid metabolism of 3 was observed in the HT1080 xenograft
homogenate (t1/2≥ 8.8 min). In comparison, 3 was relatively
stable in plasma (t1/2≫90 min), murine liver (t1/2≥17.0 min),
and murine kidney (t1/2 ≥ 38.1 min). The liver
homogenate is a “worse case scenario” for 3’s stability due to a
high proportion of extracelluar and intracellular proteases. 3
displayed relative stability in mouse plasma and liver and kidney
homogenates and associated rapid metabolism in tumor
homogenates.
■CONCLUSIONS
Targeted cancer therapies offer the potential of reduced side
effects along with benefits of prolonging drug exposure to
cancerous tissues, enabling improved tumor response and
survival rates.38,39 Harnessing the elevated enzymatic activity of
MMPs within the tumor microenvironment to selectively
convert a nontoxic prodrug into a potent chemotherapeutic
agent is one such approach with significant potential
therapeutic scope.40,41 In this study a reiterative approach using
in silico docking coupled to in vitro biochemical proteolytic
assessment has been applied to enable the development of
anticancer prodrugs selectively activated by MMP-2 but not by
close family homologue MMP-9 or the MMP-2 activator
MMP-14. Proof-of-concept for this ther- apeutic approach was
demonstrated against a glioma cell line in vitro, with the
involvement of MMPs confirmed using pharmacological
inhibition and by tumor-selective activation with ex vivo tumor
xenografts. This study has shown that it is feasible to utilize in
silico predictive approaches to rationally
Figure 4. (Left) Docked complexes of 3 (white sticks), catalytic
domain of human MMP-2 (PDB code 1QIB) (red), and MMP-9
(PDB code 1GKC) (green). Catalytic and structural zinc ions are
shown as purple spheres, and active-site cleft residues (αβ-helix loop
and the specificity loop) are shown as green. (Right) Schematic
representation of 3 substrate: active site binding interactions in MMP-
2 and MMP-9 are shown in red and green, respectively. Substrate
chemical structure and its scissile bond are shown in black, and zinc
ion coordinated by histidine is indicated in blue.
Journal of Medicinal Chemistry
to a negative effect on the predicted binding affinity, due to  
conformational alteration.
The zinc ion in MMP-2 demonstrated interaction with 3 at
carboxylate between homophenylalanine (Hof)-Leu bond (1.9
Å), indicating the predicted cleavage site. Residues of MMP-2
tightly bind with 3 as demonstrated by strong interactions with
the bulge-edge segment molecules (Gly162 to His166) and the
wall-forming segment molecules (Tyr223 to Thr229) with
interatomic distances ranging from 1.8 to 2.8 Å. The docked
complex of 3 and MMP-2 has an overall binding energy of 805
kcal/mol. In MMP-9 the zinc interaction is not detectable and
the predicted binding energy is negative (−107 kcal/mol),
suggesting the modified peptide residues should give selectivity
of MMP-2 over MMP-9 (Figures 4, S18, and S19). Similarly,
Figure 5. Therapeutic activity of 3 against human cancer: (A)
expression of MMP-2 and MMP-9 mRNA in the U87-MG glioma cell
line; (B) MMP activity in the U87-MG cell line, as demonstrated by
activation of 1 substrate Dnp-Pro-β-cyclohexyl-Ala-Gly-Cys(Me)-His-
Ala-Lys(N-Me-Abz)-NH2; (C) cytotoxicity of doxorubicin, Leu-Dox,
and 3 against U87-MG cell line. MMP-selective activation of 3 in the
presence of a pan-MMP inhibitor (Ilomastat).
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design  MMP-selective  prodrugs  with  possible  utility  in  the
treatment of cancer.
■EXPERIMENTAL SECTION
3D Molecular Modeling. Refer to method  S30.
Synthesis of MMP-Targeted Peptide Conjugates . Custom
designed peptide sequences with Cbz (benzyloxycarbonyl) as the
chemical endcap were supplied (Bachem, Switzerland) or synthesized
using solid phase strategy. Activation of the preloaded 2-chlorotrityl
resin was carried out in a fritted polypropylene reaction chamber. 0.1
mmol of resin was weighed into the reaction chamber and 2 mL of dry
DCM added. The reaction vessel was shaken for 45 min. After this
time, DCM was removed and the resin washed further with DCM.
Single couplings were carried out using 5 equiv of peptide (compared
to resin), 5 equiv of benzotriazol-1-yloxytripyrrolidinophosphonium
hexafluorophosphate (PyBOP), 10 equiv of N,N-diisopropyl-
ethylamine (DIPEA), and 2 mL of DMF under agitation for 45 min.
Double peptide couplings were carried out (2  45 min couplings for
each residue addition), the reaction was drained after each coupling,
and fresh reagents were added. After each set of coupling reactions, the
reaction solution was drained and resin washed with 5 portions of 2
mL of DMF. Removal of the Fmoc group was carried out using 5 mL
of a solution of 20% piperidine in DMF for 5 under agitation.
Piperidine solution was drained and fresh solution added for a further
10 min under agitation. Piperidine solution was drained and the resin
rinsed using 5 portions of 2 mL of DMF. Peptide-resin was treated
with a solution of 20% hexafluoroisopropanol in DCM for 1 h. The
resin was removed by filtration and the solvent removed from the
filtrate under reduced pressure before precipitation using ether and
decanting of the liquid (followed by subsequent ether washes). The
resulting solid peptide (Cbz-GPIQ(Trt)-E(tBu)-hPhe-L-OH) was
dissolved in deionized water and acetonitrile mix and lyophilized.
Purification of peptides was carried out using Perking Elmer HPLC.
Samples were injected into a column and a gradient of 0−100%
solvent B (solvent A =95% H2O, 5% MeCN, 0.01% TFA, solvent B =
95% MeCN, 5% H2O, 0.01% TFA) over 95 min with a flow rate of 2.0
mL/min. Doxorubicin was conjugated to the peptide C-terminus as
follows: doxorubicin·HCl (0.0012 g, 0.002 mol, 1 equiv), peptide
(0.0022 g, 0.002 mol, 1 equiv), PyBOP (0.0015g, 0.003 mol, 1.3
equiv), and hydroxybenzotriazole hydrate (0.0073 g, 0.0054 mol, 2.6
equiv) were added together under nitrogen in anhydrous DMF (2
mL). DIPEA (8 equiv, 0.016 mol) was added, and the reaction mixture
was stirred overnight in the absence of light. Solvent was removed in
vacuo and the mixture triturated with cold Et2O (5 mL) to precipitate
the crude peptide which was then obtained through centrifugation to
obtain the crude solid peptide conjugate. The product was then
purified using a C18 column and reverse phase HPLC (H2O/MeCN)
gradient system using mass spectrometry as confirmation of molecular
mass to give a pale red solid (0.0021 g, 70% yield).
Liquid Chromatography and Mass Spectrometry (LCMS)
Detection of Substrates . LC Conditions. High-purity HPLC-grade
solvents (Sigma-Aldrich), analytical grade chemicals (Sigma-Aldrich),
and triple distilled water were used throughout. Reverse-phase
chromatographic separation of substrates was performed using an
Acquity UPLC comprising a BEH C18 1.7 μm column (2.1 mm 100
mm) (Waters, U.K.). Mobile phases were as follows: Mobile phase A
consisted of 90% HPLC grade water, 10% HPLC grade MeCN, and
0.1% HCO2H. Mobile phase B consisted of 40% HPLC grade water,
60% MeCN, and 0.1% HCO2H.
MS Conditions. A Micromass ZMD single quadrupole electrospray
MS was used in positive mode (Micromass, Manchester, U.K.), and
MassLynx software was used to identify substrates and anticipated
metabolites. MS source parameters were optimizedto desolvation gas
375 L/h, cone gas 33 L/h, capillary 2.9 kV, sample cone 16 V,
extraction cone 5 V, fR lens 0.1 V, source block temperature 150  C,
and desolvation temperature 200  C. Parent compounds and
metabolites were detected as singularly charged ions using selected
ion readings (SIRs).
Cleavage of Substrates b y Recombinant MMPs. Refer to  
method S31.
Determination of MMP mRNA Express ion b y Semiquanti -
tative RT-PCR Analys is. Refer to method  S32.
MTT Assay. Refer to method S33.
Metabol ism of 3 in Tissues ex Vivo. Refer to method S34.
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Pyridylphosphinate metal complexes: synthesis,  
structural characterisation and biological activity†
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For the first time, a series of 25 pseudo-octahedra l pyridylphosphinate metal complexes (Ru, Os, Rh, Ir)
has been synthesised and assessed in biological systems. Each metal complex incorporates a pyridylphos-
phinate ligand, a monodentate halide and a capping η6-bound aromatic ligand. Solid- and solution-state
analyses of two complexes reveal a structural preference for one of a possible two diastereomers. The
metal chlor ides hydrolyse rapidly in D2O to form a 1 : 1 equilibrium ratio between the aqua and chlor ide
adducts. The pKa of the aqua adduct depends upon the pyridyl substituent and the metal but has little
dependence upon the phosphinate R’ group. Toxicity was measured in vitro against non-small cell lung
carcinoma H460 cells, with the most potent complexes reporting IC5 0 values around 50 μM. Binding
studies with selected amino acids and nucleobases provide a rationale for the variation in toxicity
observed within the series. Finally, an investigation into the ability of the chelating amino acid L-His to dis-
place the phosphinate O–metal bond shows the potentia l for phosphinate complexes to act as prodrugs
that can be activated in the intracellular environment.
Introduction
In the field of bioinorganic chemistry, p lat inum group met al
complexes have found application in cellular imaging,1 in
enzyme inhibit ion2 and as molecular probes of biological
activity.3 The therapeutic ant icancer activity of these complexes
is also often probed bot h in vitro and in vivo.4 In t he context of
therapeutics, t he advant ages t hat metal complexes offer over
purely organic species include: a variety of met al geometries and
coordinat ion numbers, allowing access to intricate 3-dimen-
sional structures ; numerous metal oxidation stat es, allowing
redox-activated drugs; tuneable ligands to vary sterics and elec-
tronics about the met al centre; exchangeable ligands , for in situ
activation and binding to biomolecules; s imple and modular
syntheses, allowing rapid det ermination of st ructure t o activity
relat ionships. Despite t he wide-spread clinical use of t he plati-
num-based drugs, cisplatin, oxaliplatin and carboplat in,5 t here
remains issues associat ed with side-effects, including dose-limit-
ing systemic toxicities6 and acquisit ion of drug res istance, which
reduce t he efficacy and clinical utility of these drugs.7
One class of met al complexes t hat has shown great promise
as alternatives t o Pt drugs are t he pseudo-octahedral p iano stool
complexes,8 in which a low-spin d6 met al ion is cap p ed by an
η6-phenyl or η5-cyclopentadienyl ligand, with t he remaining 3  
coordination sites occupied by tri- bi- or mono-dentate ligands.
Over t he p ast decades, many examples of p iano stool met al
complexes have been rep ort ed t hat show excellent in vitro9 and
in vivo10 activity against cancers (Fig. 1). Variation of each com-
p onent of t he p iano stool arrangement alt ers t he activity of t he
complex. For example, in t he series [(η6-arene)Ru(en)Cl]PF6 a
Fig. 1 Examples o f  metal complexes assessed for their anticancer  
activity.
aDepartment of Chemistry, Durham University, South Road, Durham, DH1 3LE, UK.
E-mail: james.walton@durham.ac.uk
bSchool of Medicine, Pharmacy and Health, Durham University, W olfson Research  
Institute, Queen’s Campus, Stockton on Tees, TS17 6BH, UK
† Elect ronic supp lement ary in fo rmation (ESI) available: Full experi ment al pro-
cedu res an d X-ray structural da ta . CCDC 1457275 an d 1457276. For ESI an d crys-
tallographic d a t a i n CIF or o t h er electronic format see DOI: 10.1039/c6dt01264g
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3-fold increase in activity against human ovarian cancer cell
line A2780 is observed when the arene is varied from benz ene
to bipheny l.11 Similarly, modulat ion of t he mono-dent ate
halide in t he series [(η6-p-cym)Ru( p-Azpy-NMe2)X]PF6 from
chloride t o iodide results in a decrease in IC50, t he concen-
trat ion of complex required to inhibit cell proliferation by
50%, from 13 μM t o 0.69 μM in t he A2780 cell line.12 Finally,
complexes wit h t he same ligand can vary in activity, dep ending
up on the central met al. In the [(η6-p-cym)M( picolinat e)Cl]
series, IC50 values (A2780 cell line) of 45 μM (ref. 13) and
4.5 μM (ref. 14) were rep ort ed for t he Ru and Os complexes,
respectively. Beyond Ru(II) and Os(II), t here are also a hos t of
Ir(III) and Rh(III) piano-stool complexes, whose activity oft en
surp asses that of related Ru(II) complexes.15 Although oft en
not well unders t ood, t he mechanism of act ion of t hese com-
plexes may involve DNA binding,16 int eract ions with hist one
p roteins,1 7 redox modulat ion1 8 or enzyme inhibit ion.19
The vast majority of report ed p iano stool complexes in t he
bioinorganic chemistry field incorporate polypyridyl, carboxy-
lat e or halide ligands . Only rarely are li gands explored t hat
include elements ot her t han C, N and O. However, t here are a
host of alternatives t hat may offer s ignificant advant ages over
t he more tradit ional ligand systems. In t his study we p resent a
novel ligand for p lat inum group metal complexes : t he pyridyl-
phosp hinat es. We rep ort t he synthesis , s tructural charact eris-
at ion, aqueous prop ert ies and biological activities, including
in vitro cytotoxicit ies, of a series of p iano stool met al com-
plexes incorporating t he pyridylphosphinat e ligand (Fig. 1).
Lanthanide complexes incorp orat ing t his ligand have found
app licat ion in cellular imaging.20 However, t he p iano stool pyr-
idy lp hosphinate complexes have never been s t udied. Advan-
tages of t he pyridylp hosphinate ligand include:
biocomp atibility ; t he presence of a 31P-NMR spectroscopic
handle; control over lipophilicity at phosp horus ; modular syn-
t hes is allowing rap id structure–act ivity relat ionship profile
and, finally, t he p resence a stereogenic p hosphorus , which
p resents an opportunity to develop enantiomerically p ure  
met al-based complexes.21
Despite t he host of p iano stool complexes t hat have been
report ed, there is oft en a lack of informat ion on biological be-
haviour, such as int eract ions between biologically relevant
molecules (amino acids , p rot eins and nucleobases) and t he
met al complexes . This informat ion is needed as the changes
in structure of t he complexes t hat take place in t he cellular
environment will have a p rofound effect up on the biological
activity. Herein, we interrogat e t he behaviour of t he novel pyri-
dy lphosphinat e complexes in biological systems, by monitor-
ing met al-halide hydrolysis, measuring pKa values of t he
result ant aqua complexes and carrying out det ailed binding
s t udies with selected biomolecules.
Synthesis and structural characterisation
A series of complexes were synt hesised in order t o assess the
factors t hat det ermine aqueous biological behaviour. Systema-
tic variation in t he met al–arene combinat ion, t he met al-bound
halide, the p hosphorus R′ group and t he pyridyl R group led t o
a library of 25 new comp ounds (Scheme 1). Synthes is involves
Pd-catalysed coupling of t he p hosphinat e (HPO(OEt)R′) and
bromo-pyridyl precursors .22 Quantitat ive hydrolysis of t he phos-
phinat e ester was followed by neutralisation with NaOMe and
complexat ion wit h t he appropriat e met al dimer [(arene)MX2]2.
Purification by recrystallisation from CHCl3/Et2O gave t he final
complexes with 30–50% yields.†
The synthesis of complexes 7 and 8 (Scheme 2) p roceeds via
t he 4-fluoropyridylphosphinate int ermediat e L1, which under-
goes nucleophilic aromat ic subst itut ion to form t he electron-
rich 4-OCD3- or electron-poor 4-Cl-pyridylphosphinate ligand,
dep ending up on hydrolysiscondit ions .
Single crystals suit able for X-ray diffraction s t udies were
grown of complexes 3 and 20 (Fig. 2A and 3). Complex 3 crys-
tallises in t he monoclinic crystal system and t he P21/c space
group and displays t he expected p seudo-tetrahedral geometry,
Scheme 1    General synthetic pathway and list o f  new complexes.
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with t he η6-p-cymene occupying one vertex. Ru–Cl (2.4155(6)
Å), Ru–O (2.0809(14) Å) and Ru–N (2.1109(17) Å) bond lengt hs
are almost ident ical to t hose reported for t he analogous picoli-
nat e complex [(η6-p-cym)Ru( picolinate)Cl],13 however, t he N–
Ru–O bit e angle is s lightly larger in complex 3, at 80.50(6) 
(bit e angle in picolinate complex is 77.95(7) ), reflecting t he
larger s ize of t he p hosphinat e group. Intriguingly, of t he four
possible s t ereoisomers (R or S at Ru and P, denot ed RuR/S and
PR/S , respectively), only one enant iomeric p air is observed in
t he solid st ate s tructure – RuSPR and RuRPS. 1H-NMR indicates
t hat a single dias tereomer is also p resent in solut ion, evi-
denced by one set of diast ereot opic p-cymene p rotons in the
region 5–6 p p m (Fig. 2B). The origin of t his stereoselectivity,
which has also been observed in lant hanide pyridylphosphi-
nat e complexes,23 can be rat ionalised in t erms of t he steric
int eract ions between t he p-cymene ligand and the P-phenyl
group, which are minimised in t he observed diast ereomer.
Weak int ramolecular hydrogen bonds between t he P vO and
p-cymene methyl-H (2.587 Å) and t he P-phenyl and pyridyl
met hyl-H (3.065 Å) may also influence the observed stereo-
chemist ry. In solution, slight broadening of t he pyridyl Me
p eak reflects its proximity t o t he P-phenyl aromat ic system, but
t he p resence of a sharp singlet p eak for t he p-cymene Me
group  suggests free rot at ion of t he p-cymene ligand, as  is  
expected for η6-arene–metal bonds .2 4
The solid stat e s t ructure of t he Cp*–Ir complex 20 (Fig. 3)
shows several differences from complex 3, including a Cc space
group, longer bond lengt hs between t he central met al and
coordinat ed ligands and a wider N–met al–O bit e angle of
82.00(11) . Despit e t he presence of t he less sterically challen-
ging P-methyl p hosphinat e ligand, once again only a single
diast ereoisomer is observed – IrSPR and IrRPS . No intra-
molecular H-bond int eract ions can be observed in t he crystal
st ructure, which p resents further quest ions over t he origin of
t his stereoselectivity. It may be t hat stereoselectivity originates
from the initial attack of t he p hosphinat e ligand on t he met al
dimer, during t he formation of t he complex.
Aqueous behaviour of the complexes
To gain an unders t anding of t he intracellular behaviour of
met al complexes wit h biological application, it is essential to
have an appreciat ion of t he aqueous behaviour of new com-
pounds . Upon dissolving complex 1 in a D2O: CD3OD (9 : 1)
mix, equilibrium is es t ablished between t he chloride (complex
1) and aqua (complex 1a) species (Fig. 4). 1H-NMR of the p-
cymene p rotons indicat es t hat an approximat e 1 : 1 (chloride :
aqua) equilibrium is reached wit hin 5 min and does
Fig. 2 (A) X-ray crystal structure o f  complex 3 and (B) 1H-NMR spectrum (CD3OD, 298 K, 4 0 0 MHz,), with expansions o f  the single set o f  diastereo-
topic p-cymene protons and o f the two methyl groups.
Scheme 2 Fig. 3   X-ray crystal structures o f  Ir complex 20.
This journalis©The Royal Society of Chemistry 2016 Dalton Trans., 2016, 45, 12807–12813  |12809
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not shift over t he course of 24 h (Fig. 4A). To confirm t hat t he
observed species are t he chloride and aqua adducts, the
complex was dissolved in 100 mM NaCl (Fig. 4B) and in
aqueous AgNO3, followed by filtrat ion of AgCl (Fig. 4C),
leading to t he selective format ion of t he chloride and aqua
adducts, respectively, each showing a characterist ic set of dia-
stereot opic p rot ons. The analogous Ru–iodide complex also
undergoes rapid hydrolysis wit h around 60% of t he complex
remaining as t he int act iodide species.
At the extracellular chloride concentrat ion (approx. 100
mM), t he pyridylphosphinat e complexes remains int act as the
chloride adduct , but at lower intracellular chloride concen-
trat ion (approx. 20 mM in cytoplasm)25 significant amount s of
t he aqua adduct are p resent . With t his in mind, we sought to
measure t he pKa of t he bound water molecule and t o est ablish
how t he pKa varies with t he choice of central met al and co-
ordinat ed  ligands.  pK *  (pKa  measured  in D2O)  values werea
measured  by  monit oring  t he  31P- and  1H-NMR  spectra  of
selected aqua complexes in D 2O: CD3OD (9 : 1) as a funct ion of  
pH*  ( p H values  in D2O  solut ion, Fig.  5),  according t o estab-
lished p rocedures25  (see ESI† for full details). pK *  values were
convert ed t o p Ka values
a
us ing t he equat ion
a
* 26
a a
pK   ¼ 0:929pK þ 0:42. By  comp aring pK   values of selected
aqua comp lexes (T able 1), it is ap p arent that a more elect ron
donat ing pyridyl ligand leads t o a higher pKa. This is shown by
t he increase in values in t he order 5a < 3a < 7a for comp lexes
with 4-Me, 3-Me and OCD3 pyridyl subs t ituents, respectively.
This order reflects t he higher pH required t o deprot onat e H2O
bound to a more elect ron-rich met al centre. The p hosphorus-
bound R′ group has little effect on pKa, as can be seen by com-
p aring values for 3a and 4a. Finally, as expected, t he pKa value
for t he Ir complex 20a is lower t han t hat of t he equivalent Rh
complex 25a, reflect ing t he increased metal–oxy gen bond
st rength of the heavier congener.27 For each of t he studied Ru
complexes, t he hydroxyl-bridged dimer D1 (Fig. 5) forms at
28
strongly bas ic p H (typically >pH 11), with concomit ant loss of
t he pyridylphosphinat e ligand.† The format ion of this dimeric
species from Ru p iano stool complexes at elevated p H has
been observed previous ly and t he dimer is known to be non-
cytotoxic. NMR exp eriments indicate that dimer format ion is
partially reversible up on lowering t he pH, but that comp lete
regenerat ion of t he s t arting complex does not take place.
Cytotoxicity studies
The toxicity of each complex was assessed against non-small
cell lung carcinoma H460 cells. Each complex was incubat ed
with H460 cells for 96 h at concentrations ranging from 0.1 t o
200 μM (aqueous media cont aining 0.1% DMSO) and IC50
values were measured us ing t he MTT assay (see ESI† for
det ails ). The solubility of complexes at t hese concentrat ions
was assessed to ensure t he comp ounds are fully dissolved (see
ESI† for details). Selected result s are shown in Table 2 and rep-
resent t he mean value for dat a from at least t hree experiments.
All Ru comp lexes incorporating chloride ligands are non-toxic
up to 200 μM. The most cytotoxic sp ecies are t he iridium–Cp*
complexes 21 and 22, each with IC50 values of 50  5 μM,
respectively. The p resence of t he iodide ligand appears t o play
Fig. 5    Measurement o f  the pK* o f  aqua complex 5a by monitoring thea
31P-NMR spectrum (D2O: CD3OD 9 : 1, 298 K, 162 MHz) as a function o f
pH*. For Ru complexes, at approx. pH* >11 formation o f  the hydroxy-
bridged dimer D1 isobserved.
Table 1    pKa  values  for selected  aqua  complexes (D2O: CD3OD 9 : 1,
298 K).  pK* values  were measured by monitoring changes in  31P-NMR
*
a a
pK  ¼ 0:929pK  þ 0:42
a
and   1H-NMR   spectra   and   converted   to   pKa   using   the equation
2 6
Complex R R′ {M(arene)} pKa
3a 3-Me P h {Ru(p-cymene)} 9.34  0.04
4a 3-Me Me {Ru(p-cymene)} 9.18  0.19
5a 4-Me P h {Ru(p-cymene)} 7.76  0.13
7a 4-OCD3 P h {Ru(p-cymene)} 10.08  0.05
20a 4-Me Me {Ir(Cp*)} 9.31  0.07
25a 4-Me Me {Rh(Cp*)} 10.95  0.04
Fig. 4    1H-NMR  spectra  (D2O:  CD3OD  9 : 1,  298  K,  4 0 0  MHz)  o f (A)
complex 1  and  1a  at approximately 1 : 1  equilibrium ratio, (B)   chloride
complex 1, following addition o f  100 mM NaCl and (C) aqua complex1a,  
following addition o f  AgNO3 and filtration o f AgCl.
12810  |  Dalton Trans., 2016, 45, 12807–12813 This journal is©The Royal Society of Chemistry 2016
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an import ant role in t he observed toxicity, as t he analogous
chloride complexes, 18 and 19, gave IC50 values >200 μM. Com-
p aring complexes 21 (P-phenyl) and 22 (P-methyl), it would
appear that t he phosphorus-R group has little influence up on
t he toxicity. However, t his is not t he case when comp aring the
Ru-p-cymene complexes 10 and 11, for which t he P-phenyl ana-
logue has significantly greater cytotoxicity t han the P-methyl
complex. A comp arison with cisplat in (IC50 = 0.80  0.01 under
t he experiment al condit ions), shows t hat in general t his class
of complexes have low cytotoxicity. While ineffect ive as cyto-
toxic agents , this feat ure may bode well for uses in appli-
cat ions such as enzymeinhibit ors.
A general feature wit hin t his series is t hat  t he complexes  
incorp orating monodentate iodide ligands have higher toxici-
ties t han t he corresp onding chloride complexes . The ext ent of
hydrolysis of t he iodide complexes is less t han t hat of t he
chloride complexes, leading t o t he conclus ion that a mechan-
ism of act ion involving hydrolysis and DNA binding, as is
oft en prop osed for p iano stool met al complexes , may not be
t he main mechanism of act ion op erat ing for t his series of
complexes . Whatever t he mechanism, t he observat ion of
higher toxicity for iodide complexes is cons ist ent with pre-
viously p ublished reports12,29 for bot h Ru- and Os-based anti-
cancer complexes. St udies are ongoing to elucidat e a p ot ent ial
mechanism of act ion for t hese species.
Binding studies
In general, t he Ru complexes herein have IC50 values greater
t han 200 μM. In an att empt t o underst and t his low cytotoxicity,
binding st udies were carried out with several biomolecules.
Addition of AgNO3 t o complex 1 dissolved in D2O, followed by
filtration of t he result ing AgCl precipit ate, gave t he aqua
adduct , 1a. Mass spectrometry and NMR spectroscopy (1H and
31P) were used t o identify t he p resence and extent of biomole-
cule binding after addit ion of one and two equivalents of bio-
molecule t o 1a, at 1 h and 16 h t ime-points (Fig. 6 and Table
3). The biomolecules selected for investigat ion were L-alanine
(L-Ala), L-threonine (L-Thr), L-histidine (L-His), imida- zole and
9-ethylguanine (9-EtG). No evidence for binding between 1a
and 1 equivalent of amino acids L-Ala and L-Thr
was observed after 1 h. In contrast, addit ion of 1 equivalent of
9-EtG led t o a p eak in the mass sp ectrum corresp onding t o the
9-EtG adduct of 1a, following loss of H2O. 1H-NMR analysis
indicat ed t he formation of a bond between Ru and N7 on
Table 2 IC50 values for selected complexes measured using the MTT
assay (96 h) against the non-small cell lung carcinoma H460 cell line.
Entries are the mean value for data from at least three experiments.
Complexesn o t included were found to have IC50 > 200 μM
Complex R R′ M Arene X IC50/μM
1 H P h Ru cym Cl >200
10 H P h Ru cym I 65  12
11 H Me Ru cym I >200
18 H P h Ir Cp* Cl >200
19 H Me Ir Cp* Cl >200
20 4-Me Me Ir Cp* Cl 140  40
21 H P h Ir Cp* I 52  2
22 H Me Ir Cp* I 53  4
25 4-Me Me Rh Cp* Cl 135  17
Cisplatin — — — — — 0.80  0.01
Fig. 6 Mass spectra for complex 1a in the presence of (A) L-alanine, (B)
9-ethylguanine, (C) L-histidine and (D) imidazole. Peaks labelled a –f co r-
relate to peaksin Table 3.
Table 3 Proposed species that give rise to mass peaks in Fig. 6, upon
addition o f selected biomolecules. Tabulated m/z values a–f correspond
to masspeaksin Fig.6
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9-EtG, with around 50% bound complex in solution. This mode
of binding is consist ent with previous reports t hat have pro-
posed a mechanism of action for t he anticancer behaviour of
Ru complexes t o involve DNAbinding, leading t o apoptosis.16
Up on addition of 1 equivalent of L-His, an adduct  was  
observed,   cons is t ent  with   rep lacement  of   H2O   for L-His,
binding t hough an imidazole N. When t he samp le was sub-
jected t o a second equivalent of L-His and left t o equilibrate
over 16 h, a species formed in which t he p y ridylphosphinate
ligand is disp laced and the L-His binds κ3 (Fig. 7). T he
observed Ru–(L-His) complex, 1c, is known to be non-cyto-
toxic30 and its format ion presents a pot ent ial exp lanation of
t he low cytotoxicity of Ru chloride complexes described in t his
report. It follows t hat the higher cytotoxicity of t he iodide-com-
plexes, 10, 21 and 22, is due to t he metal– iodide bond being
less labile towards aquat ion and therefore less likely to
undergo decomplexat ion by chelat ing biomolecules. It should
be not ed t hat t he only t ested biomolecule able t o displace t he
pyridylphosphinate ligand was L-His. Addit ion of 2 equivalents
of imidazole (16 h) leads to 1 : 1 adduct format ion, with loss of
H2O, but no ligand disp lacement . The cytotoxicity of the dis-
placed ligand of complex 1 (shown in Fig. 7A) was assessed
us ing t he MTT assay and found to by non-cytotoxic up t o 200
μM. In fut ure st udies it may be possible t o t une the lability of
pyridylphosphinate ligands , so t hat t he complexes remain
int act in t he high chloride concent rat ion of the extracellular
medium but are able t o release some useful payload wit hin
t he cell where t he chloride concentration is lower.
Conclusions
A series of 25 new piano-st ool py ridylphosphinate complexes
has been synthesised, charact erised and assessed in biologi-
cally-relevant systems. The p rop ert ies of t he complexes dep end
up on their various comp onents – met al ion, arene, pyridyl sub-
st it uent and P-alkyl group – which can be varied with relative
ease. Aqueous solubility and stability is good. Ru–Cl comp lexes
are non-toxic up to 200 μM, which bodes well for t heir use as a
scaffold for met al-based enzyme inhibit ors . Ir–I complexes are
more toxic t o cells , so may have t he p ot ent ial to act as anti-
cancer agents, although toxicity remains low compared to cis-
plat in. It was discovered t hat decomplexation of t he ligand
from complex 1 occurs in the presence of excess L-His, follow-
ing hydrolysis of t he Ru–Cl bond. This has t he pot ential t o be
exploited in t he form of complexes t hat deliver and release
useful payloads t o t he cell. The rate of aquat ion and t he pKa of
t he resulting aqua species can be t uned by varying t he pyridyl
subst it uent and t he judicious choice of met al–halide combi-
nat ion. Studies are ongoing t o investigat e t he cell upt ake,
localisat ion and any p ot ential ant imet ast at ic behaviour of
t hese excit ing new complexes and t o exploit t he lability of t he
pheny lphosphinat e Ru bond t o des ign responsive biologically
active complexes.
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